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Alterations in gut microbiota and metabolome occur during colon carcinogenesis and 
metabolic syndrome, but these changes may be reduced by exposure to bioactive compounds in 
foods. We hypothesized that bioactive compound-rich diets improve colon microbiota and 
metabolism to mitigate: 1) azoxymethane- (AOM) induced colon carcinogenesis in rats, 2) HZE 
radiation-induced alterations in the microbiota in mice, and 3) risk factors that define metabolic 
syndrome in human subjects. 
A dried plum (DP) containing diet reduced preneoplastic lesions and led to lower Nos2, 
Tlr2 and Tlr4 expression than basal diet counterparts. DP increased Bacteroidetes and decreased 
Firmicutes in the distal colon, and increased Actinobacteria and decreased Lactobacillus 
throughout the colon. DP reduced fecal short chain fatty acid (SCFA) concentrations and 
increased luminal concentrations of compounds derived from microbial metabolism of plant 
derivatives. Microbial metagenome prediction revealed alterations in KEGG pathways related to 
metabolism and pathway analysis of distal metabolites suggests DP altered critical regulators of 
colon carcinogenesis and inflammation. 
Exposure to 1 Gy of Fe (RAD) did not affect luminal SCFA, however, DP+RAD mice 
had a lower percentage of propionate compared to DP+SHAM, control diet (CD)+SHAM and 
CD+RAD groups. RAD increased the abundance of Akkermansia; however, DP increased 
Akkermansia, Lachnospiraceae, Anaeroplasma, and Coriobacteriaceae and reduced 
Oscillospira, Ruminococcaceae, Lactobacillus, and Clostridiaceae. Evidence of an interaction 




Sumac sorghum (SS) increased the anti-inflammatory genus Faecalibacterium, but had 
no effect on serum markers of inflammation, blood lipids, fasting blood sugar, percentage body 
fat, or fecal SCFA. Metabolomics of plasma showed an increase in 3-hydroxyhippurate 
following SS consumption, and a reduction of three gamma-glutamyl AAs. Targeted fecal 
metabolite quantification revealed increased concentrations of 3-(3-hydroxyphenol)propionic, 3-
phenylpropionic, and benzoic acid, and reduced quinic acid following 100 g/day SS 
consumption. Correlation between plasma metabolites and fecal microbes revealed hippurate 
was positively correlated with Akkermansia, while Faecalibacterium was negatively associated 
with several gamma-glutamyl amino acids. 
Both DP and SS modified the colon metabolome and microbiome, increased putatively 
beneficial bacteria and microbially-derived compounds associated with positive health outcomes. 
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GO  gene ontology 
HAT  histone acetyltransferase 
HDAC  histone deacetylase 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW* 
 
Introduction 
Colon cancer is associated with various risk factors including abdominal obesity, chronic 
inflammation, and mutagen exposure (2-6). The classically-defined hallmarks of cancer are: 1) 
self-sufficiency in growth signals, 2) insensitivity to growth-inhibitory signals, 3) evasion of 
apoptosis, 4) limitless replicative potential, 5) sustained angiogenesis, and 6) tissue invasion and 
metastasis (7, 8). More recently, two emerging hallmarks of cancer have been proposed: 1) 
deregulated cellular energetics, and 2) avoidance of immune destruction (9). Indeed, cancer cells 
are known to exhibit altered metabolism (i.e., the Warburg effect) (10-12). In addition, tumor-
promoting inflammation, and genome instability and mutation have been proposed as cancer 
enabling characteristics (9). Alterations in the epigenome, such as global hypomethylation and 
site-specific hypermethylation of tumor suppressor genes, regulate gene expression patterns and 
have been associated with colon carcinogenesis (13). 
The fundamental model of sporadic cancer development involves three steps: initiation, 
promotion, and progression (14). Initiation refers to an irreversible mutation event in the DNA 
sequence following exposure to mutagens, such as ionizing radiation, aromatic amines, 
polycyclic hydrocarbons, and oxygen free radicals (14, 15). Promotion is characterized by 
alterations in cell apoptosis and proliferation that occur intrinsically in response to initiation 
                                                 
* Part of this chapter is reprinted with permission from Shaping functional gut microbiota using dietary bioactives to reduce 
colon cancer risk by Seidel DV, Azcarate-Peril MA, Chapkin RS, and Turner ND, 2019. Semin Cancer Biol. 2017 Oct;46:191-




(e.g., overexpression of mutant p53) and/or to promoters that drive proliferation and/or inhibit 
apoptosis of initiated cells (14). Progression is characterized by structural changes in cell 
karyotype, further accumulation of genetic mutations, anaplasia, development of malignant 
neoplasms, as well as tumor invasion and metastatic growth (14, 16). Interestingly, cells within 
the primary tumor are known to harbor heterogeneous mutation profiles making targeted 
treatment strategies more difficult (16). Therefore, significant efforts are made to inhibit 
carcinogenesis at the initiation and promotion stages. 
Colon epithelial cells exist in a mutualistic relationship with bacteria residing in the 
lumen. The gut microbiota is estimated to contain over 1,000 different ‘species-level’ phylotypes 
(17). One recent metagenomics study reported a microbial gene catalog of 3.3 million genes, 
which is ~150 times larger than the human gene complement (17-19). The microbial 
metagenome permits a repertoire of metabolic functions that supplement host metabolism, and 
the gut microbiota has been implicated in a number of physiological processes, including 
modulation of intestinal motility, regulation of luminal pH, stimulation of immune function, and 
metabolism of undigested food (20). Dysbiosis refers to perturbations in microbial populations, 
and has been linked to obesity, cancer, and promotion of colonic inflammation (e.g., 
inflammatory bowel disease (IBD) and colitis) (3, 21-26). Inflammation can occur in response to 
a variety of biological insults, including infection by pathogens, immune sensitivity, 
autoimmunity, and exposure to ionizing radiation, and has been implicated in both sporadic 
colorectal cancer (CRC) and colitis-associated colon cancer (CAC) (3, 6, 27-30). 
Diet is a major contributor to mammalian health and metabolism, and research has 
demonstrated that diet also contributes to the composition and metabolism of the gut microbiota 




whole grains reduces CRC risk (33-35). The chemoprotective activity afforded by fruit, 
vegetable, and whole grain consumption is believed to be due to the fiber content, antioxidant 
compounds, and other bioactive compounds (i.e., extra-nutritional elements of food that can 
affect living tissue) (33, 34, 36). Diets containing bioactive compounds that directly inhibit 
proliferation and promote apoptosis of transformed cells are promising strategies for the 
prevention of colon cancer. Additionally, certain food constituents can undergo metabolism by 
the microbiota to produce secondary bioactive compounds that then affect host physiology, such 
as the fermentation of dietary fiber into short-chain fatty acids (SCFA) (37-41).  
Literature Review 
Host and microbe-associated alterations as contributors to colon carcinogenesis 
Epithelial perturbations and their outcomes 
Colonocytes serve several important functions including nutrient absorption, mucin 
secretion, and endocrine activity. The differentiated cell types performing these functions are 
derived from stem cell precursors that reside at the base of the intestinal crypt (42). To date, 
there has been extensive debate regarding the identity of stem cells within the colon crypt. 
However, the leucine-rich-repeat-containing G-protein-coupled receptor 5 positive (Lgr5+) crypt 
base columnar cells are a strong candidate, as these cells undergo cell division daily and their 
daughter cells constitute the transit-amplifying crypt compartment (42). Furthermore, lineage 
tracing studies using an inducible Cre knock-in allele and the Rosa26-lacZ reporter strain have 
demonstrated restricted expression of Lgr5+ cells to the base of the crypt that can generate all 
epithelial lineages over a 60-day period (42, 43). Daughter cells derived from the stem cell 
population will continue to divide and eventually differentiate into mature colonocytes as they 




cells, which are lost at the luminal surface via sloughing or spontaneous apoptosis, are normally 
replaced at an equal rate by proliferating cells (44). Coordinated proliferation and migration of 
colonic epithelial cells are necessary for the maintenance of barrier function and epithelial 
restitution following an injury to the epithelial cells (44, 45). 
Adult colon stem cells sustain self-renewal and are target cells for cancer-initiating 
mutations (43, 46). Tissue-specific mutation accumulation in colon stem cells resulting in 
alterations in differentiation/plasticity, and stem cell location/proliferation are generally believed 
to represent the earliest step towards colon tumorigenesis (47, 48). The onset of colon 
tumorigenesis is often driven by mutations in the Wnt signaling pathway (49-51). Specifically, 
adenomatous polyposis coli (APC) loss-of-function or β-catenin gain-of-function mutations 
result in stabilization of free β-catenin, which leads to aberrant Wnt signaling that can drive 
tumorigenesis (49-51). Importantly, mutational activation of the Wnt pathway in Lgr5+ cells 
gives rise to intestinal tumors with greater efficiency than other intestinal cell types (43). 
According to the cancer stem cell hypothesis, the population of cells that propagate tumor 
formation is self-renewing and multipotent (52). Thus, intestinal stem cells are considered the 
cell-of-origin of cancer because these cells already exhibit self-renewing capacity and 
multipotency (42, 43, 53). In addition to the concept that cancer stem cells are the direct products 
of neoplastically transformed normal adult stem cells, there is also evidence that transit 
amplifying cells with mutant genomes can dedifferentiate and enter the stem cell state (54). 
Adding to the complexity, recent evidence indicates that multiple stem cell hierarchies exist in 
the intestine and that plasticity within stem cell hierarchies mediates cellular fate in response to 
extrinsic factors such as nutrition, inflammation, and physical stress signals (55-59). 




Although the expansion of initiated cells is required for tumor formation, previous work 
has shown cell proliferation to be a poorer predictor of tumor development than markers of 
differentiation and apoptosis (64). Furthermore, tissues with relatively higher rates of 
proliferation do not appear to exhibit a higher incidence of spontaneous tumor development (65). 
Apoptosis is a key regulator of physiological development and tissue homeostasis (66). To date, 
two major mechanisms of apoptosis induction in mammalian cells have been elucidated in detail. 
The extrinsic (i.e., death receptor) and intrinsic (i.e., mitochondrial) apoptosis pathways involve 
caspase activation cascades leading to controlled cell death (66). The extrinsic apoptosis pathway 
requires activation of membrane receptors of the tumor necrosis factor (TNF) receptor 
superfamily such as CD95 (APO-1/Fas) or TNF-related apoptosis-inducing ligand (TRAIL) 
receptors (66, 67). Activation of the intrinsic pathway, which is often dysregulated in colon 
cancer, involves mitochondrial outer membrane permeabilization (MOMP) and subsequent 
release of cytochrome c and other proteins from the mitochondria, triggering caspase-3 
activation through the formation of an apoptosome complex (68, 69). B-cell lymphoma-2 (Bcl-2) 
family proteins, among other factors, regulate the intrinsic mitochondrial apoptosis pathway and 
appear to dictate the sensitivity or resistance of the cell to apoptosis induction (69-71). 
Activation of the intrinsic pathway in response to DNA damage provides a mechanism whereby 
DNA damaged cells can be removed from the tissue, thus preventing the propagation of 
transformed cells or retention of mutated progenitor cells (69). Inhibition of apoptosis is an 
important mechanism of tumor promotion that can arise from genetic and epigenetic alterations 
(e.g., p53 loss-of-function mutations or bcl-2 promoter hypomethylation, respectively) and 
exposure to chemical promoters (72-75). Additional evidence of epigenetic alterations 




MutL homolog 1 (hMLH1), which has been linked to microsatellite instability (MSI) associated 
colon carcinogenesis (76). Therefore, dietary bioactives targeting the colonocyte epigenome are 
promising strategies for reprogramming aberrant processes associated with colon cancer, such as 
inhibition of apoptosis in transformed cells (14, 73, 77).  
The unique molecular and genetic features observed in normal and diseased tissues of the 
proximal and distal colon reveal differing susceptibilities and mechanisms for disease initiation. 
One study examining gene expression profiles carried out on healthy adult human biopsy 
samples revealed more than 1000 differentially expressed genes between the ascending and 
descending colon (78). The Cancer Genome Anatomy Project (CGAP) functional grouping of 
the differentially expressed genes revealed major pathways implicated in colon cancer including 
epidermal growth factor (EGF), transforming growth factor beta (TGF-β), Wnt, Ras, insulin, and 
integrin signaling (78). Differences in gene expression between the proximal and distal colon 
may result from the observed differential DNA methylation patterns in colonocytes (79). Studies 
comparing cancers of the proximal and distal colon have revealed numerous differences in 
molecular and clinicopathological features, which reflect different susceptibilities to neoplastic 
transformation, such as the frequency of V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene 
Homolog (KRAS) and B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) mutations, and 
the prevalence of MSI (80-82). In response to dietary fiber and carcinogen treatment, differences 
in colonocyte proliferation and differentiation between the proximal and distal rat colon have 
been observed (83). Furthermore, it is well documented that the gut microbiome is spatially 
heterogeneous, forming discrete microbial communities throughout the intestinal tract that 
differentially affect the host physiology (84).  Research into the unique characteristics of these 




As mentioned previously, inflammation is a known promoter of sporadic colon cancer 
and CAC. Although the cause of onset remains unknown, CAC is characterized by elevated 
reactive oxygen species (ROS), increases in pro-inflammatory cytokines and elevated expression 
of transcription factors involved in inflammation signaling (3). This chronic inflammation can 
lead to genome instability and mutations in critical regulatory genes, such as the tumor 
suppressor gene, p53, that can drive carcinogenesis (27, 72, 85). For example, we have recently 
demonstrated that loss of p53 function in stem cells enables colonic tumor formation only when 
combined with DNA damage and chronic inflammation (53). In sporadic CRC, inflammation is 
often a result of immune cell migration to the tumor site where activated immune cells produce 
ROS, reactive nitrogen intermediates, and pro-inflammatory cytokines, which can further 
damage DNA and drive cell proliferation (3, 30, 86). Additionally, there is evidence linking 
inflammation to carcinogenesis via epigenetic modifications at critical regulatory gene loci (87-
90). It is apparent that inflammation can impact all stages of colon cancer development, and 
nutritional strategies aimed at modulating inflammation and ROS production may help mitigate 
disease risk. 
Changes to microbiome/metabolome and their role in tumorigenesis 
Currently, investigations into the physiological mechanisms by which the microbiota can 
influence colon cancer risk are limited due to the diversity and complexity of the microbiota. 
Despite the ongoing discussion concerning whether changes in the microbiota occur prior to or 
as a result of colon carcinogenesis, some significant observations have been made that suggest a 
causal role of the microbiota in the disease process. For example, studies employing rodent 
models of spontaneous, chemically-induced (e.g., azoxymethane, AOM), or genetically 




raised animals versus germ-free or antibiotic-treated animals, suggesting a promotive effect of 
the microbiota on tumor formation (91-97). Often, the enhanced tumorigenicity in 
conventionally raised mice is attributed to microbially-sustained levels of chronic low-grade 
inflammation that acts as a tumor promoter. However, activation of the innate immune system 
through toll-like receptor (TLR) and NOD-like receptor (NLR) agonists has been shown to 
enhance anti-tumor activity of the innate immune system (98, 99). Taken together, these 
observations suggest a double-edged role of the microbiota in colon carcinogenesis that may be 
dependent on the degree and mechanism of the innate immune response activation.  
Because inflammation is a known driver of CRC, work has been conducted to better 
understand how the microbiota are altered by, or contribute to, pro-inflammatory states. A recent 
metagenomics study revealed that the fecal microbiome of patients with IBD has, on average, 
25% fewer microbial genes than individuals not suffering from IBD (19). These findings are in 
agreement with other studies documenting a reduction in gut microbe diversity in association 
with IBD (100-102). An experimental animal model of IBD has shown that increases in colonic 
injury are negatively associated with Firmicutes, Actinobacteria, Lactobacillales and 
Lactobacillus (103). Dysbiosis has also been observed following spaceflight and radiation 
exposure in rodent models demonstrating the susceptibility of the microbiota to environmental 
factors other than the host diet (104). These observations suggest that microbial dysbiosis may 
act as a driver and/or may be a consequence of colon disease development.  
Fecal profiling experiments of CRC patients and healthy subjects have revealed 
numerous taxonomic differences in the microbiota and these findings should be useful in 
directing mechanistic studies. The 454 pyrosequencing of fecal samples from 46 CRC patients 




segregation of normal and CRC samples by UniFrac analysis (105). OTUs belonging to the 
genera Enterococcus, Escherichia/Shigella, Klebsiella, Streptococcus, and Peptostreptococcus 
were significantly more abundant in CRC patients. Conversely, OTUs related to the genus 
Roseburia and other butyrate-producing members of Lachnospiraceae were less abundant in 
CRC patients. In addition, quantitative polymerase chain reaction (qPCR) analysis of microbial 
butyrate synthesis genes confirmed lower levels of butyrate-producing bacteria in CRC patients, 
supporting the identity of butyrate-producing microbes as contributors to intestinal health. These 
observations were similarly replicated in a more recent study that found nine OTUs represented 
by the butyrate-producing genera Faecalibacterium and Roseburia to be significantly less 
abundant in CRC patients versus healthy control subjects (106). Another study revealed a greater 
presence of Fusobacterium nucleatum and Enterobacteriaceae in CRC patients versus healthy 
control subjects (107).  
In addition to overall changes in the gut microbiota of CRC patients versus healthy 
controls, there is evidence demonstrating microbial differences between normal and diseased 
tissue sites within a given individual. One study characterizing the microbial structure of the 
intestinal lumen, cancerous tissue, and matched noncancerous normal tissue, revealed numerous 
differences between these sampling sites (108). Microbial diversity was significantly lower in 
tumor tissue than noncancerous tissue, suggesting a more selective microenvironment exists in 
proximity to diseased tissue. In cancerous tissue, Lactobacillales was enriched, whereas 
Faecalibacterium was reduced. With respect to mucosa-adherent bacteria, Bifidobacterium, 
Faecalibacterium, and Blautia were reduced in CRC patients whereas Fusobacterium, 
Porphyromonas, Peptostreptococcus, and Mogibacterium were increased. Lastly, in the lumen, 




Erysipelotrichaceae, Prevotellaceae, and Coriobacteriaceae, were increased in CRC patient 
samples. In another study, a lower abundance of Staphylococcus and Bacillus and a higher 
abundance of Escherichia-Shigella and Prevotella were observed in polyp-derived mucosal 
samples compared to adjacent healthy tissue biopsies (107). Altogether, these findings suggest 
certain bacteria may better compete in the transformed niche and that characterizing these 
microenvironments could reveal novel mechanisms by which the microbiota influence disease 
progression.  
Metabolomics analysis of CRC patients versus healthy controls is a useful tool for 
investigating alterations in co-metabolism or metabolic exchange between host cells and the gut 
microbiota and permits identification of novel CRC metabolite biomarkers. Studies of the fecal 
metabolome have revealed alterations in SCFA, amino acid (protein), and unsaturated fatty acid 
metabolism in CRC patients (109). Another study using serum samples from colorectal adenoma, 
CRC, or healthy control subjects, revealed pathways for urea, caffeine, and galactose metabolism 
were related to CRC progression (110). Similar to microbial observations between normal and 
diseased tissue, metabolomics analyses have revealed different metabolite signatures between 
stool, cancers, and healthy adjacent mucosa (111). In that study, metabolic pathway analysis of 
significantly different metabolites revealed aberrant SCFA metabolism, fructose, mannose, and 
galactose metabolism, and glycolytic, gluconeogenic, and pyruvate metabolism in CRC tissue of 
17 CRC patients, versus healthy adjacent tissue. Furthermore, whereas nearly all of the 
metabolites detected in CRC tissue were found in adjacent mucosa, less than 50% of metabolites 
(213 out of 500 total metabolites) detected in the stool were shared with either tissue site. These 




sampling sites to enhance biomarker discovery and personalized treatment and prevention 
strategies.  
To define a beneficial microbiota composition that is capable of suppressing CRC, it will 
be important to first understand the mechanisms by which the microbiota can predispose host 
cells to carcinogenesis. Some bacteria have been shown to directly initiate carcinogenesis via the 
production of toxins that can damage DNA (112). For example, colibactin toxin produced by E. 
coli belonging to the B2 phylogroup causes DNA crosslinks and double strand breaks (DSB) that 
can lead to mutations (113). Bacteroides fragilis toxin is known to activate Wnt and NF-κB 
signaling pathways, increase cell proliferation, enhance epithelial release of pro-inflammatory 
molecules, and induce DNA damage in vitro (114-116). More recently, the gene encoding 
Bacteroides fragilis toxin was found to be more abundant in tumor mucosa samples than control 
biopsies, especially in late-stage CRC, suggesting that the bacteria capable of synthesizing the 
toxin play a persistent role in promoting tumor growth through sustained activation of tumor-
promoting pathways (117). The Salmonella protein AvrA has recently been shown to activate the 
STAT3 pathway in a CAC mouse model (AOM plus dextran sulfate sodium, DSS) (118). The 
role of the STAT3 pathway and signaling in colon cancer has been well established (119-122). 
Indirect effects of specific bacteria on carcinogenesis have been characterized that are largely 
dependent on the immune system for manifestation. In addition to inducing DNA modifications, 
the E. coli strain that produces colibactin has recently been shown to encourage pro-tumoral 
activities of tumor-associated macrophages by infecting and persisting within the immune cells. 
As a result, these bacteria induce sustained cyclooxygenase-2 (COX-2) expression by 
macrophages, which is a hallmark of the inflammation associated with colon cancer (123). A 




by Wang and Huycke (124) in which macrophage polarization to an M1 phenotype by 
commensal bacteria leads to a trans-4-hydroxy-2-nonenol (4-HNE) mediated bystander effect in 
colon epithelial cells. The 4-HNE released by M1 macrophages in response to commensal 
invasion during periods of intestinal barrier dysfunction causes mutations, DSB, and spindle 
dysfunction leading to CIN in epithelial cells. Taken together, these experiments demonstrate the 
potential of direct and indirect mechanisms of the gut microbiota to initiate and promote colon 
carcinogenesis. 
Radiation effects on colon physiology and microbiota  
Ionizing radiation (IR) is a form of radiation which is capable of removing electrons from 
atoms and can take the form of particles (e.g., electrons, protons, neutrons, heavy charged 
particles, etc.) or electromagnetic waves (e.g. x-rays and gamma rays) (125). Linear energy 
transfer (LET) refers to the energy transferred from the radiation source to the medium per unit 
length of the track (125). In radiation biology, the medium is the tissue or cells that the particle 
traverses as it deposits energy. In general, electromagnetic radiation is considered low LET and 
particulate radiation is considered high LET (125). High LET radiation is densely ionizing and 
the DNA damage it creates is more difficult to repair than sparsely ionizing low LET radiation 
(125). In space, astronauts are exposed to ionizing radiation emitted from the Sun (i.e., solar 
radiation) and from other celestial bodies (i.e., galactic cosmic radiation; GCR) (126). Solar 
radiation is mostly protons and electrons of lower energy than GCR, which is composed mostly 
of high energy protons (83%), alpha particles (14%), high charge, high energy ions (HZE, 1%), 
and electrons (2%) (126). Both particulate and electromagnetic ionizing radiation can damage 
DNA directly by ionizing atoms in the DNA molecule (125). Alternatively, ionizing radiation 





-) and hydroxyl radicals (OH-), which can interact with the DNA molecule (125, 
127). This DNA damage can manifest as base pair loss, base modification, single or double 
strand breaks, cross-links, and chromosomal aberrations (125). Following DNA damage 
recognition, a cell may undergo apoptosis immediately, or may initiate p53-dependent cell cycle 
arrest in order to repair the damage (128). If the repair process is successful, the cell may 
continue as normal; however, incorrect repair can lead to mutations, chromosome aberrations, 
and/or genomic instability, which can lead to cell death or fixation of the mutation in the genome 
(128). Thus, the decision between life and death for the cell is related to the complexity of the 
DNA damage, the fidelity of the repair process, the ratio of proteins involved in the regulation of 
apoptosis (e.g., bax, bcl-2, etc.), and the presence of survival and death signals (128). In 
summary, DNA damaged cells that avoid apoptosis, or fail to correctly repair the damage, can 
develop tumor-initiating mutations that lead to carcinogenesis.   
A recent estimate for the shortest round trip to Mars (180 days without surface time) 
indicates an equivalent dose of 0.66 Sievert (Sv) (129). To put this into perspective, the current 
career limit imposed on astronauts is 1 Sv, which corresponds to an increased risk of fatal cancer 
of approximately 5.5% (129).  The most recent estimates for probability of causation for cancer 
risk indicate the colon to be the third most susceptible organ-site to tumorigenesis following 
exposure to GCR (130).   
Microbial dysbiosis has been observed following spaceflight and radiation exposure in 
rodent models (104). These observations suggest that microbial dysbiosis may act as a driver 
and/or a consequence of disease development in these experimental conditions. Therefore, 
understanding how diet and other environmental factors, such as radiation exposure, can affect 




Dietary interventions aimed at modulating dysbiosis directly (i.e., probiotics) or by promoting 
the growth of beneficial bacteria (i.e., prebiotics) may be advantageous for at risk populations, 
such as astronauts. 
Dietary mediators of colon tumorigenesis 
A recent review points to the importance of many different diet-derived biologically 
active compounds in the inhibition of carcinogenesis (8). Dietary compounds may reach the 
colon because they are: 1) too large to be absorbed in the small intestine, 2) bioavailable 
compounds that escape deglycosylation and absorption in the small intestine, or 3) aren’t 
accessible to the host due to their intercalation in the food matrix (40). Those compounds 
absorbed in the small intestine, conjugated by the liver, and returned to the intestine via 
enterohepatic circulation also may reach the large intestine (40). Additionally, there is research 
to suggest that processing bioactive-containing foodstuffs can affect the bioaccessibility of 
bioactives, which may result in some molecules reaching the colon that otherwise might have 
been absorbed in the small intestine (131, 132). 
Dietary bioactives have the potential to directly modify and/or mitigate tumorigenic 
processes via multiple pathways. These pathways may be microbe-independent (i.e., direct) or 
microbe-dependent (i.e., indirect), or both. Microbe-independent bioactivity refers to actions of 
the non-metabolized bioactive compounds directly on host cells and tissues, which we would 
anticipate also observing in a germ-free animal. Alternatively, microbe-dependent pathways 
would depend on the metabolism of the native bioactive compound by the microbiota into 
secondary metabolites that then exert some bioactive function. Furthermore, the microbe-
dependent process could refer to diet-induced modifications to the number, composition, and/or 




metabolites from non-bioactive substrates (e.g., bioactive compounds selecting for microbes that 
more effectively generate SCFA from dietary fiber) (133). Indeed, some dietary components 
exert bactericidal functions and are, therefore, direct modifiers of the gut microbiota (134-136). 
Similar to the observed differences in physiology and cancer phenotype/genotype between the 
proximal and distal colon mentioned previously, the composition of the microbiota is also known 
to differ spatially along the colorectal axis and between mucosal and luminal sites (18, 137, 138). 
The observed differences between lumen- and mucosa-associated microbial communities likely 
reflect the nature of the host-microbe interaction for these sub-populations and importantly, the 
availability of their preferred substrates. 
The most often ascribed function of dietary bioactives, particularly for polyphenolics, is 
their antioxidant capacity, and studies have estimated that 90-95% of dietary polyphenols escape 
absorption in the small intestine due to their size (139). The gut microbiota are capable of a 
variety of metabolic reactions that affect the structure and functional groupings of bioactives 
including ring-C cleavage, dehydroxylation, decarboxylation, deglycosylation, and 
demethylation (40). Indeed, there is substantial evidence that much of the biological response to 
dietary bioactives is due to microbial derivatives rather than the native compounds (140-143). A 
large consortium of authors reviewing the potential of bioactive compounds in cancer inhibition 
stressed the importance of exposure to these molecules during the early stages of cell 
transformation (8). They noted their efficacy is greatest during this time when most of the 
cellular changes are likely to be epigenetic in nature. 
Fiber and prebiotics 
Nondigestible carbohydrates (i.e., dietary fiber) pass through the small intestine into the 




Many bacteria preferentially metabolize carbohydrates over other energy sources such as protein 
(145). Predominantly saccharolytic fermentation occurs in the cecum and proximal colon of 
humans and rodents, where most SCFA production takes place (146-148). The metabolic fate of 
fiber depends largely on the solubility/fermentability of the fiber itself and the microbiota present 
in the colon during digestion (149). Readily fermentable fibers such as oat bran, pectin, and guar 
are easily fermented by the microbiota to produce methane, carbon dioxide, and SCFA, whereas 
cellulose and wheat bran are poorly fermented (149, 150). Acetate, propionate, and butyrate are 
the most abundant SCFA in the colon, and concentrations typically decrease from the proximal 
to the distal colon (18, 80). Benefits of consuming both readily fermentable and poorly 
fermentable fibers have been established, with the latter being due to its hydrophilic bulking 
activity, which serves to dilute carcinogens, pro-carcinogens, and other potential tumor 
promoters in the intestinal lumen (151). Furthermore, stool-bulking agents have also been shown 
to increase the rate of digesta passage through the intestine, which can both minimize exposure 
to toxic compounds in the lumen and increase the levels of butyrate in the distal colon (152). In 
rats exposed to AOM, consumption of a wheat bran diet significantly lowered tumor incidence 
compared to animals consuming an oat bran diet (153). In addition, consumption of the wheat 
bran diet was associated with lower body weight, more normalized ratios of SCFA in the 
intestinal lumen, and increased fecal mass and bulk, which suggests increased bulking ability and 
dilution potential of wheat bran versus the more readily fermentable oat bran diet. 
If dietary fiber and resistant carbohydrates are limiting, the gut microbiota in the distal 
colon will need to rely on proteolytic fermentation to meet their energy needs (145). Proteolytic 
fermentation results in SCFA, along with a number of putatively toxic metabolites such as 




butyrate utilization as a high protein diet has been found to decrease expression of the proton 
coupled monocarboxylate transporter 1 (MCT1, a butyrate transporter) in the colon of piglets 
(154). In contrast, Liu et al. found no effect of dietary protein on MCT1 expression or luminal 
butyrate levels in rats (155). 
Butyrate is a four carbon SCFA and the preferred energy substrate of colonocytes (156). 
In healthy humans, absolute concentrations of butyrate range from 11 to 25 mM in the feces 
(148). Bacteria synthesize butyrate from butyryl-coenzyme A (CoA) derived from acetyl-CoA 
using one of two enzymes, butyrate kinase or butyryl-CoA:acetate-CoA transferase (157). 
Butyrate is absorbed by colonocytes via passive diffusion and by active transport with various 
ion exchange transporters, such as the sodium-coupled monocarboxylate transporter 1 (Slc5a8) 
and MCT1 (also known as Slc16a1) (148). Butyrate has been intensively studied for its ability to 
inhibit inflammation and carcinogenesis, reduce oxidative stress, and promote colonic barrier 
function (148). Butyrate has also been shown to affect gene expression via epigenetic 
modification of chromatin. In cancer cells exhibiting the Warburg effect, butyrate accumulates in 
the cell and inhibits histone deacetylase (HDAC) activity and stimulates histone acetyltransferase 
(HAT) activity by acting as an acetyl-CoA donor, thereby regulating genes that enhance 
apoptosis and reduce cell proliferation (156, 158). Our lab has demonstrated increased bcl-2 
promoter methylation and levels of apoptosis in rats consuming a fish oil and pectin diet versus 
animals consuming a diet containing corn oil and cellulose (73). Additional in vitro experiments 
demonstrate butyrate’s ability to reduce global and Bcl-2-like protein 11 (BCL2L11) promoter 
methylation in HCT-116 colon cancer cells (77). These data support the identity of butyrate as a 
modifier of the epigenome and promoter of apoptosis in colon cancer cells. Colonic mucosa from 




synthase (iNOS), a marker of inflammation, in addition to genes of the interferon gamma (IFN-γ) 
and TGF-β signaling pathways compared to wild-type mice (159). Indeed, Slc5a8 plays a critical 
role in the ability of butyrate to suppress colon inflammation and cancer (160-162). Additionally, 
butyrate was shown to suppress colonic inflammation by two mechanisms: 1) inhibition of 
STAT1 phosphorylation by IFN-γ in colonic epithelial cells leading to a reduction in iNOS 
expression, and 2) inhibition of Fas promoter-bound HDAC1 leading to increased T cell 
expression of Fas and, thus, enhanced sensitivity to apoptosis of activated T cells thereby 
reducing T cell production of IFN-γ (159). Butyrate has also been shown to induce apoptosis via 
a non-mitochondrial, Fas-mediated, extrinsic pathway in colonocytes (163, 164).  
Research has also demonstrated the ability of SCFA to affect immune function. Kim et al. 
recently demonstrated that SCFA impact the metabolism of B lymphocytes by increasing acetyl-
CoA levels, oxidative phosphorylation, glycolysis, and fatty acid synthesis, and that these 
changes in metabolism support the production of antibodies necessary for preventing infection 
by pathogens (165). SCFA were also found to regulate gene expression programs needed for 
plasma B cell differentiation. Importantly, dietary fiber and SCFA both increased intestinal 
(Immunoglobulin A, IgA) and systemic (IgA and IgG) antibody levels supporting the notion that 
the gut microbiota, by way of metabolism of dietary fiber, promotes systemic immunity. The gut 
microbiota and its metabolites (SCFA, particularly butyrate) have also been shown to affect the 
differentiation of naïve T cells in the gut epithelium (166). The mechanisms responsible for the 
differentiation of naïve T cells into Treg cells include direct actions of butyrate on naïve T cells 
(i.e., histone H3 acetylation at the Foxp3 locus and Gpr109a activation) and indirect actions via 




Taken together, these observations support a pleiotropic role of butyrate on the colon 
epithelium as a modulator of inflammation and colonocyte physiology. Interestingly, there is 
some evidence that butyrate may promote colon tumorigenesis (167-169) or that some dietary 
interventions reduced colon carcinogenesis in a manner not related to fecal butyrate levels (153). 
These findings suggest that microbial metabolites such as short chain fatty acids contribute to 
colon cancer risk in a complex, context-dependent manner. Additional work needs to be 
conducted to better understand how gut microbial metabolites impact gut health. Specifically, 
understanding how other dietary components may interact with microbial metabolite production 
and their effects on host tissue should be explored if we are to identify dietary patterns capable of 
suppressing colon carcinogenesis. 
Phenolic bioactives and other small bioactive compounds 
Most fruits and vegetables contain bioactive compounds. The phytochemical profile can 
vary between different varieties of the same food and can be influenced by how the foods are 
processed (170-172). The concentration of phytochemicals also varies throughout the fruit (e.g. 
seed, peel, pulp) and is typically highest in the fruit peel where the compounds function as 
antioxidants to prevent damage from ultraviolet radiation (173, 174). Many phytochemicals are 
known to have anti-microbial and anti-inflammatory properties (175-177). The mechanisms by 
which the compounds exert these effects in vivo and to what extent they are absorbed and 
metabolized by the host and gut microbiota remains to be fully characterized. For example, 
polyphenols are a structural class of phytochemicals with multiple phenolic units found naturally 
in fruits, vegetables, and whole grains (178-181). Numerous studies have revealed 
chemoprotective effects of polyphenolic compounds in vivo and in vitro (182-185). Additionally, 




mechanisms (186-188). The bioavailability of polyphenols varies depending on the individual 
compound; however, it has been shown that human colonic bacteria can metabolize polyphenols 
into lower-molecular-weight bioactive compounds, which may be more bioavailable to the host 
(141, 185, 189, 190). Further, consumption of dietary polyphenols is known to alter the 
composition of the gut microbiota, which can affect host health (191-193). Understanding how 
foods containing dietary polyphenols can shape the microbiota composition and metabolism will 
be important for defining bioactive profiles. Likewise, characterizing the metabolites generated 
from microbial metabolism of polyphenols, and their presence in the intestinal lumen and 
systemic circulation will be important for future studies seeking to elucidate biomolecular 
mechanisms. 
Because a whole food (e.g., fruit or vegetable) and combinations of foods contain a 
mixture of bioactive compounds in combination with the micro and macronutrients of the food, it 
will be important to characterize how compounds synergize in vivo. Within a whole food, such 
as prunes (dried plums), there are a variety of bioactive compounds including phenolic acids 
(e.g., quercetin, chlorogenic acid, and neochlorogenic acid), sugar alcohols (e.g., sorbitol and 
mannitol), and hydroxycinnamic acids (e.g., sinapinic acid), as well as a mixture of soluble and 
insoluble fiber (194, 195). Prune consumption is commonly associated with a reduction in 
constipation and improved intestinal motility (194). These effects can be attributed in part to the 
dietary fiber found in prunes; however, they are also noted when consuming prune juice, which 
lacks the insoluble fiber found in the whole fruit. Hence, not all of the bioactive properties 
ascribed to prune consumption are due to its fiber content. Our lab has shown that quercetin and 
chlorogenic acid influence fecal SCFA concentrations, suggesting alterations in the gut 




demonstrated the ability of quercetin to reduce the numbers of high multiplicity aberrant crypt 
foci (HMACF), which are thought to be most indicative of eventual tumor formation (197, 198). 
A reduction in proliferation and an increase in apoptosis were also observed in rats fed quercetin, 
and these effects are thought to be related to observed reductions in pro-inflammatory mediators, 
cyclooxygenase 1 and 2 (COX-1 and COX-2) (198), as well as through impacts on other 
signaling pathways including NF-κB, PI3K/Akt/mTOR, and JNK/JUN (198-201). Quercetin has 
also been shown to reduce the incidence, multiplicity, and size of colorectal tumors in male F344 
rats treated with AOM, compared to control diet animals (202). Sorbitol is a sugar alcohol found 
in high concentrations in dried plums and contributes to the laxative effect associated with prune 
consumption (203). Sorbitol has been shown to induce apoptosis in HCT-116 cancer cells via 
activation of the p38 mitogen-activated protein kinase (MAPK) pathway, which activates the 
mitochondrial death cascade (204). Additionally, in rats consuming a dried plum powder, 
analysis of the microbial metagenome revealed a reduction in the relative abundance of 
microbial genes responsible for the synthesis of secondary bile acids, which are known to induce 
DNA damage and promote colon cancer (205-207).  
Another major source of dietary phytochemicals is whole grains (179, 208). For example, 
sorghum is an ancient grain predominantly grown in dry, arid zones. Sorghum varieties contain 
different levels and types of phenolic and polyphenolic compounds (179). Sumac sorghum 
contains high levels of condensed tannins (i.e., polymerized flavonols), which contribute to its 
high phenolic content and oxygen radical absorbance capacity (179). Indeed, sumac sorghum has 
been characterized as having greater antioxidant capacity than many other grains, blueberries, 
and pomegranates (209, 210). Decortication of the sorghum grain to produce sorghum bran 




(210). Our lab has previously shown that polyphenol-rich sorghum brans alter the microbial 
composition and beneficially affect microbial diversity and richness in a rat model of colitis 
(103). In addition, we have shown that less soluble fibers with lower fermentability, such as 
sorghum bran and cellulose, are more protective against colonic injury during bouts of colitis 
than highly fermentable fibers, such as pectin (211). Although these findings are in contrast to 
the previously discussed protective effects of soluble fibers during carcinogenesis, it is evident 
that fibers of varying fermentability/solubility exert their effects on the colonic mucosa in a 
disease-dependent context that likely depends on the composition of the gut microbiota. 
Furthermore, our lab has demonstrated that diets containing sumac bran alter fecal SCFA levels, 
suggesting these polyphenol-rich fiber sources may alter microbial metabolism or host SCFA 
absorption (212). 
As previously mentioned, it will be important to characterize the mechanisms by which 
dietary bioactives exert their chemoprotective activities in order to better understand how 
specific phytochemicals can prevent or inhibit specific diseases. This includes identifying and 
characterizing receptors for native phytochemicals and their microbial metabolites.  
Integrating microbiome, metabolome, and gene expression/pathology data  
The ultimate goal for microbial community profiling is to accurately assess which 
microbes are present in a sample and their collective genomes (metagenomics), the genes being 
transcribed and proteins translated (metatranscriptomics and metaproteomics, respectively), and 
the metabolites present (metabolomics). Indeed, the composition of bacteria between individuals, 
in terms of taxonomic identity, tends to be more unstable than the functional profile of a 
microbiome sample (213-215). A recent study employing systematic comparison of 




of microbial gene transcripts were not differentially regulated relative to their genomic 
abundance and that the microbial transcriptome profile was significantly more individualized 
than the metagenome profile (223). Metabolome profiling enables the relative assessment of 
thousands of metabolites including microbe-, diet-, and host-derived molecules and represents an 
instantaneous index of the combined cellular processes taking place in the sample. However, 
because of the complexity of system being sampled, it will be difficult to attribute the production 
of specific metabolites with specific bacteria, especially when the genes responsible for encoding 
a given function are conserved across species. More work will be needed to determine which 
level of information provides the best opportunity to study specific physiological and ecological 
states.  
The challenge of integrating multiple ‘omics’ profiles, such as microbe and host 
functions occurring simultaneously, was a goal of the second phase of the Human Microbiome 
Project (HMP), termed the Integrative Human Microbiome Project (iHMP) (216). The 
consolidation of data from these and other similar projects into in silico networks, will allow the 
study of the dynamic interactions occurring between the host and the microbiome during various 
disease states to identify causal bio-molecular mechanisms for targeted study. For example, 
research conducted by Sridharan et al. used in silico microbial metabolism reaction networks 
coupled with two independent mass spectrometry metabolomics analyses to identify and 
characterize microbial metabolites which were then used in vitro to determine mechanisms of 
action (224).       
Early investigations to characterize and profile the microbiome utilized culture methods 
and microscopy, but these efforts were limited by cultivability, nonspecific substrate utilization, 




next-generation-sequencing techniques enabled the classification of bacteria from a sample at the 
taxonomic level by sequencing variable regions of the 16S ribosomal RNA (rRNA) gene. 
Taxonomic microbial profiling from 16S rRNA sequencing yields relative abundances of 
bacteria classified into OTUs, based on sequence similarity of sample reads to known bacterial 
sequences (218). These data can be used to estimate diversity within and between samples based 
on the number of species in a sample (richness) and their relative abundance (evenness) (219). 
However, marker gene surveys such as 16S sequencing only permit the identification of bacteria 
present in a given sample and provide no information about the functional gene content of the 
microbiome sample as a whole, which is often argued to be substantially more informative (215). 
This information can be obtained using deep metagenome shotgun sequencing, but is much 
costlier and computationally intensive than marker gene survey sequencing. Therefore, strategies 
have been designed to use marker gene survey data to predict the functional gene content (i.e., 
the metagenome) of a microbiome sample using the same input data (220). Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) is one such 
tool that predicts the metagenome information (i.e., gene counts) of a 16S marker gene survey 
data set, which are then collapsed into KEGG pathways (220). In traditional metagenome 
sequencing, sequences are aligned to a gene catalog and the functional potential assessed by 
mapping genes to a KEGG database or through gene ontology (GO) enrichment analysis (221, 
222). 
Despite the overall reduction in colon cancer incidence, the increase in distal cancer 
incidence in individuals younger than the previously recommended initial screening age (50 
years old) supports the need for earlier screening (223). Recently, the American Cancer Society 




This recommendation is likely driven by CRC data indicating individuals aged ≤50 years old 
with CRC often present with more advanced cancers and a concomitant higher risk of mortality 
(1). Earlier colon screening coupled with fecal microbial profiling to identify cancer-associated 
microbes would enhance colon cancer prevention and treatment. It is estimated that the transition 
from precancerous cell to malignant colorectal tumor takes ~10-15 years implicating a 
substantial window for pre-cancer screening and implementation of prevention techniques (224). 
As critical bioinformatics approaches become available for the integration of ‘multi-omics’ 
analyses and as the required sample input continues to decrease it will be extremely beneficial to 
adopt more precise sampling procedures for characterizing the microbiota and interactions within 
a given microenvironment. The resolution afforded by passive fecal collection is useful as a 
clinical diagnostic test for cancer associated microbes; however, patients already diagnosed with 
colon cancer or found to have polyps following colonoscopy could benefit from more precise 
diagnostic protocols. Similar to the procedures used for genotyping a tumor biopsy to inform 
targeted therapeutic strategies, targeted tumor- or polyp-associated microbial profiling could 
reveal additional host-microbe signaling networks that can be targeted for therapy. 
Distinguishing between host- and microbial-derived growth signals could help explain the 
discrepancy in treatment responses of CRC patients. Although challenging, identifying critical 
microbial biomarkers should improve screening and early disease detection (168). For example, 
the discovery of hydrogen sulfide producing bacteria (i.e., sulfidogenic bacteria) and its 
contribution to inflammation and colorectal cancer (31, 225-227). Dietary bioactives can then be 
used to select against (or promote the growth of) specific bacteria (versus broad-spectrum 




inactivate harmful byproducts of metabolism, which will improve the usefulness of diagnostic 
fecal microbiome profiling.   
Nutrigenomics and nutrigenetics are ‘multi-omics’ manifestations aimed at understanding 
nutrient-gene interactions. Indeed, diet can function at multiple levels to regulate the flow of 
genetic information (228-231). These sciences and the knowledge acquired from them will be 
necessary for the development of personalized nutrition and disease prevention/treatment 
strategies, many of which are already used to some degree for the treatment of diet-related 
diseases, such as inflammatory bowel disease, obesity, diabetes, and cancer (232). Understanding 
how and to what extent specific nutrients affect the expression of microbial genes adds an 
additional layer of complexity due to the considerable microbial variation between individuals 
and the ostensibly infinite number of combinations between host and microbial genomes. 
Presumably, however, better health outcomes from nutritional interventions would be achieved 
by taking into consideration an individual’s inherited and acquired genetic characteristics, age, 
dietary and lifestyle preferences, and gut microbiome profile. 
 Our understanding of the capacity of the gut microbiota to affect host physiology 
continues to increase and reinforces the necessity to study modifiers of the gut microbiome. It is 
irrefutable that the gut microbiota plays a critical role in regulating the intestinal epithelium and 
that the consequences of alterations in the gut microbiome can extend beyond the intestines. The 
concept that the gut microbiota can impact the development and activity of the host immune 
system, that the host immune system is a governor of the gut microbiota, and that microbial 
profiles are far more individualized than originally perceived, underscores the necessity to 
understand how individual genetic polymorphisms can personalize the gut microbiota and, 




composition and function of the gut microbiota and that the microbiota can influence the health 
of the host beyond the intestinal epithelium implies a third mechanism by which diet can 
promote intestinal health; physiological changes in response to microbially-derived metabolites 
or ligands in other tissue sites (e.g., liver, muscle, etc.) may provide feedback to the intestinal 
epithelium that affects colon cancer risk and the risk of other associated diseases. Recent 
evidence suggesting a role of the gut microbiota in modulating host satiety and brain function 
(i.e., gut-brain axis) is remarkably fascinating and further emphasizes the need for understanding 
the capacity for diet to shape gut microbiota function and metabolism (233-237). 
 Despite the increasing acceptance of this paradigm, causative roles for specific bacteria 
are only suggested by current research. Experiments attempting to define the direct contribution 
of specific bacterium (or bacteria) to colon health/disease will require tightly controlled animal 
studies utilizing well-characterized dietary, environmental and disease conditions. Data produced 
by these studies may be more generalizable to human populations. Although fecal bacteria 
profiling has not yet been employed as a clinical tool for CRC diagnosis, research into this area 
of noninvasive diagnosis shows promise (238). Similarly, despite changes in the microbiota 
being associated with disease, there are no clear bacterial biomarkers of colorectal cancer; 
however, elucidation of microbial pathways involved in the synthesis or detoxification of 
genotoxic agents (e.g., colonic sulfur metabolism, secondary bile acid production, etc.) will 
enable identification of novel compounds and biomarkers for this purpose. With respect to colon 
health, the gut microbiota influences cellular processes by internal and external mechanisms, 
which include receptor binding and signal transduction/inhibition, modulation of gene and 
protein expression, epigenetic modifications, changes in metabolism, and cell 




metabolism of the microbiota can synergize with their direct effects, or those of other bioactives, 
to enhance or alter their bioactivity. Importantly, for compounds with unknown mechanisms but 
observed phenotypic responses, it is entirely possible that the function is completely microbial-
dependent and the efficacy, therefore, contingent on the presence of the microbe(s) and their 
metabolic response to the dietary stimulus.  
Hypothesis and Specific Aims 
Our overall goal is to better understand the impact of dietary bioactives on the 
composition and metabolism of the colon microbiota and how this may alter colon health. Our 
overarching hypothesis is that chemoprotective diets containing bioactive compounds will 
protect the host by modulating the composition, metabolism, and spatial distribution of the colon 
microbiota thereby mitigating the response to insults such as obesity, carcinogens, or radiation 
exposure. These investigations will employ a variety of experimental paradigms: (1) using a 
chemical inducer of colorectal cancer in a rat model of carcinogenesis, (2) using whole body 
HZE radiation exposure of C57BL/6 mice, and (3) using overweight/obese human subjects. The 
knowledge generated from these studies is important for understanding the development of colon 
cancer with an emphasis on the host-microbe interaction. These findings will enhance the 
development of novel disease prevention strategies which are dietary in nature, thereby 
mitigating the financial and healthcare burden imposed by chronic, metabolic diseases such as 
obesity, diabetes, cardiovascular disease, and cancer. 
Aim 1: Determine the ability of dried plums to suppress colon cancer by creating a 
microenvironment that promotes a healthy colonic epithelium and beneficial microbial growth 




Hypothesis 1.1: AOM-induced alterations in bacterial populations, fecal SCFA 
concentrations, and the expression of genes related to microbial recognition, inflammation, and 
SCFA absorption and metabolism will be mitigated by dried plum consumption 
Hypothesis 1.2: Dried plum consumption, via alterations to the composition and 
metabolism of colonic bacteria, will increase plant- and microbe-derived metabolites throughout 
the colon.     
Hypothesis 1.3: Consumption of dried plum will reduce the incidence of pre-neoplastic 
lesions induced by exposure to AOM. 
Hypothesis 1.4: Consumption of dried plum will increase the number of apoptotic cells in 
the distal colon.  
Aim 2: Determine if dried plum consumption can mitigate alterations in the gut 
microbiota and luminal SCFA levels in mice exposed to HZE radiation.  
Hypothesis 2.1: HZE exposure will affect the colon luminal environment by modifying 
bacterial populations and luminal SCFA concentrations. 
Hypothesis 2.2: Dried plum consumption will protect against alterations in bacterial 
composition and luminal SCFA levels that occur as a result of HZE radiation exposure.  
Aim 3: Determine if a sumac-sorghum dietary intervention containing condensed tannins 
is capable of modifying fecal microbiota composition and the presence of metabolites of 
microbial origin in the feces and plasma of overweight human subjects to improve biomarkers 
related to metabolic syndrome.    
Hypothesis 3.1: Consumption of a sumac-sorghum dietary intervention will beneficially 
impact fasting glucose, triglyceride and cholesterol levels, and plasma biomarkers of 




Hypothesis 3.2: Consumption of a sumac-sorghum dietary intervention rich in condensed 
tannins will increase the abundance of bacteria associated with improvements in conditions 
contributing to metabolic syndrome. 
Hypothesis 3.2: Consumption of a sumac-sorghum dietary intervention will increase 
plasma and fecal concentrations of microbially-derived metabolites of sorghum/polyphenol 





DRIED PLUMS PROTECT AGAINST CHEMICALLY-INDUCED COLON 
CARCINOGENESIS IN SPRAGUE DAWLEY RATS 
 
Introduction 
 Despite a continued overall decline in incidence and mortality, colorectal cancer (CRC) 
remains the third most commonly diagnosed cancer among men and women in the United States 
(239). In contrast, the incidence of colorectal cancer for individuals under the age of 50 is 
increasing and is solely due to tumors of the distal colon and rectum (239). Recently, the 
American Cancer Society recommended the screening age for CRC be lowered to 45 years for 
average risk individuals. This recommendation is likely driven by CRC data indicating 
individuals aged ≤50 years old with CRC often present with more advanced cancers and a 
concomitant higher risk of mortality (239). Therefore, colon cancer chemoprevention is 
necessary to reduce the contribution of colon cancer to the national healthcare burden.  
Interventions that are easily achievable in daily routines and incorporated into dietary patterns 
are more likely to be successful countermeasures.      
Epidemiological studies have revealed that consumption of fruits, vegetables, and dietary 
fiber contributes to a reduction in CRC risk (33-35). The chemoprotective activity afforded by 
fruit and vegetable consumption is believed to be due to the fiber content, antioxidant 
compounds, and other bioactive compounds (i.e., extra-nutritional elements in food that can 
affect living tissue) (33, 34, 36). Moreover, certain food constituents can be metabolized by gut 
microbiota to produce secondary bioactive compounds that then affect host physiology, such as 




and microbial physiology between the proximal and distal colon likely contribute to the unique 
pathology of cancers at these sites (18, 78, 137). Therefore, dietary strategies which promote 
beneficial microbial populations and patterns of metabolism throughout the colon may better 
protect against CRC.    
The digestive benefits of dried plums have been recognized for ages, yet a clear picture of 
the mechanisms whereby the digestive tract benefits remains to be developed. Dried plums 
contain a variety of bioactive compounds, such as phenolic acids (e.g., quercetin, chlorogenic 
acid, and neochlorogenic acid), sugar alcohols (e.g., sorbitol and mannitol), and 
hydroxycinnamic acids (e.g., sinapinic acid), as well as a mixture of soluble and insoluble fiber 
(194, 195). Dried plum consumption is commonly associated with a reduction in constipation 
and improved intestinal motility (194). These effects can be attributed in part to the dietary fiber 
found in dried plums; however, they are also noted when consuming dried plum juice, which 
lacks the fiber found in the whole fruit. Therefore, not all of the bioactive properties ascribed to 
dried plum consumption are due to its fiber content.  
Development of an undesirable population of colonic bacteria promotes colon 
inflammation, a known promoter of colon cancer (3). One mediator of inflammation that is 
greatly elevated in colon cancer is COX-2 (240). We have previously demonstrated a reduction 
in activation of NF-κB and COX-2 expression in healthy rats consuming quercetin or 
chlorogenic acid (196). Quercetin and chlorogenic acid also influence fecal SCFA 
concentrations, suggesting alterations in the gut microbe composition, their metabolism, or in the 
absorption of SCFA by the host (196). Furthermore, our lab has demonstrated the ability of 
quercetin to reduce the numbers of HMACF. Part of these changes may be attributable to the 




that were all reduced in animals challenged with an inflammatory agent (198). These outcomes 
indicate changes in microbial metabolism and in expression of genes involved in mediating 
signaling between bacteria and colonocytes in response to dietary exposure to polyphenolic 
molecules. These data from our lab were generated using isolated compounds, which precluded 
our understanding of potential additive or synergistic effects generated by a complete food, such 
as dried plum, which contain multiple bioactive compounds in complex with dietary fiber. 
In this experiment, we compared microbial populations and their metabolic products in 
healthy rats and those exposed to a colon carcinogen while consuming either a basal diet or one 
containing dried plum. Profiling of the luminal microbiome and metabolome and epithelial gene 
expression analyses were conducted using samples from the proximal and distal colon segments 
to monitor the changes throughout the colon. 
Materials and Methods 
Animals and experimental design 
All animal work was approved by the Institutional Animal Care and Use Committee of 
Texas A&M University (AUP number 2012-0252) and conformed to NIH guidelines. Fifty-one 
male Sprague Dawley rats (28-d old, Envigo, USA) were individually housed and acclimated to 
the specific pathogen-free animal facility for 1 wk prior to starting the experimental diets 
(Figure 1). Rats were pre-fed their experimental diets for 3 wk before receiving their first 
injection of azoxymethane (AOM, 15 mg/kg body weight) or saline (equivalent volume). Twenty 
rats served as saline controls and 31 rats received subcutaneous injections of azoxymethane to 
induce colon carcinogenesis. All rats were given a second injection 1 wk later and terminated 8 
wk following the second injection by CO2 asphyxiation and cervical dislocation. Within the 




(PD+S). Within the AOM group, 15 rats received the basal diet (BD+A) and 16 rats received the 
dried plum diet (PD+A). (One extra animal was received from Envigo and assigned to the PD+A 
group.) No animals died until their scheduled termination. 
Experimental diets 
Proximate analysis of the dried plum puree (Sunsweet Growers, Inc., Yuba City, CA) 
was conducted (Covance Laboratories, Princeton, NJ) to determine macronutrient levels prior to 
diet formulation to maintain essentially equivalent macronutrient content and fiber solubility 
between the basal and plum diet. The dried plum puree was included at 5% of total calories, 
which is similar to the recommended daily serving size of dried plums (40 g) and its 
corresponding calorie content (100 calories) for a normal 2000 calorie diet. The powdered diets 
were a modified standard AIN-76A formulation (Appendix Table 1) and were provided ad 





Figure 1. Timeline of AOM treatments for AOM group rats in each experimental group. Saline 
animals were injected with saline at the same time as their AOM counterparts. After 3 wk of 
experimental diets, AOM injections were given (15 mg/kg body weight, 1 wk separation, 2 





Animal weight and food intake was measured at several time points (167). Multiple fecal 




tissues were collected. Colons were excised and 1 cm of the proximal and distal colon (241) was 
fixed in 4% paraformaldehyde. Luminal contents collected from the proximal and distal 
segments were immediately flash frozen in liquid nitrogen. The colon was flushed with ice cold 
phosphate buffered saline (pH 7.4) and opened longitudinally to expose the mucosal surface. 
One longitudinal half-section was fixed for aberrant crypt foci (ACF) analysis and the other half-
section was cut into proximal and distal segments for mucosal scraping. 
Aberrant crypt foci 
The number and multiplicity of ACF was determined in ethanol-fixed tissue using our 
standard procedures (180, 181). Briefly, the tissues were fixed in 70% ethanol for 24 h and then 
placed in fresh 70% ethanol until scoring. The specimens were stained with 0.05% methylene 
blue dye and observed under a light microscope. The number, multiplicity, and location of each 
aberrant crypt or ACF was recorded in a blinded fashion and the identity of the sample remained 
unknown until all samples had been scored.    
In situ apoptosis measurement 
Apoptosis was measured by TdT-mediated UTP-biotin nick end labeling (TUNEL) assay 
(ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit; S7101; EMD Millipore) of 
fragmented pieces of DNA using 4 μm sections of PFA-fixed, paraffin-embedded tissue as 
previously described (242). See Appendix B for full protocol. Apoptotic cells with condensed 
chromatin, apoptotic bodies and intense brown staining were counted in 30 crypt columns for 
each animal. Results are reported as the number of apoptotic cells per crypt column.  
Colonocyte gene expression  
Scraped mucosal samples from the proximal and distal colon were placed into RNA 




analysis using our standard procedures (243, 244). Real-time PCR was performed using Applied 
Biosystems (Foster City, CA) card arrays on a 7900HT Fast Real-Time PCR System for the 
following genes: Toll-like receptor 2 and 4 (Tlr2, Tlr4), Toll interacting protein (Tollip), Solute 
carrier family 16 member 1 (Slc16a1), Solute carrier family 5 member 8  (Slc5a8), Nuclear 
factor kappa b subunit 1 (Nfkb1), NFKB inhibitor alpha (Nfkbia), Prostaglandin-endoperoxide 
synthase 2 (Ptgs2), Nitric oxide synthase 2 (Nos2), Acyl-CoA dehydrogenase short chain 
(Acads), and Acyl-CoA dehydrogenase medium chain (Acadm)(245). The expression of Gapdh 
transcripts in each sample was used to normalize gene expression. Assay IDs for all primers are 
compiled in Appendix Table 2. Quality RNA could not be obtained for one BD+A rat (n=14 of 
15) and two PD+A rats (n=14 of 16). 
SCFA analysis 
 The SCFA analyses were conducted using our standard protocols (153, 167). Frozen 
fecal samples were ground, mixed with an internal standard (2-ethylbutyric acid), extracted in 
70% ethanol, and aliquots of supernatant were mixed with heptanoic acid prior to injection onto 
a HP-FFAP column in a Varian 3900 GC (Agilent Technologies, Santa Clara, CA). 
Concentrations in the samples were determined by comparison to a commercially available mix 
of standards. 
Microbial DNA isolation 
Luminal contents collected from the proximal and distal colon at termination were flash 
frozen and stored at -80°C. Three samples were not available from the BD+A rats, leaving 13 
and 14 samples from the proximal and distal colon, respectively in that group. DNA was isolated 




concentration was determined using a Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen, 
Carlsbad, CA) in preparation for downstream 16S rRNA gene surveys (103). 
Microbial sequencing (454/Roche pyrosequencing) 
Total microbial DNA was amplified using forward (27F: 5’-
AGAGTTTGATCCTGGCTCAG-3’) and reverse (338R: 5’-TGCTGCCTCCCGTAGGAGT-3’) 
primers targeting regions flanking the variable regions 1 through 3 (V1-3) of the bacterial 16S 
rRNA gene (246). The forward primer was tagged with 10 bp unique barcode labels at the 5' end 
and with the adaptor sequence to allow multiple samples to be included in a single 454 GS FLX 
Titanium+ sequencing plate at a sequencing depth of approximately 10,000 reads per sample 
(247, 248). The sequencing was performed on a GS FLX Titanium+ instrument (Roche, 
Florence, SC) in the Microbiome Core Facility at University of North Carolina School of 
Medicine at Chapel Hill. 
Bacterial sequence analysis 
Analysis of sequencing data was carried out using the QIIME pipeline (249) in which raw 
sequencing data and relevant metadata describing the samples were de-multiplexed and filtered. 
Next, data were denoised using Denoiser software with standard parameters (250) and sequences 
were grouped into operational taxonomic units (OTUs) at a 97% level to approximate genus-
level phylotypes using Uclust (251). OTU sequences were aligned and OTU tables containing 
the counts of each OTU in each sample were used to calculate mean species diversity of each 
sample (alpha diversity) and the differentiation among samples (beta diversity). Alpha and beta 






Microbial metagenome prediction 
 The Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 
(PICRUSt) was used to predict the microbial metagenome (220). Briefly, sequencing data were 
prepared as described for taxonomic identification, but sequences were then clustered into OTUs 
using a closed-reference OTU picking protocol [http://qiime.org/scripts/pick_closed_reference_o 
tus.html] using Greengenes 13.8 as the reference database at 97% sequence similarity. The OTU 
table generated from this procedure was then normalized by the predicted copy number(s) of the 
microbial 16s rRNA gene for each OTU. PICRUSt analysis was then used with the normalized 
OTU table to predict each samples metagenome. The metagenome profile is calculated by 
multiplying the normalized OTU abundance by each KEGG ortholog (KO) abundance in the 
genome and summing the KO abundances together for each sample. This process yields a table 
containing KO abundances for each metagenome sample in the input OTU table. The data was 
then rarefied to an even sequencing depth (10000 sequences/sample) before further analyses 
were conducted.     
Metabolomics  
Untargeted metabolic profiling of fecal samples was performed by Metabolon Inc. 
(Durham, NC) (252, 253). Briefly, the protocol employed for this analysis combined three 
independent platforms: ultrahigh performance liquid chromatography/tandem mass spectrometry 
(UHPLC/MS/MS2) optimized for basic species, UHPLC/MS/MS2 optimized for acidic species, 
and gas chromatography/mass spectrometry (GC/MS). Protein was precipitated from the fecal 
samples with methanol and the resulting supernatant was split into equal aliquots for analysis on 
the three platforms. Metabolites were identified by automated comparison of the ion features in 




retention time, molecular weight (m/z), preferred adducts, and in-source fragments as well as 
associated MS spectra, and were curated by visual inspection for quality control using software 
developed at Metabolon (254). 
Statistical analyses  
ACF data were analyzed by 2-sample t-test using GraphPad (PRISM) software. 
Apoptosis data was analyzed by one-way ANOVA. Microbial abundance and gene expression 
data were analyzed using the General Linear Model (GLM) procedure in SAS (version 9.3) to 
determine the main effects and interaction of diet and injection for the proximal and distal colon 
separately. Paired sample t-tests were used to compare proximal and distal expression levels 
within a group (e.g., BD+S proximal versus BD+S distal). Interactions between location and 
diet/injection were not tested. Permutational analysis of variance (PERMANOVA) was 
performed on unweighted beta-diversity principal coordinate data to determine if clustering due 
to effect variables was significant. SCFA data from each time point were analyzed separately. At 
baseline SCFA data were analyzed using a 2-sample t-test to determine differences in fecal 
SCFAs exclusively attributed to diet. SCFA data from 48 h and 8 wk after the second AOM 
injection were analyzed using the GLM procedure in SAS for diet, injection and diet*injection 
interaction. Data presented are least squares means (LSM) ± standard error of the mean (SEM) 
unless otherwise noted. Differences are considered significant at p<0.05. 
PICRUSt data at Level 3 KEGG pathway consolidation were first filtered to remove KO 
functions with >50% zeros across all samples. The resulting data was checked for normality and 
a square root transform or ranked test was used for non-normal KO functions. The KO functions 
were then analyzed by a 2-factor ANOVA (diet and injection) for the proximal and distal colon 




adjusted FDR P-value (Q-value) is presented. A Q-value<0.1 was considered significant. The 
same was performed for Level 2 KEGG pathway analysis except the >50% zeros exclusion was 
not necessary at this level.  
For statistical analyses and data display purposes of the metabolomics data, any missing 
values were assumed to be below the limits of detection and these values were imputed with the 
compound minimum (minimum value imputation) (255). Statistical analysis of log-transformed 
data was performed using “R” (http://cran.r-project.org/). Pairwise comparisons were performed 
using Welsh’s t-Tests. Multiple comparisons were accounted for by estimating the false 
discovery rate (FDR) using Q-values (256). 
Results  
Animal health 
Food intake and animal weight were not adversely affected by the treatments (Figure 2 
and 3). Food intake averaged over a 48 h period was elevated for PD rats at 3 wk compared to 
BD rats (21.09 g vs. 18.89 g; P<0.05); however, no differences in food intake were observed 
among the groups at later time points. At 3 wk, PD+S rats weighed more than BD+A rats (255 g 
vs. 244 g; P<0.05). At termination, rats that had received AOM injections weighed 4.32% less 
than their saline counterparts (P<0.05). 
Aberrant crypt foci and apoptosis 
Neither injection nor diet had an impact on colon length (Table 1). As expected, there 
were no aberrant crypts in animals treated with saline. BD+A animals had 73% more (P<0.05) 
aberrant crypts (AC) and 63% more (P<0.05) ACF than PD+A animals (Table 2). Most 
importantly, the number of high multiplicity aberrant crypt foci (HMACF, foci containing four 





Figure 2. Daily food intake (averaged over 48 h) at experimental day 20, 55, and 82. At d 20, 
animals assigned to the plum diet had increased diet intake, compared to basal diet counterparts. 
Data are means±SEM. At each time point, bars not sharing a common letter differ significantly 
(P<0.05). 
 
             
Figure 3. Average body weights at experimental day 0, 21, 28, 56 and 84. At d 21 and 56, PD+S 
animals weighed more than BD+A animals. At d 84, PD+S animals weighed more than BD+A 
and PD+A animals, and BD+S animals weighed more than BD+A animals. Data are 
means±SEM. At each time point, bars not sharing a common letter differ significantly (P<0.05). 
 
 
Table 1. Total number of AC1, ACF, and HMACF were reduced in rats treated with AOM and 
fed a dried plum diet, versus basal diet counterparts.  
Group2 n Colon length (cm) Total AC ACF HMACF 
BD+S  10 11.5 ± 1.0 0 0 0 
PD+S  10 11.0 ± 1.0 0 0 0 
BD+A 15 11.0 ± 1.5 156 ± 20 49 ± 06 18 ± 02 
PD+A 16 11.5 ± 1.5 90 ± 11* 30 ± 03* 9 ± 02* 
1AC, aberrant crypts; ACF, aberrant crypt foci; HMACF, high multiplicity aberrant crypt foci (foci with number of 
AC≥4). 2BD+S, basal diet+saline; PD+S, plum diet+saline; BD+A, basal diet+AOM; PD+A, plum diet+AOM. Data 




were 100% greater in the BD+A rats compared to PD+A rats (P<0.05). No differences were 
detected in the number of apoptotic cells/crypt column or in the proportion of apoptotic 
cells/crypt column in the distal colon (Appendix Figure 1 and 2, respectively). 
Gene expression 
To better understand how the diet may be affecting the cells of the colonic epithelium, 
genes involved in host-microbe crosstalk, as well as select genes down-stream of this interaction, 
were assessed for their relative expression levels (Table 2). The majority of genes surveyed were 
differentially expressed between the proximal and distal colon. Tlr2, which recognizes a variety 
of microbial cell-wall components, such as peptidoglycan matrix, lipoteichoic acid and various 
lipoproteins, was expressed at higher levels in the distal colon than the proximal colon in all rats, 
but was unaffected by diet or AOM treatment in the distal colon. 
In the proximal colon, PD animals had lower Tlr2 expression than BD rats (P-
diet=0.0491) with PD+A animals being significantly lower than BD+S and BD+A groups 
(P<0.05). Similarly, the expression of Tlr4, which recognizes lipopolysaccharide, was also 
greater in the distal colon of all animals (P<0.05). PD+A rats had significantly lower Tlr4 
expression than BD+A rats (P-interaction=0.0107).  
Expression of Slc5a8 (Na+ coupled) and Slc16a1 (H+ coupled) SCFA transporters was 
greater in the distal colon of all groups except for BD+A animals, whose proximal and distal 
Slc16a1 levels were equivalent. The expression of Slc5a8 was unaffected by diet or AOM 
injection regardless of location; however, Slc16a1 expression was reduced in the distal colon as a 
result of AOM treatment (P-AOM=0.0013). The expression of Nfkb1 and its inhibitor, Nfkbia, 




Table 2. Colonocyte gene expression1 levels in rats treated with AOM, or saline, and fed a basal 
or dried plum diet.  
1 Relative amount of target gene normalized to Gapdh. BD+S, basal diet+saline; BD+A, basal diet+AOM; PD+S, 
plum diet+saline; PD+A, plum diet+AOM. Data are least square means ± SEM. a,b,c Values in the same row not 
sharing a common superscript differ, (P<0.05). * Indicates significant difference in gene expression between 


















Diet AOM Diet*AOM 
Tlr2 9.96±1.38a 10.37±1.17a 8.89±1.38ab 6.25±1.17b 0.0491 0.3908 0.2411 
Tlr4 3.03±0.47ab 4.20±0.40a 3.70±0.47ab 2.55±0.40b 0.2623 0.9836 0.0107 
Tollip 2.31±0.44 2.67±0.37 2.68±0.44 1.94±0.37 0.6583 0.6477 0.1815 
Slc5a8 7.19±1.53 8.61±1.30 8.27±1.53 6.05±1.30 0.6036 0.7797 0.2068 
Slc16a1 1.32±0.21 1.50±0.18 1.58±0.21 1.20±0.18 0.9206 0.6286 0.1621 
Nfkb1 2.53±0.47 3.05±0.39 2.98±0.47 2.26±0.39 0.7040 0.8207 0.1558 
Nfkbia 8.44±1.38 9.39±1.17 9.20±1.38 6.58±1.17 0.4258 0.5161 0.1697 
Ptgs2 (Cox2) 10.64±1.14 9.63±0.97 10.64±1.14 7.80±0.97 0.3887 0.0755 0.3923 
Nos2 (Inos) 1.82±0.61ab 3.36±0.52a 0.81±0.65b 1.41±0.52b 0.0139 0.0697 0.4236 
Acads 9.13±1.55 10.71±1.31 11.95±1.55 9.02±1.31 0.6960 0.6410 0.1244 
Acadm 8.41±1.25 9.71±1.06 9.79±1.25 7.20±1.06 0.6280 0.5833 0.1001 














Diet AOM Diet*AOM 
Tlr2 20.19±3.17 20.87±2.68 20.01±3.17 21.22±2.68 0.9768 0.7490 0.9284 
Tlr4 12.75±1.21 12.73±1.02 11.68±1.21 10.87±1.02 0.1970 0.7124 0.7263 
Tollip 4.83±0.56 3.80±0.48 4.66±0.56 3.88±0.48 0.9319 0.0894 0.8040 
Slc5a8 21.75±2.93 16.14±2.48 21.59±2.93 18.36±2.48 0.7068 0.1101 0.6637 
Slc16a1 2.32±0.24ac 1.57±0.21b 2.55±0.24c 1.74±0.21ab 0.3966 0.0013 0.8954 
Nfkb1 4.95±0.69 4.39±0.58 5.00±0.69 4.52±0.58 0.8949 0.4149 0.9532 
Nfkbia 16.97±2.11 14.13±1.79 17.37±2.11 14.06±1.79 0.9340 0.1231 0.9061 
Ptgs2 (Cox2) 21.85±2.40 17.75±2.03 18.37±2.40 15.66±2.03 0.2170 0.1322 0.7560 
Nos2 (Inos) 1.42±1.05a 8.17±0.89b 1.84±1.05a 6.02±0.89b 0.3753 <0.0001 0.1919 
Acads 19.64±2.30 14.57±1.94 20.39±2.30 16.54±1.94 0.5247 0.0417 0.7752 
Acadm 13.40±1.38ab 9.95±1.16a 13.87±1.38b 10.84±1.16ab 0.5990 0.0146 0.8694 
 Fold change (Distal/Proximal) 
Gene BD+S BD+A PD+S PD+A 
Tlr2 2.03* 2.01* 2.25* 3.40* 
Tlr4 4.21* 3.03* 3.16* 4.26* 
Tollip 2.09* 1.42* 1.74* 2.00* 
Slc5a8 3.03* 1.88* 2.61* 3.04* 
Slc16a1 1.76* 1.05 1.61* 1.45* 
Nfkb1 1.96* 1.44 1.68* 2.00* 
Nfkbia 2.01* 1.51* 1.89* 2.14* 
Ptgs2 (Cox2) 2.05* 1.84* 1.73* 2.01* 
Nos2 (Inos) 0.78* 2.43* 2.27* 4.27* 
Acads 2.15* 1.36 1.71* 1.83* 




for all groups except for BD+S, which had greater expression in the proximal colon. The 
expression of Nos2 was increased in response to AOM treatment, but only in the distal colon (P-
AOM<0.0001). In the proximal colon, PD rats had lower Nos2 expression (P-diet=0.0139) than 
BD rats, with PD+A rats having significantly lower expression than BD+A rats. 
Colon microbiota  
Fecal microbial characterization was carried out using samples collected from the 
proximal and distal colon at termination. Diet and AOM treatment affected the abundance of 
several bacterial phyla throughout the colon (Table 3). AOM treatment increased the abundance 
of Bacteroidetes in the distal colon (P-AOM=0.0285) irrespective of diet. Changes in various 
genera in response to AOM are presented in Appendix Table 1. The impact of PD consumption 
on microbe composition appeared to be more pronounced in the distal colon, where changes in 
four phyla were observed versus only two in the proximal colon. In the proximal colon, PD rats 
had higher abundances of Actinobacteria (P-diet=0.0003) and Proteobacteria (P-diet=0.0158) 
than BD rats. In the distal colon, PD rats, had higher abundances of Actinobacteria (P-
diet=0.0003) and Bacteroidetes (P-diet=0.0003), and lower abundances of Deferribacteres (P-
diet=0.0119), Firmicutes (P-diet=0.0054), and bacteria classified as ‘Other’ (P-diet=0.0102) than 
BD rats.  
At the order level, the abundance of Bacteroidales was significantly higher in the distal 
colon of PD rats versus BD rats (P-diet <0.001) (Figure 4). Lactobacillales was higher in BD+S 
rats than all other groups in the proximal and distal colon (P<0.05), and PD animals had 
significantly lower abundances in the proximal and distal colon compared to BD (P-diet =0.0248 




Table 3. Percent abundance of dominant phyla in rats treated with AOM, or saline, and fed a basal or dried plum diet. 














Diet AOM Diet*AOM 
Unassigned 4.88±2.79 6.35±2.44 7.73±2.79 5.24±2.20 0.7357 0.8444 0.4450 
Other 2.42±0.45 1.89±0.40 1.70±0.45 2.30±0.36 0.7173 0.9350 0.1859 
Actinobacteria 0.12±0.07a 0.24±0.06ac 0.54±0.07b 0.33±0.06c 0.0003 0.5146 0.0176 
Bacteroidetes 29.24±3.24ab 21.29±2.84a 31.54±3.24b 28.04±2.56ab 0.1361 0.0616 0.4596 
Cyanobacteria 0.11±0.09a 0.14±0.08a 0.17±0.09ab 0.38±0.07b 0.0573 0.1247 0.2777 
Deferribacteres 0.03±0.01 0.02±0.01 n.d. 0.02±0.01 0.1527 0.8430 0.1052 
Elusimicrobia 0.04±0.02ab 0.04±0.02ab 0.02±0.02a 0.07±0.01b 0.7109 0.1209 0.1770 
Firmicutes 60.00±4.48ab 65.62±3.93a 53.28±4.47b 57.90±3.54ab 0.0872 0.2205 0.9109 
Fusobacteria <0.01 <0.01 <0.01 <0.01 0.4992 0.6672 0.9448 
Proteobacteria 2.85±0.68a 3.60±0.60ab 4.59±0.68ab 5.03±0.54b 0.0158 0.3507 0.8022 
Tenericutes 0.31±0.30 0.76±0.26 0.35±0.30 0.69±0.24 0.9609 0.1563 0.8417 
Verrucomicrobia 0.03±0.03 0.06±0.03 0.08±0.04 <0.01 0.9573 0.4277 0.1734 














Diet AOM Diet*AOM 
Unassigned 5.60±1.24 2.80±1.04 3.33±1.24 2.76±0.98 0.3116 0.1423 0.3308 
Other 2.71±0.55a 1.79±0.46ab 1.00±0.55b 0.81±0.43b 0.0102 0.2753 0.4717 
Actinobacteria 0.18±0.09a 0.31±0.08a 0.54±0.09b 0.59±0.07b 0.0003 0.2891 0.6193 
Bacteroidetes 23.99±3.00a 27.50±2.54a 32.07±3.00a 40.96±2.37b 0.0003 0.0285 0.3315 
Cyanobacteria 0.17±0.07 0.15±0.06 0.24±0.07 0.18±0.05 0.4270 0.5380 0.7275 
Deferribacteres 0.08±0.02a 0.02±0.02b <0.01b n.d. 0.0119 0.1009 0.1032 
Elusimicrobia 0.05±0.02 0.04±0.02 0.06±0.02 0.08±0.02 0.3093 0.8913 0.4648 
Firmicutes 62.98±3.34a 63.01±2.82a 58.89±3.34a 49.26±2.64b 0.0054 0.1227 0.1203 
Fusobacteria <0.01 <0.01 n.d. <0.01 0.1822 0.0834 0.6966 
Proteobacteria 3.42±0.66 3.60±0.56 3.34±0.66 4.39±0.52 0.5576 0.3171 0.4773 
Tenericutes 0.76±0.25 0.72±0.21 0.52±0.25 0.96±0.20 0.9968 0.3827 0.3080 
Verrucomicrobia 0.07±0.04 0.06±0.03 0.01±0.04 0.01±0.03 0.1039 0.8781 0.7367 
1BD+S, basal diet+saline; BD+A, basal diet+AOM; PD+S, plum diet+saline; PD+A, plum diet+AOM. Data are least square means ±SEM. a,b Values in the 
same row not sharing a common superscript differ, (P<0.05). “n.d.” denotes sequences were not detected in any samples of the respective group. Phyla 





Figure 4. Percent abundance of major bacterial orders by diet/injection group and location. Bars 






in the proximal colon of PD+A rats compared to BD+S rats (P<0.05), but no differences were 
detected in the distal colon. PD rats had lower abundances of Erysipelotrichales than BD rats in 
the distal colon (P-diet=0.0212). Additionally, Coriobacteriales, which largely comprises the 
Actinobacteria phylum, was higher in PD rats, irrespective of location surveyed compared to BD 
rats (P-diet<0.001 for both locations, data not shown). A number of significant alterations 
occurred in various genera throughout the colon with potential health relevance in response to 
AOM treatment and diet consumed (Appendix Table 3 and 4, respectively). For example, PD 
rats had increased abundances of Bacteroides (~64%, P-diet=0.0005), Parabacteroides (~132%, 
P-diet=0.0024), S247 (~34%, P-diet=0.0268), and decreased Lactobacillus (~48%, P-
diet=0.0011) and Allobaculum (~52%, P-diet=0.021) (Appendix Table 2). 
Alpha-diversity estimates representing diversity within a sample (e.g., Chao, Shannon, 
and total number of observed species) revealed no significant differences between samples due 
to diet, AOM treatment, or location surveyed (data not shown). Beta-diversity analysis, or 
diversity between samples, illustrated with principal coordinate analysis (Figure 5) and 
confirmed by PERMANOVA of principal coordinate data (Table 4), revealed significant 
separation between samples taken from different diet groups without species abundance 
weighting factors (P-diet=0.001). Principal coordinates analysis of weighted beta-diversity 
analysis, which considers species abundance, is presented in Figure 6. 
Microbial metagenome prediction 
 Thousands of predicted KEGG ortholog functions can be organized into KEGG Pathways 
using the categorize_by_function.py script. KEGG pathway data can take on three levels (i.e., 






Figure 5. Unweighted UniFrac beta-diversity analysis illustrated with principle coordinate plots 
reveals separation of samples based on diet.    
 
 







Figure 6. Weighted UniFrac beta-diversity analysis illustrated with principle coordinate plots 
reveals separation of samples based on diet with maximum separation occurring between distal 
colon microbial samples. 
 
Variable Sample size # groups F-statistic P-value # permutations 
Diet  99 2 (Plum vs. Basal) 4.101 0.001 999 
Injection   99 2 (AOM vs. Saline) 1.211 0.060 999 




>Order). Level 1 data is the broadest functional characterization with the following categories: 
Cellular Processes, Environmental Information and Processing, Genetic Information Processing, 
Human Diseases, Metabolism, Organismal Systems, and Unclassified. No changes were detected 
in Level 2 or 3 pathway data in response to AOM treatment for either colon location. Analysis of 
Level 2 data revealed six pathways altered by diet in the proximal colon and 27 pathways altered 
by diet in the distal colon (Table 5). For example, in the proximal colon KEGG pathways 
associated with Energy Metabolism, Amino Acid Metabolism, and Metabolism of Cofactors and 
Vitamins were significantly altered in response to diet. In the distal colon, KEGG pathways 
related to Membrane Transport, Cancers, Infectious Diseases, Energy Metabolism, Metabolism 
of Other Secondary Metabolites, and Lipid Metabolism were among the 27 pathways found to be 
affected by diet. KEGG pathway consolidation at Level 3 provides the most information 
regarding functional changes in the predicted metagenome. Significant changes of select KEGG 
pathways at Level 3 consolidation are presented in Table 6. Interestingly, KEGG pathways 
related to Fatty acid biosynthesis, Indole alkaloid biosynthesis, and Phenylalanine, tyrosine, and 
tryptophan biosynthesis were modified by diet in the proximal and distal colon. Furthermore, 
KEGG pathways identified as colorectal cancer, pathways in cancer, tryptophan metabolism, 
primary and secondary bile acid biosynthesis, metabolism of xenobiotics by cytochrome P450, 
and polycyclic aromatic hydrocarbon degradation were identified as pathways modified by diet 
in the distal colon. Relative prevalence of gene families related to the KEGG pathways identified 
in Plum versus Basal animals is also indicated in Table 6 in the Comparison column. A post hoc 
Tukey’s multiple comparison test of the Shannon-Weaver alpha diversity index for predicted 





Table 5. Predicted microbial metagenome KEGG functional pathways (Level 2 pathway 
consolidation) significantly altered by diet in the proximal and distal colon of rats consuming a 











Function Level 1 Function Level 2 P-value Q-value Transform 
Genetic Information Processing Folding Sorting and Degradation 0.000 0.008 Rank 
Metabolism Energy Metabolism 0.000 0.000 None 
Metabolism Amino Acid Metabolism 0.002 0.021 None 
Metabolism Metabolism of Cofactors and Vitamins 0.005 0.030 None 
Organismal Systems Endocrine System 0.004 0.030 None 
Unclassified Cellular Processes and Signaling 0.002 0.020 None 
Distal Colon 
Function Level 1 Function Level 2 P-value Q-value Transform 
Cellular Processes Transport and Catabolism 0.000 0.000 None 
Cellular Processes Cell Motility 0.000 0.001 Rank 
Environmental Information Processing Membrane Transport 0.000 0.000 Rank 
Genetic Information Processing Folding Sorting and Degradation 0.000 0.000 Rank 
Genetic Information Processing Transcription 0.004 0.009 SqRt 
Genetic Information Processing Translation 0.015 0.024 Rank 
Human Diseases Metabolic Diseases 0.004 0.009 None 
Human Diseases Cardiovascular Diseases 0.007 0.014 Rank 
Human Diseases Infectious Diseases 0.009 0.015 None 
Human Diseases Cancers 0.029 0.042 SqRt 
Metabolism Energy Metabolism 0.000 0.000 None 
Metabolism Metabolism of Cofactors and Vitamins 0.000 0.000 None 
Metabolism Glycan Biosynthesis and Metabolism 0.000 0.000 SqRt 
Metabolism Amino Acid Metabolism 0.000 0.000 None 
Metabolism Metabolism of Other Amino Acids 0.001 0.002 Rank 
Metabolism Biosynthesis of Other Secondary Metabolites 0.003 0.007 None 
Metabolism Lipid Metabolism 0.004 0.009 None 
Metabolism Metabolism of Terpenoids and Polyketides 0.008 0.014 Rank 
Metabolism Enzyme Families 0.016 0.025 Rank 
Organismal Systems Endocrine System 0.000 0.000 None 
Metabolism Biosynthesis of Other Secondary Metabolites 0.003 0.007 None 
Organismal Systems Digestive System 0.000 0.000 Rank 
Organismal Systems Environmental Adaptation 0.000 0.000 SqRt 
Organismal Systems Immune System 0.000 0.001 None 
Organismal Systems Excretory System 0.002 0.004 SqRt 
Organismal Systems Circulatory System 0.011 0.018 Rank 
Organismal Systems Nervous System 0.028 0.042 Rank 




with PD groups having greater diversity than their BD counterparts (PD+A vs BD+A and PD+S 
vs BD+S, P<0.05 for both, data not shown). This increase in pathway diversity was not observed 
in the proximal colon. No differences between diet+injection groups were observed for the other 




Table 6. Select predicted microbial metagenome KEGG functional pathways (Level 3 pathway 
consolidation) significantly altered by diet in the proximal and distal colon of rats consuming a 























1 Indicates which diet the prevalence of the gene families associated with the KEGG pathway was greater. Plum, P; 




Fecal short chain fatty acids  
Short chain fatty acids are the metabolic end product of microbial fermentation of dietary 
fiber. Because both diets were matched for the level and composition of dietary fiber, the intent 
Proximal Colon 
Function Level 3 P-value Q-value Transform Comparison1 
Phe, Tyr and Trp biosynthesis 0.001 0.022 None P>B 
Indole alkaloid biosynthesis 0.010 0.076 Rank P>B 
Fatty acid biosynthesis 0.006 0.060 SqRt P>B 
Distal Colon 
Function Level 3 P-value Q-value Transform Comparison 
Colorectal cancer 0.008 0.015 Rank P>B 
Pathways in cancer 0.027 0.048 SqRt P<B 
Indole alkaloid biosynthesis 0.000 0.000 SqRt P>B 
Phe, Tyr and Trp biosynthesis 0.000 0.000 None P>B 
Tryptophan metabolism 0.000 0.000 None P<B 
Fatty acid biosynthesis 0.000 0.000 Rank P>B 
Primary bile acid biosynthesis 0.027 0.048 Rank P>B 
Secondary bile acid biosynthesis 0.025 0.044 Rank P>B 
Drug metabolism-cytochrome P450 0.006 0.012 SqRt P>B 
Metabolism of xenobiotics by cytochrome P450 0.006 0.012 Rank P>B 
Polycyclic aromatic hydrocarbon degradation 0.037 0.061 SqRt P<B 
Phe, Tyr and Trp biosynthesis 0.001 0.022 None P>B 
Indole alkaloid biosynthesis 0.010 0.076 Rank P<B 




of this comparison was to understand how other components of dried plums may be affecting the 
metabolism of SCFAs.  
Following 3 wk of experimental diet consumption, there was no difference in total fecal 
SCFA concentrations between the BD and PD rats (P-diet=0.1048); however, PD rats had lower 
levels of isobutyrate (P-diet<0.0001), isovalerate (P-diet<0.0001), and valerate (P-diet=0.0002) 
(Table 7).  
Forty-eight hours after the second injection BD+A rats had greater total SCFAs compared 
to BD+S rats (P-interaction=0.0469). The increase in total SCFA levels observed in BD+A 
animals at this time point was largely due to an increase (~64%) in acetate. The level of 
propionate was greater in BD+A vs. BD+S rats; however, the levels of propionate were not 
affected by AOM in the PD rats (P-interaction=0.0094). The level of isobutyrate decreased 
following AOM injection (P-AOM=0.0049) and was lower overall in PD rats versus BD rats  
 (P-diet<0.0001). Isovalerate and valerate also decreased following AOM injection (P-
AOM=0.0114 and 0.0445, respectively) and were lower overall in PD rats versus BD rats (P-
diet=0.0013 and 0.0025, respectively).  
Eight weeks after the second injection, only propionate was significantly affected by diet 
with PD rats having greater levels than BD rats (P-diet=0.0229).  Interestingly, the levels of fecal 
butyrate remained comparable between all groups throughout the study; however, the proportion 
of butyrate was greater in animals consuming the plum diet at the 3 wk post-diet start (P-








Table 7. Rat fecal SCFA levels at 3 wk post-diet start, and 48 h and 8 wk following the second 
AOM injection, organized by diet+injection group for each time point. 
1BD, basal diet; PD, plum diet; BD+S, basal diet+saline; BD+A, basal diet+AOM; PD+S, plum diet+saline; PD+A, 
plum diet+AOM. Data are means ± SEM. a,b Values not sharing a common super script differ, (P<0.05).  
3 Wk Post-Diet 
Start 
Concentration, 








Acetate 15.08±1.15 12.87±0.73 0.1047 
Propionate 5.88±0.33 5.97±0.27 0.8350 
Isobutyrate 0.93±0.05a 0.60±0.04b <0.0001 
Butyrate 5.65±0.50 5.87±0.48 0.7256 
Isovalerate 2.23±0.13a 1.45±0.09b <0.0001 
Valerate 1.78±0.09a 1.23±0.10b 0.0002 
Total 31.55±1.79 27.99±1.25 0.1048 
% Acetate 47.13±1.20 45.65±1.24 0.3990 
% Propionate 18.92±0.78 21.96±1.27 0.0510 
% Isobutyrate 3.08±1.80a 2.23±0.16b 0.0009 
% Butyrate 17.67±0.80a 20.50±1.12b 0.0476 
% Isovalerate 7.42±0.49a 5.27±0.38b 0.0010 
% Valerate 5.88±0.31a 4.27±0.32b 0.0007 
48 H Post-AOM 
2 
Concentration, 














Diet AOM Diet*AOM 
Acetate 14.66±2.18a 22.14±1.78b 15.40±2.18a 15.06±1.72a 0.1154 0.0770 0.0533 
Propionate 5.08±0.46a 7.14±0.38b 6.53±0.46b 6.31±0.37b 0.4596 0.0338 0.0094 
Isobutyrate 0.91±0.06a 0.72±0.05b 0.64±0.06bc 0.50±0.05c <0.0001 0.0049 0.7365 
Butyrate 6.19±0.75 6.54±0.61 7.20±0.75 6.15±0.59 0.6508 0.6153 0.3083 
Isovalerate 2.08±0.16a 1.52±0.13b 1.41±0.16b 1.17±0.13b 0.0013 0.0114 0.2810 
Valerate 1.68±0.11a 1.54±0.09a 1.43±0.11ab 1.15±0.09b 0.0025 0.0445 0.5160 
Total 30.59±3.05a 39.61±2.49b 32.61±3.05ab 30.34±2.41a 0.1964 0.2280 0.0469 
% Acetate 47.30±2.03a 54.00±1.66b 46.00±2.03a 49.25±1.61a 0.1079 0.0097 0.3547 
% Propionate 16.70±1.49a 19.07±1.21ab 21.40±1.49b 20.88±1.17b 0.0197 0.4978 0.2888 
% Isobutyrate 3.10±0.30a 1.93±0.24b 2.00±0.30b 1.63±0.24b 0.0121 0.0064 0.1490 
% Butyrate 19.80±1.12a 16.53±0.92b 21.30±1.12a 20.19±0.89a 0.0148 0.0367 0.2954 
% Isovalerate 7.00±0.72a 4.40±0.59b 4.70±0.72b 4.06±0.57b 0.0505 0.0175 0.1421 
% Valerate 6.00±0.39a 4.07±0.31b 4.60±0.39b 3.81±0.30b 0.0221 0.0003 0.1079 
8 Wk Post-AOM 
2 
Concentration, 





SCFA BD+S BD+A PD+S PD+A Diet AOM Diet*AOM 
Acetate 15.95±1.80 15.55±1.47 15.19±1.80 15.67±1.42 0.8458 0.9817 0.7894 
Propionate 4.94±0.47ab 4.84±0.38a 5.68±0.47ab 6.10±0.37b 0.0229 0.7153 0.5397 
Isobutyrate 1.00±0.06a 0.97±0.05a 0.95±0.06ab 0.84±0.05b 0.0858 0.1893 0.4050 
Butyrate 5.20±0.54 5.47±0.44 6.40±0.54 5.95±0.43 0.0956 0.8570 0.4648 
Isovalerate 2.34±0.16a 2.12±0.13ab 2.16±0.16ab 1.91±0.12b 0.1725 0.1091 0.9245 
Valerate 1.69±0.11 1.72±0.09 1.66±0.10 1.51±0.08 0.2092 0.5473 0.3220 
Total 31.12±2.58 30.68±2.11 32.03±2.58 31.97±2.04 0.6403 0.9149 0.9367 
% Acetate 48.70±1.84 50.40±1.50 47.10±1.84 47.88±1.45 0.2223 0.4617 0.7827 
% Propionate 15.70±0.90a 15.87±0.73a 17.90±0.90ab 19.56±0.71b 0.0007 0.2658 0.3618 
% Isobutyrate 3.50±0.27 3.27±0.22 3.10±0.27 3.06±0.22 0.2302 0.5884 0.6953 
% Butyrate 17.80±1.09 18.07±0.89 19.50±1.09 18.25±0.86 0.3473 0.6225 0.4484 
% Isovalerate 8.60±0.74a 6.87±0.61ab 6.80±0.74ab 6.44±0.59b 0.1050 0.1269 0.3146 




Luminal metabolome profiling  
Based on our microbial data, dried plum consumption appears to exert its greatest 
influence on microbe composition in the distal colon. Similarly, the impact of AOM treatment on 
the expression of genes related to microbe recognition, SCFA metabolism, and inflammation was 
greatest in the distal colon. Thus, we sought to characterize the changes in the luminal 
metabolome in the distal colon to better understand the impact of dried plum consumption on 
colon health. The untargeted analyses of distal samples from BD+A and PD+A rats identified 
490 metabolites. Between these groups, 147 metabolites were different (P-diet≤0.05, data not 
shown) and of these, 104 where upregulated in PD+A animals. The top 30 metabolites 
significantly altered by dried plum consumption are presented in Table 8. As expected, PD+A 
rats had increased relative concentrations of a number of food-derived metabolites versus BD+A, 
such as the sugar alcohol compounds mannitol/sorbitol, which is one of the more concentrated 
compounds found in dried plums and often cited for its laxative effect (194, 203, 259). PD+A 
animals also had significant increases in 5-hydroxymethylfurfural (HMF), a compound derived 
from the dehydration of sugars and commonly formed when sugar-containing foods are exposed 
to heat (e.g., drying or cooking) versus BD+A (194). Dried plums are known to contain up to 
2200 mg/kg of HMF and its primary metabolite, 5-hydroxymethyl-2-fuoric acid (HMFA), was 
also highly elevated in PD+A animals compared to BD+A (260). Similarly, a number of plant-
derived/associated compounds were elevated in PD+A animals compared to BD+A, including: 
quinate, salicylate, gentisate, sinapate, 1H-quinoline-2-one, and the amino acid asparagine, 
which is highly concentrated in dried plums (261). Furthermore, a number of microbially-derived 
metabolites were significantly altered in PD+A animals as a result of increased diversity in 




Table 8. Top metabolites affected by dried plum in the distal colon, their super pathway classification, database identifiers (if known), 
and fold of change (PD+A/BD+A, Least square means). Metabolites are sorted by increasing Q-values (i.e., FDR adjusted P-value). 
 
 
Metabolite  Super Pathway KEGG HMDB PUBMED Fold of Change Q-value 
5-hydroxymethylfurfural Xenobiotics C11101 HMDB34355 237332 637.65 0.00E+00 
Quinate Xenobiotics C00296 HMDB03072 6508 124.27 0.00E+00 
4-hydroxycyclohexylcarboxylic acid Xenobiotics C04404 HMDB01988 151138 39.62 0.00E+00 
N-acetylvaline Amino Acid  HMDB11757 66789 27.57 0.00E+00 
Mannitol/sorbitol Carbohydrate C00794 HMDB00247 5780 20.88 0.00E+00 
Gentisate Amino Acid C00628 HMDB00152 3469 14.87 0.00E+00 
Sinapate Xenobiotics C00482 HMDB32616 637775 6.22 0.00E+00 
Arabonate/xylonate Carbohydrate    4.39 0.00E+00 
2-oxindole-3-acetate Xenobiotics  HMDB35514 3080590 7.59 7.00E-15 
Enterolactone Xenobiotics   10685477 6.54 5.97E-13 
Asparagine Amino Acid C00152 HMDB00168 6267 4.10 9.28E-12 
Carboxyethyl-GABA Amino Acid  HMDB02201 2572 2.87 1.86E-10 
1H-quinolin-2-one Xenobiotics C06415  6038 7.13 6.49E-10 
Homocitrulline Amino Acid C02427 HMDB00679 65072 4.59 1.70E-09 
Deoxycarnitine Lipid C01181 HMDB01161 134 11.92 9.68E-09 
Maleate Lipid C01384 HMDB00176 444266 2.82 2.25E-07 
Enterodiol Xenobiotics   123725 6.00 2.28E-06 
N-methylpipecolate Xenobiotics   11862129 4.38 3.36E-06 
2'-deoxyinosine Nucleotide C05512 HMDB00071 65058 0.35 4.79E-06 
7-methylguanine Nucleotide C02242 HMDB00897 11361 12.78 5.40E-06 
Bilirubin (Z,Z) Cofactors/Vitamins C00486 HMDB00054 5280352 5.09 8.19E-06 
Galactitol (dulcitol) Cofactors/Vitamins C00486 HMDB00054 5280352 3.33 8.83E-06 
5-hydroxymethyl-2-furoic acid Amino Acid C20448 HMDB02432 80642 5.54 1.51E-05 
2-oxo-1-pyrrolidinepropionate Xenobiotics   3146688 2.94 1.89E-05 
N1-methyladenosine Nucleotide C02494 HMDB03331 27476 1.96 2.21E-05 
1-methylimidazoleacetate Amino Acid C05828 HMDB02820 75810 1.68 3.58E-05 
N6-acetyllysine Amino Acid C02727 HMDB00206 92832 2.21 4.34E-05 
Pipecolate Amino Acid C00408 HMDB00070 849 3.39 6.02E-05 
Hippurate Xenobiotics C01586 HMDB00714 464 4.54 6.24E-05 
1-methylxanthine Xenobiotics C16358 HMDB10738 80220 12.33 8.96E-05 
Eicosapentaenoate (EPA; 20:5n3) Lipid C06428 HMDB01999 446284 2.07 0.0832 
Linoleate (18:2n6) Lipid C01595 HMDB00673 5280450 1.77 0.0831 
Linolenate [α or γ; (18:3n3 or 6)] Lipid C06426 HMDB03073 5280934 1.86 0.0715 
Dihomo-linolenate (20:3n3 or n6) Lipid C03242 HMDB02925 5280581 3.27 0.0161 




compounds enterolactone and enterodiol, derived from microbial metabolism of plant lignans, 
were both significantly enriched in PD+A animals versus BD+A (262). Other microbial 
metabolites associated with plant intake were similarly increased, including: 4-
hydroxycyclohexylcarboxylic acid, hippurate, and 2-oxindole-3-acetate. Lastly, several 
polyunsaturated fatty acids were also found at greater levels in the distal colon of plum rats 
compared to basal counterparts, including: eicosapentaenoate (EPA; 20:5n3; 2.07-fold), linoleate 
(18:2n6; 1.77-fold), linolenate (α or γ 18:3n3 or 6; 1.86-fold), and dihomo-linolenate (20:3n3 or 
n6; 3.27-fold). Moreover, dihomo-linolenate was also significantly greater in the proximal colon 
of plum rats versus basal. Following these observations, a fatty acid profile of both diets was 
generated via gas chromatography (263) using two samples obtained from each diet. Diets were 
checked for palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1N-9), linoleic acid (18:2N-
6), and alpha linoleic acid (18:3N-3). The results from this analysis are presented in Table 9 and 




Table 9. Fatty acid profiles* of basal and plum diets used in the experiment.   
 Average (% mol) 
Diet Palmitic 16:0 Stearic 18:0 Oleic 18:1N-9  Linoleic 18:2N-6 Alpha-linoleic 18:3N-3 
Basal (n=2) 13.70 1.99 28.42 54.91 0.98 
Plum (n=2) 13.73 1.94 28.45 54.82 1.05 




Ingenuity pathway analysis  
 To better interpret the changes observed in the metabolome data, Ingenuity Pathway 
Analysis (IPA; Qiagen) was employed to determine metabolic pathways that may be affected by 




identification of new targets and/or candidate biomarkers within the context of biological 
systems. Its analyses are based on a ‘master’ network derived from the Ingenuity Knowledge 
Database, which is itself derived from experimental data (264). Due to the pronounced changes 
in the distal gut microbiota, fold change data of metabolites with known database identifiers 
were used to identify pathways impacted by the dried plum diet in the distal colon. The 
workflow utilized for the IPA analysis is presented in Figure 7. 
The resulting analysis detected several canonical pathways altered by dried plum 
consumption. The top five most significant canonical pathways discovered in response to dried 
plum consumption included IL-10 signaling, L-cysteine degradation I, II, and III, and heme 
degradation. The canonical pathways, number of compounds related to the pathway found in the 
dataset, and P-value of the pathway relationship is seen in Table 10. IL-10 signaling and Heme 
degradation shared the same two metabolites, bilirubin and biliverdine, which were ~5-fold and 





Figure 7. IPA workflow for network discovery using metabolites found to be significantly 
different between distal colon samples of Plum+AOM and Basal+AOM animals. 
 
Table 10. Top canonical pathways detected by IPA software, number of compounds in the 
dataset related to the pathway, and their respective P-values.  
 




Top Canonical Pathways # molecules P-value 
IL-10 signaling 2 5.12E-03 
L-cysteine degradation II 2 5.12E-03 
Heme degradation 2 1.69E-02 
L-cysteine degradation III 2 1.69E-02 




L-cysteine pathways shared the same compounds, L-cysteine and pyruvic acid, which were ~1.4-
fold and ~2.1-fold higher, respectively, in plum diet animals.    
Use of IPA’s Network discovery feature also revealed a number of potential relationships 
for investigation in future experiments aimed at further elucidating the bioactivity of dried plum 
in the colon. The top network associated with the distal colon metabolomics data in our AOM 
treated animals was comprised of three interrelated cellular functions: 1) Free radical 
scavenging, 2) Cell death and survival, and 3) Reproductive system development and function. 
The network generated from our input data and the Ingenuity Knowledge Database is presented 





Figure 8. Graphical representation of the top ID Associated Network Functions generated by 
IPA: Free Radical Scavenging, Cell Death and Survival, Reproductive System Development and 
Function. Arrows indicate associations between nodes. Red and green indicate increases and 





The microbiota and their metabolites are known modifiers of cancer and inflammation, a 
well-established promoter of carcinogenesis (265). Therefore, understanding the contribution of 
the gut microbiota to colon cancer risk and progression and how the diet might impact this 
dynamic is a critical objective for disease prevention and treatment. The increased expression of 
inflammatory genes as a result of gene mutations, such as Nos2 and Ptgs2 contribute to the 
promotion phase of AOM-induced carcinogenesis in the model (266). Previous work using 
individual bioactive compounds derived from dried plums suggests chemoprotective and anti-
inflammatory activities that may be enhanced when consuming the whole fruit (183, 187, 205, 
261, 267, 268).  
A previous study by Yang and Gallaher (205) utilized a dried plum powder to investigate 
the impact of dried plum consumption on AOM-induced colon cancer. Despite no mitigation of 
pre-neoplastic lesion formation in response to AOM, they were able to document putatively 
beneficial microbial changes, specifically the abundance of genes involved in the generation of 
secondary bile acids, which are known mutagens (206). The objective of this study was to 
expand upon the current knowledge regarding the protective bioactivity of dried plums, and their 
impact on colon microbe composition and metabolism in the context of colon cancer. 
Incorporation of a dried plum puree, as 5% of total diet calories, reduced the incidence of 
HMACF induced by AOM treatment by 50%. The increased expression of the inflammatory 
promoter Nos2 in the proximal colon following AOM treatment was mitigated in PD+A animals, 
whose levels remained comparable to BD+S animals. Tlr2 and Tlr4 are upstream of critical 
inflammatory pathways (e.g., Nfκβ) which are activated by recognition of microbial pathogen 




BD+A, in combination with the reductions in iNOS, suggest that dried plum may be able to 
suppress the pro-inflammatory response to various microbial antigens that may otherwise 
exacerbate the response to AOM treatment. In the distal colon, neither diet was able to mitigate 
the AOM-induced changes in gene expression. Decreases in the expression of the proton coupled 
SCFA transporter, Slc16a1, and the short- and medium chain acyl-CoA dehydrogenases in the 
distal colon of AOM-treated animals suggests an impaired ability to actively transport and 
metabolize SCFAs produced by gut bacteria. Decreased expression of Slc16a1 and similar 
transporters is known to occur during CRC (270). Higher relative expression of toll-like receptor, 
SCFA transporters and metabolism enzymes, and inflammatory genes in the distal colon 
suggests greater signaling activity between epithelial cells and the microbiota. Indeed, it is well 
established that the relative microbial load is greatest in the distal intestines (84).   
 This experiment demonstrated that the consumption of dried plum can modify microbial 
abundances throughout the colon, most notably, by decreasing the ratio of 
Firmicutes/Bacteroidetes in the distal colon. In the distal colon, Lactobacillus and Allobaculum 
contributed ~30% of the bacterial sequences detected in basal diet animals, but only ~15% in 
plum diet animals, suggesting substantial alterations in dominant bacteria when animals consume 
dried plum. Lactobacillus and Allobaculum are both gram-positive genera, which are specifically 
recognized by the Tlr2 receptor, whose gene expression was decreased in plum diet animals. 
Allobaculum-like bacteria have previously been associated with 1,2-dimethylhydrazine induction 
of colon cancer and the order they belong to (i.e., Erysipelotrichales) has been positively 
correlated with colon inflammation and CRC (271, 272). The alpha diversity indices of Chao, 
number of observed species, and Shannon index revealed no significant differences in the 




shown). However, analysis of unweighted beta diversity revealed significant clustering of 
samples based on diet consumed. Altogether, these observations confirm that dried plum 
significantly impacts the composition of the colon microbiota including dramatic shifts in 
dominant bacterial groups; however, it is inappropriate to draw any conclusions regarding the 
mechanism of protection of dried plum consumption on the formation of ACF solely based on 
the observed changes in microbe composition. As previously mentioned, there is research 
associating certain groups of bacteria with specific disease states, but only a few have been 
mechanistically linked to contributing to disease conditions, such as hydrogen sulfide producing 
bacteria with colitis and colon cancer (273).    
It has been argued that the functional profile of the microbiome is more important than 
the composition of the microbiota (215). Certainly, the information collected from the 
metagenome, and metatranscriptome, of the gut microbiota would help to better elucidate 
potential pathways governing the mechanisms associated with host-microbe interactions during 
healthy and diseased states. To gain a better understanding of the impact that the dried plum had 
on shaping the microbiota, OTU data were additionally analyzed using PICRUSt to predict the 
metagenome content of samples. Analysis of the PICRUSt data revealed significant alterations in 
several KEGG functional pathways. Because the OTU input file that is fed into PICRUSt is also 
used for the taxonomic characterization, we were not necessarily surprised that only the factor of 
diet had an impact on the predicted metagenome profiles. Furthermore, comparison of the 
number of significant changes in the proximal versus the distal colon agrees with the observation 
that diet had the greatest impact on microbe composition in the distal colon. PICRUSt analysis 
revealed several pathways altered by dried plum including several changes to pathways 




polyphenol and plant constituents). Interestingly, plum diet animals were found to have a 
relatively greater prevalence of KEGG orthologs (KOs) related to secondary bile acid synthesis 
than basal diet animals, which is in contrast to work done by Yang and Gallaher (205). Because 
PICRUSt data relies on OTU data generated by sequencing a small portion of a single microbial 
gene (i.e., 16S rRNA), only the portion of the full metagenome contributed by the organisms 
targeted by the primers are included in the analysis. Furthermore, the use of a closed reference 
OTU reference (e.g., Green Genes), ancestral state reconstruction and inference of unknown 
microbe functions and 16S copy number, inherently compounds the inaccuracy and, thus, 
absolute confidence in the data. Nevertheless, PICRUSt is an extremely useful tool for low cost 
prediction of changes in the metagenome and has been shown to produce 80-85% accurate 
metagenomes from 16S data sets; however, it must be clearly stated that PICRUSt results are 
only suggestive and is most useful on human gut samples (220, 274). 
Our assessment of the luminal metabolome in the distal colon allowed us to explore 
potential changes in microbial metabolism. Indeed, consumption of the dietary bioactives 
contained in DP may offer chemoprotective activities in their unmetabolized form. For example, 
sorbitol has been shown to induce apoptosis in human colorectal cancer cells by p38 MAPK 
signal transduction (204). Additionally, 5-HMF has demonstrated antioxidant and anti-
proliferative properties in vitro (275). A byproduct of heating and drying, 5-HMF levels may not 
be comparable in the undried fruit, but is known to exist at high concentrations in dried plum 
juice (276). Importantly, several microbial metabolites were affected by dried plum 
consumption. Enterodiol and enterolactone created by microbial fermentation of plant lignans are 
positively associated with protection against several hormone-associated cancers (e.g., breast, 




to the cancers mentioned, a significant association between these phytoestrogens and colorectal 
cancer has not been established (277, 278). Although characterization of the fatty acid profiles of 
the basal and dried plum diet revealed no significant differences, alterations in the relative 
concentration of numerous polyunsaturated fatty acids presented as fold changes were observed 
in the proximal and distal colon. For a given diet, all PUFAs detected tended to have higher 
concentrations in the proximal colon than the distal colon. However, dried plum rats had up to 
3.3-fold higher levels of PUFAs (among other fatty acid compounds not presented) in their distal 
colons compared to rats consuming the BD. Various PUFAs have been shown to be major 
contributors to colon health in the prevention and treatment of colon cancer (63, 243, 279-288). 
These observations are particularly intriguing considering the PICRUSt data suggesting 
increased fatty acid biosynthesis in the microbial metagenome of dried plum rats. However, 
whether these data reflect differences in production or uptake/utilization remains to be 
determined. Indeed, there is surging interest in the exploitation of microbial fatty acid 
biosynthesis from plant biomass for foodstuffs and bio-fuels (289-291). Dietary approaches that 
can take advantage of microbial fatty acid biosynthesis beyond short chain fatty acids, could be 
particularly relevant for colon health.    
SCFAs are the primary product of microbial fermentation of dietary fiber and numerous 
anti-inflammatory and anti-cancer properties have been ascribed to them, as previously 
discussed. Prior to AOM treatment, animals consuming dried plum had lower levels of the 
branched chain fatty acids isobutyrate and isovalerate, which are produced from the breakdown 
of amino acids and the SCFA valerate, suggesting reductions in amino acid fermentation by the 
gut bacteria. As a result, the proportion of butyrate as a function of total SCFAs was higher in 




dried plum to mitigate alterations in fecal SCFAs observed in BD+A animals following AOM 
exposure suggests retention of beneficial patterns of microbial metabolism during early disease 
stages. Specifically, BD+A animals had nearly a 100% increase in fecal acetate levels and a 9 
µmol/g increase in total fecal SCFAs after AOM treatment, whereas, PD+A animals showed no 
change in individual or total fecal SCFA levels. At 8 wk post-AOM, fecal SCFAs in BD+A 
animals returned to BD+S animal levels, which contrasted with PD+A animals whose SCFA 
profiles remained equivalent to PD+S animals throughout the study. However, a major limitation 
of fecal SCFA measurement is that the observations do not reflect changes in SCFA production 
by bacteria nor uptake by the host. Quantification of the SCFA transport proteins in host tissue 
and/or quantification of critical microbial enzymes necessary to produce the SCFA metabolites 
could shed light on the nature of this observation. 
It is clear that the microbiota contributes significantly to the health of the colon and risk 
of colon cancer and that the diet is a potent modifier of the intestinal microbe composition and 
metabolism. This study represents the early benefits of dried plum consumption on chemically-
induced colon cancer from initiation to promotion but does not permit us to confirm a reduction 
in eventual tumor formation, which will be necessary to support subsequent human studies. 
AOM-induced colon cancer requires activation of the pre-carcinogen into the active mutagen by 
the liver and microbes, and because animals in this experiment were pre-fed with the 
experimental diets to permit microbial stabilization before initiation, it is possible that the 
metabolism and excretion of the carcinogen may have been affected. Nevertheless, this does not 
preclude an appreciation of the protection afforded by dried plum consumption. Dried plums 
may act directly on host tissues via the provision of native compounds to the host and indirectly 




increasing incidence and mortality of distal colon cancers will require dietary chemoprevention 
strategies that can protect these sites. The enhanced influence of dried plum on the composition 
of the distal colon microbiota warrants further investigation into the bioavailability and 
bioaccessibility of dried plum-derived bioactive compounds and their microbial derivatives in 
the proximal and distal colon. Furthermore, because the diets utilized in this experiment were 
matched in terms of macronutrient profiles and ratio of soluble to insoluble fibers, we can with 
some confidence attribute these changes to the extra-nutritional components of the diet (e.g., the 
bioactive compounds). This ability of dietary bioactives to impact host health directly or through 
changes in the microbiota as prebiotics without dramatic modifications to the caloric profile of 
the diet, make bioactive-rich foods an attractive strategy for colon cancer prevention and 
treatment. Future studies will need to build on the observations made in this study and focus on 
elucidating the mechanisms of protection afforded by dried plums. Protein confirmation of 
affected genes (e.g., Slc16a1, Slc5a8, Nos2, Tlr2, ACADS, ACADM, etc.) in colon samples and 
the presence of microbial genes relevant to colon cancer (i.e., butyryl-CoA/acetyl-CoA 
transferase and phoshpotranbutrylase and butyrate kinase) (157) is warranted. An experiment in 
which the animals are introduced to the dried plum diet only after AOM treatment would 
determine whether the protection is related to the metabolism, efficacy, and excretion of the 
carcinogen, and, more importantly, whether dried plum consumption affords protection after an 
initiation event. Experiments employing germ free animals would help to determine to what 
extent the gut microbiota and its metabolism contribute to the protective effect afforded by dried 
plum consumption. Furthermore, it will be important to determine whether dried plum 
consumption has any effect on eventual tumor formation. Lastly, individual metabolites native to 




experiment could be used to conduct cell culture experiments for targeted or screening-based 









Exposure to ionizing radiation is a risk factor for development of colorectal cancer, and is 
known to affect the colon microbiota composition (104). Altered gut microbe compositions have 
been associated with colonic diseases including cancer and irritable bowel disease (23-25, 106, 
292). Diet is a potent modifier of the microbiota and microbial metabolism, with the potential to 
attenuate harmful alterations resulting from exposure to ionizing radiation (104, 211, 293). We 
have previously demonstrated that dried plum consumption in rats affects the composition and 
metabolism of bacteria in the colon, and that consumption of dried plums protects against 
chemically-induced colon carcinogenesis. Therefore, the objective of this experiment was to 
determine if consumption of a dried plum diet is able to prevent disruptions in colonic microbe 
composition and SCFA levels in mice exposed to high-charge, high-energy (HZE) ionizing 
radiation.  
Materials and Methods 
Animals and diets 
Adult mice (C57BL/6; N=40), in a 2x2 factorial design, either received 1 Gy of 56Fe 
whole-body radiation (600 MeV/n, 10 cGy/min) or were sham irradiated (NSRL, Brookhaven 
National Laboratory, Upton, NY) and received a dried plum diet (DP+Sham or DP+Rad) 
containing a dried plum powder as 25% of total diet weight, or a control diet (AIN93M, 




luminal contents were collected and immediately snap frozen in liquid nitrogen. All animals 
were singly housed throughout the entirety of the experiment. 
Luminal microbe profiling 
Luminal bacterial profiling was conducted similarly to the methods previously described 
in Chapter II. Isolation of total DNA from stool samples was carried out as described (294-296). 
Total bacterial DNA was amplified using primers targeting the V1-V2 region of the 16S rRNA 
gene and overhang adapter sequences appended to the primer pair for compatibility with 
Illumina index and sequencing adapters (297). Master mixes used 2x KAPA HiFi HotStart 
Ready-mix (KAPA Biosystems, Wilmington, MA). Each 16S rRNA amplicon was purified using 
AMPure XP reagent (Beckman Coulter, Indianapolis, IN). In the next step each sample was 
amplified using a limited cycle PCR program, adding Illumina sequencing adapters and optional 
dual‐index barcodes (index 1 (i7) and index 2 (i5)) (Illumina, San Diego, CA) to the amplicon 
target. The final libraries were again purified using AMPure XP reagent, quantified and 
normalized prior to pooling. The DNA library pool was then denatured with NaOH, diluted with 
hybridization buffer and heat denatured before loading on the MiSeq reagent cartridge and on the 
MiSeq instrument (Illumina). Automated cluster generation and paired-end sequencing with dual 
reads was performed. Samples were rarefied to 1000 sequences/sample before downstream 
analyses.  
Analysis of 16S rRNA amplicon-sequencing data was carried out using the QIIME 
pipeline (249) as described (294-298). Briefly, the combined raw sequencing data plus metadata 
was de-multiplexed and filtered for quality control. Sequences were grouped into Operational 
Taxonomic Units (OTUs) using UCLUST (251). After taxonomic assignation of OTUs, 




perform alpha and beta diversity calculations, measurements that were used with sample 
metadata to create graphic visualizations for scientific interpretation. A combination of Unifrac 
significance and PCoA using Fast Unifrac (300) were done to compare samples based on 
relevant parameters. OTU sequences were aligned and OTU tables containing the counts of each 
OTU in each sample were used to calculate mean species diversity of each sample (alpha 
diversity) and the differentiation among samples (beta diversity). Alpha and beta diversity 
measures were used to calculate the Shannon–Weaver diversity index for each sample. 
SCFA analysis 
The SCFA analyses were conducted using our standard protocols (153, 167). Fresh 
samples were flash frozen and stored at -80°C. Frozen samples were ground, mixed with an 
internal standard (2-ethylbutyric acid), and extracted in 70% ethanol. Extracts were centrifuged 
and aliquots of supernatant removed and mixed with another internal standard (heptanoic acid) 
prior to injection onto a HP-FFAP column in a Varian 3900 GC (Agilent Technologies, Santa 
Clara, CA). SCFA concentrations in the samples were determined by comparison to a 
commercially available mix of standards. 
Results 
Microbial profiling 
Overall, microbial analyses revealed that the dried plum powder diet increased the 
abundance of bacteria belonging to the phylum Actinobacteria (P<0.0024), Tenericutes 
(P<0.0196), and Verrucomicrobia (P<0.0113), and reduced the proportion of sequences 
classified as unknown. Additionally, exposure to 1 Gy of 56Fe ions increased bacteria belonging 
to Verrucomicrobia (P=0.0432). However, interpretation of these statistical results is confounded 








Figure 9. Relative abundance of bacterial phyla at 30 d post-IR in C57BL/6 mice consuming a 




Table 11. Alterations in bacterial phyla and genera in C57BL/6 mice consuming a control or dried plum diet and exposed to 1 Gy of 
HZE radiation or sham irradiated. 
a,b Groups not sharing a common superscript letter are significant (P<0.05). Data are LS means ± SEM. Standard error uses a pooled estimate of error variance. 
All groups n=10. 
 
 Microbial Abundance (% sequences)  
 Control Diet  Dried Plum Diet P-Values 
Phylum Sham  1 Gy Fe Sham 1 Gy Fe Diet Radiation Interaction 
Unassigned 6.64 ± 1.01a 6.40 ± 1.01a 0.75 ± 1.01b 0.66 ± 1.01b <0.0001 0.8715 0.9414 
Actinobacteria 0.15 ± 0.07a 0.14 ± 0.07a 0.36 ± 0.07b 0.36 ± 0.07b 0.0028 0.9409 0.9409 
Bacteroidetes 61.44 ± 6.90a 58.29 ± 6.90ab 56.26 ± 6.90ab 40.73 ± 6.90b 0.1081 0.1844 0.3757 
Firmicutes 29.18 ± 4.46ab 32.19 ± 4.46ab 36.40 ± 4.46a 22.40 ± 4.46b 0.7750 0.2262 0.0647 
Verrucomicrobia 2.49 ± 2.86a 2.92 ± 2.86a 4.83 ± 2.86a 16.38 ± 2.86b 0.0089 0.0432 0.0596 
Tenericutes 0.06 ± 0.30a 0.08 ± 0.30a 1.35 ± 0.30b 0.29 ± 0.30a 0.0165 0.0897 0.0785 
Proteobacteria 0.01 ± 4.94a 0.01 ± 4.94a 0.00 ± 4.94a 19.16 ± 4.94b 0.0607 0.0605 0.0605 
 Control Diet Dried Plum Diet P-Values 
Genus Sham 1 Gy Fe Sham 1 Gy Fe Diet Radiation Interaction 
Unassigned 6.64 ± 1.01a 6.39 ± 1.01a 0.65 ± 1.01b 0.76 ± 1.01b <0.0001 0.8600 0.9445 
S24-7 61.43 ± 6.90a 58.27 ± 6.90ab 56.25 ± 6.90ab 40.72 ± 6.90b 0.1082 0.1841 0.3761 
Akkermansia 2.50 ± 2.86a 2.92 ± 2.86a 4.84 ± 2.86a 16.39 ± 2.86b 0.0089 0.0433 0.0594 
Enterobacteriaceae 0.01 ± 4.60a 0.01 ± 4.60a 0.00 ± 4.60a 15.70 ± 4.60b 0.0967 0.0965 0.0963 
Oscillospira 4.17 ± 0.71a 4.86 ± 0.71a 2.85 ± 0.71ab 1.37 ± 0.71b 0.0018 0.5848 0.1385 
Ruminococcaceae 3.72 ± 0.56a 3.88 ± 0.56a 2.71 ± 0.56ab 2.04 ± 0.56b 0.0151 0.6572 0.4627 
Lachnospiraceae 1.06 ± 0.78a 1.53 ± 0.78a 4.97 ± 0.78b 2.74 ± 0.78a 0.0022 0.2649 0.0900 
Enterococcus 0.00 ± 3.42a 0.00 ± 3.42a 5.99 ± 3.42a 3.34 ± 3.42a 0.1814 0.7005 0.7008 
Lactobacillus 1.49 ± 0.35a 1.42 ± 0.35a 0.09 ± 0.35b 0.15 ± 0.35b 0.0005 0.9803 0.8488 
Ruminococcus 0.10 ± 0.01a 0.12 ± 0.01a 0.05 ± 0.01b 0.02 ± 0.01b <0.0001 0.7699 0.0608 
Turicibacter 0.91 ± 0.20a 0.76 ± 0.20a 0.01 ± 0.20b 0.01 ± 0.20b 0.0002 0.7267 0.7289 
Anaeroplasma 0.01 ± 0.30a 0.01 ± 0.30a 1.35 ± 0.30b 0.25 ± 0.30a 0.0120 0.0756 0.0761 
Coprococcus 0.35 ± 0.08ab 0.40 ± 0.08ab 0.50 ± 0.08a 0.18 ± 0.08b 0.6975 0.1047 0.0232 
Clostridiaceae 0.70 ± 0.14a 0.65 ± 0.14a 0.02 ± 0.14b 0.01 ± 0.14b <0.0001 0.8321 0.9012 
Coriobacteriaceae 0.00 ± 0.06a 0.00 ± 0.06a 0.31 ± 0.06b 0.32 ± 0.06b <0.0001 0.9345 0.9345 




11). Four animals in the DP+Rad group had near complete loss of bacteria belonging to the 
Bacteroidetes phylum (~0.1% of sequences assigned to Bacteroidetes), which comprised ~61% 
of sequences in Con+Sham animals, ~58% of sequences in Con+Rad animals, and ~56% of 
sequences in DP+Sham animals. Of these four, three also had significant loss of Firmicutes 
bacteria (2-10% of sequences). These three animals had 51.7-67.9% of sequences identified as 
belonging to Proteobacteria and 20.8-38.9% of sequences identified as Verrucomicrobia. The 
fourth DP+Rad animal exhibiting loss of Bacteroidetes had 51.8% of sequences identified as 
Verrucomicrobia. Furthermore, one DP+Sham animal had near complete loss of Bacteroidetes 
(~2.5% of sequences identified) in exchange for a significantly higher abundance of Firmicutes 
(82.6% of sequences) and Verrucomicrobia (14.5% versus ~3.76% average for other animals in 
the DP+Sham group). As a result, these animals had extremely low bacterial diversity (Figure 
10). Indices of species diversity (i.e., phylogenetic diversity (PD) whole tree and Shannon) and 
species richness (Chao1 and Observed species), all indicate substantial reductions in alpha 
diversity and evenness in these samples. All variables but PD whole tree passed the test for equal 
variances, but ANOVA revealed no significant differences between means.              
At the genus level, the gut bacteria of mice were largely dominated by S24-7 bacteria 
belonging to the Bacteroidetes phylum and to a lesser extent Clostridiales belonging to 
Firmicutes. The dramatic shifts in the three previously mentioned DP+Rad animals were the 
result of decreases in these dominant genera in exchange for, primarily, increases in 
Akkermansia (Verrucomicrobia phylum) and Enterobacteriaceae (Proteobacteria phylum). One 
DP+Rad animal had 33.9% of sequences identified as Pseudomonas and another animal had a 
majority of sequences identified as Enterococcus (33.1% of sequences). The remaining two 




Enterobacteriaceae. The single DP+Sham ‘outlier’ was largely dominated by Akkermansia 
(14%), Enterococcus (59.8%), and Lachnospiraceae (14.6%).   
 
Figure 10. Alpha diversity indices of species diversity (PD whole tree and Shannon) and species 
richness (Chao1 and Observed species) at 1 month post-IR in C57BL/6 mice fed a control or 





Animals consuming the dried plum diet had significantly lower (P<0.05) concentrations 
of all SCFA in the colonic lumen than control diet animals, except for acetate, which did not 
differ between diet groups (P=0.0878) (Table 12). Consequently, dried plum animals had 




Table 12. Colon luminal SCFA concentrations in male C57BL/6J mice provided a control diet (AIN93M) or a diet containing dried 











Data are least squares means ± SEM. Standard error values are pooled estimates of variance. Values in the same row not sharing a common superscript are 
significantly different (P<0.05). N=40, group n=10. 
 
 Control Diet Dried Plum Diet P-values 
SCFA Sham 1 Gy Fe Sham 1 Gy Fe Diet Radiation Interaction 
Acetate 12.44 ± 1.30a 11.46 ± 1.30a 10.19 ± 1.30a 9.15 ± 1.30a 0.0878 0.4414 0.9820 
Propionate 2.77 ± 0.30a 2.75 ± 0.30a 2.18 ± 0.30a 1.31 ± 0.30b 0.0017 0.1472 0.1619 
Butyrate 2.85 ± 0.21a 2.32 ± 0.21a 1.50 ± 0.21b 1.35 ± 0.21b <0.0001 0.1070 0.3483 
Isobutyrate 0.27 ± 0.03a 0.23 ± 0.03a 0.10 ± 0.03b 0.10 ± 0.03b <0.0001 0.4774 0.3905 
Valerate 0.24 ± 0.02a 0.18 ± 0.02b 0.07 ± 0.02c 0.06 ± 0.02c <0.0001 0.0506 0.2249 
Isovalerate 0.26 ± 0.03a 0.23 ± 0.03a 0.11 ± 0.03b 0.08 ± 0.03b <0.0001 0.2548 0.8916 
Total 18.83 ± 1.71a 17.16 ± 1.71a 14.14 ± 1.71ab 12.05 ± 1.71b 0.0069 0.2796 0.9024 
% Acetate 64.66 ± 2.10a 65.58 ± 2.10a 72.73 ±2.10b 76.93 ± 2.10b <0.0001 0.2304 0.4401 
% Propionate 15.04 ± 1.32a 16.18 ± 1.32a 14.90 ± 1.32a 10.23 ± 1.32b 0.0275 0.1902 0.0347 
% Butyrate 16.01 ± 1.21a 14.25 ± 1.21a 10.48 ± 1.21b 11.02 ± 1.21b 0.0009 0.6131 0.3466 
% Isobutyrate 1.47 ± 0.15a 1.39 ± 0.15a 0.65 ± 0.15b 0.80 ± 0.15b <0.0001 0.8214 0.4494 
% Valerate 1.35 ± 0.12a 1.15 ± 0.12a 0.49 ± 0.12b 0.42 ± 0.12b <0.0001 0.2582 0.5846 




individual or total SCFA concentrations irrespective of diet. In terms of percent contribution of 
each SCFA, the dried plum diet led to a greater percentage of acetate and lower percentage of the 
other SCFA as a function of total SCFA. The percent of propionate in the luminal contents from 
DP+Rad was significantly lower than all other treatment groups (P<0.05). 
Discussion 
According to the USDA National Nutrient Database for Standard Reference, Release 23 
(2010), a 40-gram serving of dried plums contains approximately 26 g carbohydrate (2.8 g fiber, 
10 g glucose, 5 g fructose, and 2 g starch), 12 g water, and 1 g ash. Furthermore, dried plums 
contain a variety of compounds with known or suspected bioactive functions ascribed to them 
such as sorbitol, 4-hydroxymethylfurfural, and phenolic/polyphenolic compounds (194, 195, 
259). Polyphenols are a major class of bioactive compounds found in dried plums, specifically 
neochlorogenic acid and  chlorogenic acid, and the flavonol quercetin (194). Although most 
bacteria in the large intestine are saccharolytic (i.e., utilizing primarily carbohydrate/fiber), 
polyphenolic and phenolic compounds can also undergo metabolism by intestinal microbes to 
generate secondary metabolites (191). It has been determined that as much as 90% of polyphenol 
compounds can persist into the colon due to low bioavailability, implicating microbial 
metabolites of the polyphenols as the source of bioactivity (301, 302).  It is important to 
emphasize, however, that this relationship is not unidirectional but rather a complex, multi-
microbial, interconnected micro-ecosystem. Polyphenols can exert antimicrobial activities that 
shape the composition and, potentially, the functional profile of the intestinal microbiome (103, 
134, 192, 193). Taken together, it is the direct actions of dietary polyphenols on host tissues and 
the microbiome, and the resulting bacterial metabolites of the polyphenols which can contribute 




The work presented here indicates that the incorporation of a dried plum powder at 25% 
of total diet weight is capable of modifying the gut microbiome composition and luminal SCFA 
levels. Specifically, dried plum animals had significantly fewer bacteria classified as ‘unknown’ 
and instead had greater abundances of Verrucomicrobia, Tenericutes, and Actinobacteria. In this 
experiment, bacteria belonging to the genus Akkermansia were the sole contributor to the phylum 
Verrucomicrobia. Akkermansia muciniphila is a mucin-degrading bacteria shown to improve 
host metabolism and protect mice against diet-induced obesity (303, 304). Dietary polyphenols 
from concord grapes have recently been shown to promote the growth of Akkermansia 
muciniphila in mice, mitigating several effects of a high fat diet (305). These findings are 
consistent with our data demonstrating that dried plums containing polyphenols increase the 
abundance of Akkermansia in the mouse colon.  
Surprisingly, an effect of radiation on colon microbe composition was only observed for 
Verrucomicrobia (Akkermansia muciniphila), which was increased following HZE exposure. 
Interestingly, there is evidence of an interaction effect between the dried plum diet and HZE 
radiation exposure that drastically impacts the steady state bacterial composition in some 
animals. Body weight and food intake measurements revealed no differences between the 
uniquely affected animals and other animals in their respective groups (data not shown). 
Recently, Akkermansia was shown to be elevated in the colon of mice exposed to radiation along 
with Proteobacteria and transmission of radiated mouse microbiota into germ-free wild type 
mice rendered them susceptible to DSS-induced colitis (306). These changes occurred in concert 
with increased inflammation mediated by TNFα and IL-1β and tissue damage. However, 
investigators did not determine which specific bacteria were promotive of the inflammation and 




been associated with wound healing and mitigation of colitis in other mouse models of 
inflammation (304, 307-310). Taken together these observations suggest that the consumption of 
polyphenolic compounds, which are known to promote the growth of beneficial Akkermansia in 
addition to their direct antioxidant activities, could mitigate IR-induced colonic damage and 
inflammation. Future experiments using tissue obtained from these animals at termination would 
help to reveal whether or not these changes in the microbiome are protective.  
Mice consuming the dried plum diet had significantly lower individual (except for 
acetate) and total SCFA concentrations compared to control diet animals. Akkermansia have 
been identified as key propionate producing bacteria (303), although our data indicate a 
reduction in luminal SCFA levels in mice fed the dried plum diet. Despite this increase in 
Akkermansia, it is possible that the dried plum selects against the growth of other bacteria 
capable of producing SCFA. Additional work will be necessary to more directly assess if dried 
plum has any effect on the production of SCFA, such as quantifying microbial enzymes/genes 
responsible for SCFA production (i.e., butyryl-CoA:acetate CoA-transferase). Alternatively, 
bioactive components of dried plum or microbial derivatives thereof could regulate the uptake of 
SCFA by colonocytes (e.g., SCFA transporters slc16a1 and slc5a8) in host tissues, thereby 
affecting the luminal concentration of SCFA. Previous work in our lab failed to demonstrate a 
significant change in the expression of SCFA transporters or short- and medium-chain acyl-
dehydrogenases in response to a dried plum diet in rats (311). Nevertheless, there is potential for 
regulation of these enzymes at the protein level, which were not assessed in that experiment 
(311, 312).  
Radiation exposure had no effect on luminal SCFA levels in this experiment. Previous 




significant reductions in fecal isovaleric acid and total SCFA 24 hours after the final radiation 
bolus (104). Animals in our experiment were exposed to a single acute dose of 1 Gy Fe ions, 
which exert different biological effects compared to low LET radiation sources like gamma- and 
x-rays. Furthermore, animals in this experiment were terminated at 30 days post-IR so it is 
possible that any effects on luminal SCFA by the radiation exposure may have been missed 
and/or resolved by the time animals were terminated. Conversely, diet was a strong modifier of 
luminal SCFA levels. Our previous work presented in Chapter II employing a dried plum puree 
diet in rats demonstrated that dried plum consumption significantly lowered fecal levels of 
several branched chain fatty acids, so the response observed in this experiment was not 
necessarily unexpected. 
DP+Sham and DP+Rad animals exhibiting drastic alterations in their microbiota also had 
similar alterations in their SCFA levels versus other animals in their diet/treatment groups. 
Specifically, acetate, propionate, and butyrate were all markedly reduced in these animals, 
suggesting that decreased diversity of the microbiota as a result of interactions between the dried 
plum and radiation can affect luminal SCFA concentrations. Reduced SCFA levels and microbial 
diversity has been associated with intestinal diseases such as cancer and inflammation (100-102, 
104), which may exacerbate the response to biological insults such as ionizing radiation. 
Additional assays with tissue samples from these animals will be necessary to determine whether 
or not the dried plum diet, exposure to ionizing radiation, and their interaction resulted in an 
observable phenotypic response that would permit further interpretation of the data presented 
here. High-LET, HZE (i.e., directly ionizing) radiation is known to produce complex DNA 
damage and to a lesser extent free radicals (i.e., indirectly ionizing radiation). Therefore, we 




mitigate the indirectly ionizing component of exposure to HZE radiation. Biomarkers of 
oxidative stress and DNA damage (e.g., reactive oxygen species and 8-oxo-dG, respectively) 
have been shown to persist up to 1 year in the mouse intestine following ionizing radiation 
exposure (313). 
Over the last 20 years, dried plums have generated significant attention for their role in 
promoting and preserving bone health, particularly in post-menopausal women and animal 
models thereof (314-319). More recently, the primary investigative group of the study presented 
here published strong data demonstrating that dried plum consumption can protect against bone 
loss caused by exposure to ionizing radiation, which they attributed in part to reductions in the 
expression of genes related to bone resorption (320). Radiation exposure of skeletal tissue 
facilitates rapid cancellous bone loss, increases in osteoclast number and activity, and production 
of reactive oxygen species (320). Dried plums contain essential and important vitamins and 
minerals, such as magnesium, boron, potassium, copper, and vitamin K, which may contribute to 
the protective effects in bone (194); however, their phenolic compounds (e.g., chlorogenic acids, 
and neochlorogenic acids) are known to be potent superoxide radical scavengers (268). 
Importantly, in the experiment by Schreurs et al., an antioxidant cocktail diet containing 5 
antioxidants (ascorbic acid, N-acetyl cysteine, L-selenomethionine, dihydrolipoic acid and 
vitamin E), failed to prevent the effects of radiation on the expression of osteoclast related genes 
and subsequent bone loss (320). Interestingly, a cursory examination of the animals with 
uniquely altered microbial composition had similarly unique responses in bone health parameters 
(e.g., osteoblast colony numbers, percent bone mineralization, and bone mineral density; data not 




composition resulting from the interaction of dried plum and radiation exposure may have 
important implications beyond the intestines.  
 It is evident that dried plum is a strong modifier of the gut microbiota composition and 
luminal SCFA levels. Although there were only a few alterations observed in response to 
radiation exposure, it is possible that these changes are 1) masked by the greater effect of diet, 2) 
are transient effects that may resolve before 30 days post-IR, and/or 3) are too subtle to be 
detected with our sample size. Radiation is known to impact the composition of the gut 
microbiota, and certain microbes are known to be more radioresistant than others just as different 
mammalian cell populations can be more radiosensitive than others (321-324). In this 
experiment, radiation was only found to affect the abundance of Akkermansia, which was 
increased in response to exposure. However, these changes were seen only in 40% of DP+Rad 
and 10% of DP+Sham mice. We currently have no clear explanation for this observed 
phenomenon, but an interaction of dried plum and radiation is suggested. Animals were singly 
housed throughout the experiment which removes the potential for cage effects, and these 
animals were comparable to other animals in their diet/treatment groups with respect to diet 
intake and body weight. It is not well understood whether the impact of radiation on gut 
microbiota is stochastic (occurring over time without a threshold) or deterministic (occurring 
within a short time at a given threshold) and more research is needed to determine what the 
threshold for effect could be and how long the effect(s) could persist. Indeed, this is likely to be 
species (bacterial and host) dependent, and heavily impacted by diet. As seen in this experiment, 
a diet supplemented with dried plum powder is a much more ‘potent’ modifier of the gut 
microbiota composition and SCFA compared to HZE radiation expsoure. Without a greater 




any information regarding risk and risk mitigation from this experiment. Also, because the dried 
plum diet was a standard AIN-93M diet supplemented with a dried plum powder (25% by 
weight), which was not analyzed for macronutrient content, it will be impossible to determine 
whether these alterations are primarily due to unique components of the dried plum (i.e., 
bioactives and fiber profile), or differences in macronutrient and caloric content. As diet is such a 
strong modifier of the gut microbiota and many bacteria are known to have substrate preferences, 







POLYPHENOL-RICH SUMAC SORGHUM DIETARY INTERVENTION ALTERS 
COLON MICROBIOTA AND PLASMA METABOLITES IN HUMAN SUBJECTS 
 
Introduction 
 The prevalence of overweight and obesity continues to increase dramatically, particularly 
in developed nations where the incidence of metabolic syndrome continues to rise in parallel 
(325). Metabolic syndrome is characterized by a constellation of factors known to increase the 
risk of heart disease, cancer, diabetes, and other chronic diseases (326, 327). The main risk 
factors include: abdominal obesity, high triglyceride and fasting glucose levels, low HDL 
cholesterol level, and high blood pressure (325). Furthermore, research has demonstrated that 
health complications associated with obesity include the manifestation of chronic, low-grade 
systemic inflammation (328-330). This elevated inflammatory tone is due in large part to the 
production of immune and inflammatory cytokines such as tumor necrosis factor (TNF-α) and 
interleukin-6 (IL-6) produced in metabolically active adipose tissue depots (330); however, the 
contribution of diet and gut microbiota to systemic inflammation is less understood.     
Gut bacteria thrive in the anaerobic environment of the intestinal tract and rely on dietary 
constituents that remain in the gut due to a lack of host digestive capacity or malabsorption. Gut 
bacteria exert a variety of  functions capable of affecting host health including the digestion and 
metabolism of luminal contents and stimulation of the host immune system (331). One important 
function of certain gut microbes is the production of SCFA via fermentation of dietary fiber. 
SCFAs can be absorbed by the cells of the colonic epithelium, where they may serve as an 




butyrate is a potent mediator of the colonic inflammatory response involved in ulcerative colitis 
(UC) and colon cancer (159), and has been shown to improve insulin sensitivity and increase 
energy expenditure in mice (332). Indeed, there is growing evidence supporting the role of gut 
microbiota as a contributor to host metabolism and health (333-335).  
The composition of the gut microbiota has been shown to differ between healthy and 
diseased individuals; a phenomena referred to as ‘dysbiosis’ (23). In particular, dysbiosis has 
been observed in concordance with obesity (333, 336, 337), intestinal inflammation (24, 101), 
and colorectal cancer (23, 28, 338) and is often broadly characterized by a high Firmicutes to 
Bacteroidetes ratio (339, 340). Therefore, modulation of the gut bacteria via easily achievable 
dietary interventions may provide an effective means for metabolic disease treatment and 
prevention in the general population.      
Bioactive compounds are molecules capable of impacting the physiology of organisms 
consuming them. Plant foods (e.g. fruits, vegetables, grains, etc.) are a major source of dietary 
bioactive compounds and understanding the mechanisms by which their consumption can impact 
host physiology is a major focus in nutrition-based intervention strategies. Sorghum is an ancient 
grain predominantly grown in dry, arid climates and several varieties of sorghum contain 
different concentrations and classes of bioactive compounds. The sumac sorghum variety 
primarily contains polymers of flavonols (condensed tannins), which are also known as 
proanthocyanidins or procyanidins (179). Condensed tannins have high antioxidant activity and 
the sumac sorghum variety is among the highest in terms of polyphenol content (179, 341). 
Polyphenols, particularly condensed tannins, are poorly absorbed in their natural form due to 
their large size and their location within plant fiber matrices (342). For this reason, the bioactive-




intestine where they can be metabolized by gut bacteria to form smaller bioactive metabolites 
(40, 343, 344). Additionally, there is evidence to suggest that many bioactive compounds may 
exert bactericidal activities further enhancing their ability to modulate bacterial populations 
(345).     
 We have previously found that sumac sorghum derived products have a low glycemic 
index, and when included in foods the bioactives contained in the sumac sorghum could reduce 
the rate of starch digestion (346, 347). Our research with rodent colitis models employing 
sorghum diets has shown changes in the composition of colon bacterial populations and fecal 
SCFA concentrations, suggesting that the bioactives in combination with the fiber matrix play a 
role in modulating gut microbiota metabolism (103, 212, 245, 348). The objective of the current 
study was to determine if a sorghum-based dietary intervention is able to affect fundamental host 
metabolic characteristics and/or modulate gut microbiota and their metabolism in overweight 
individuals at risk for developing metabolic syndrome. 
Materials and Methods 
Study design and dietary intervention 
 The procedures involved in this study were approved by the Institutional Review Boards 
of Texas A&M University, Kansas State University and University of Nebraska and written 
informed consent was obtained from all subjects (n=24) who participated. Males and females 
between the ages of 25-60 y, who were: nonsmokers; not taking medications for weight loss; not 
currently dieting for weight loss (weight had not changed more than 5 kg in either direction 
during the last 3 months); and had a BMI between 26 and 29 were recruited. Subjects must have 
been able to read, write and understand the English language. Subjects were excluded if they: did 




diabetic; had cancer in the 5 y prior to the study (except basal cell skin carcinoma); had renal or 
hepatic disease; had weight loss or gain of more than 5 kg in the previous 3 months (intentional 
or unintentional); had a history of drug or alcohol abuse in the previous 6 months; were taking 
weight loss, lipid-lowering, anti-hypertensive or anti-inflammatory steroid medications; had 
Crohn's disease, ulcerative colitis or other digestive disorders that interfere with digestion or 
absorption; women who were pregnant or lactating; women who did not have a regular menstrual 
cycle; were vegetarians; or people that consumed more than 15 grams per day of fiber. The 24 
subjects (n=8 males and n=16 females) recruited for the study were comparable in terms of age, 




Table 13. Baseline characteristics of all subjects (n=24) and separated by gender.  






Age (years) 41.3 ± 13.2 35.1 ± 12.3a 44.3 ± 12.8a 
Weight (kg) 79.3 ± 13.1 85.8 ± 13.4a 76.0 ± 12.0a 
BMI (kg/m—2) 27.2 ± 4.5 27.3 ± 4.4a 27.2 ± 4.6a 
Body fat (%) 28.4 ± 8.2 22.9 ± 7.2a` 31.2 ± 7.4b 
a,b For male and female columns, within a row, data without a common superscript differ (P < 0.05). Values are 




 The study employed a randomized crossover design with two levels of sumac sorghum 
dietary intervention: low, 50 g/day and high, 100 g/day. The 50 g/day treatment was consumed at 
breakfast and the 100 g/day treatment was consumed in two sessions, one at breakfast and the 
other later in the day. The sumac sorghum intervention was an extruded cereal puff containing 
only 95% sumac flour and 5% sumac bran that resembled a cocoa puff in texture, color, and 




provided with an optional teaspoon sugar sachet to use if desired. A TX52 twin screw extruder 
(Wenger Mfg., Sabetha, KS) was used to process the extruded puffs. Subjects consumed each 
level of intervention for 4 weeks, separated by a 3-week washout period (Figure 11). Subjects 
were instructed not to change exercise regimen or diet, aside from the intervention. Samples and 
24-hour diet records were collected at baseline and washout time points and following each 
intervention period. Samples for metabolite analysis were collected and body composition was 
assessed in the morning following a 10-hour overnight fast. 
Diet records and nutrition analysis 
 Three-day diet recalls were collected at baseline and leading up to the conclusion of each 
treatment period. Diet record data were analyzed using NDS software (349) to evaluate total 





Figure 11. Experimental design and sample collection. / indicates sample collection. Use of 




Microbial DNA analysis 
 Fecal samples were collected and frozen immediately in cryotubes the day before the last 
day, or the last day of, the treatment period. DNA was extracted and sequenced as previously 
described in Chapter II; sequencing was performed at University of Nebraska-Lincoln by Dr. 




of defecation. Samples were diluted in phosphate buffered saline (PBS) in a 1:10 ratio and stored 
in an ultra-low freezer (-80°C) for genomic analysis. DNA was extracted from fecal samples to 
characterize the gut microbiome following the protocol described previously, using a 
combination of enzymatic cell-lysis (with lysozyme and proteinase-K), mechanical cell-lysis 
(bead-beating) and the QIAamp DNA Stool Mini Kit (Qiagen, Germany) (351). Once extracted, 
the DNA was stored frozen at -80°C until sequencing was performed. The V1-V3 region of the 
bacterial 16S rRNA gene was amplified and sequenced by 454 pyrosequencing using a Roche 
Genome Sequencer GS-FLX with the Titanium platform (350). The first step after sequencing 
was to de-multiplex sequences by sample, and quality control the generated reads. The quality 
control parameters were the same as those used in a previous study (351). These steps were 
performed in the QIIME pipeline (qiime.org). After quality control, an average of >3800 
sequences were obtained per sample, with an average length of 515 base pairs. These sequences 
were further used for taxonomic classification to depict the fecal microbial community. 
Essentially, two methods were used for this purpose. First, the Classifier web-tool of the 
Ribosomal Database Project (RDP http://rdp.cme.msu.edu/) was employed to taxonomically 
classify sequences from the phylum to the genus level, and second, a non-taxonomic-based 
approach was used to assign the sequences to Operational Taxonomic Units (OTUs) (97% 
similarity), comparable to species-level bins. OTU-picking was performed using the UCLUST 
algorithm in QIIME (qiime.org).  
 To standardize the resulting taxonomic data, abundance of bacterial taxa was expressed 
as percent abundance with respect to the total number of sequences in the sample. These 






 SCFA concentrations from fecal isolates were determined as previously described (153, 
167). Briefly, fresh fecal samples were collected immediately after defecation, placed into 
cryovials and frozen, followed by storage at -80°C. Frozen samples were ground, mixed with an 
internal standard (2-ethylbutyric acid), and extracted in 70% ethanol. The extract was centrifuged 
and the supernatant removed and mixed with second standard (heptanoic acid) just prior to 
injection onto a HP-FFAP (Agilent Technologies) column in a Varian 3900 GC. Concentrations 
were calculated based on comparison of peak areas with those produced by a commercially 
available mix of standards. 
Plasma metabolomics 
 Plasma was isolated from whole blood samples for metabolomic analyses in cooperation 
with Metabolon (Metabolon, Inc., Durham, NC). Briefly, profiling was performed using three 
independent platforms: ultrahigh performance liquid chromatography/tandem mass spectrometry 
(UHPLC/MS/MS2) optimized for basic species, UHPLC/MS/MS2 optimized for acidic species, 
and gas chromatography/mass spectrometry (GC/MS) (253). The original scale data, provided by 
Metabolon, was normalized in terms of raw area counts without any imputation of missing 
values.    
Fecal metabolomics 
 Frozen powdered fecal samples were extracted with a methanol:chloroform:water based 
extraction method as previously described (352). Briefly, 800 µL of ice cold 
methanol:chloroform (1:1, v:v) was added to samples in a CK-Mix lysing kit tube (Bertin, 
Rockville, MD). Sample material was extracted on a Precellys 24 (Bertin) tissue homogenizer 




second time with 800 µL of ice cold methanol:water. Six hundred microliters of ice cold water 
was added to the supernatant and vortexed for 30 seconds. Samples were centrifuged and the 
aqueous upper phase was collected. The aqueous layer was filtered through a 0.2 µm nylon filter. 
Five hundred microliters of the filtered aqueous phase was then passed through a 3 kDa cutoff 
column (Millipore, Burlington, MA) and the flow through was collected and lyophilized to 
dryness. Samples were resuspended in 50 µL methanol:water (1:1, v:v) for analysis. 
 The target compounds in samples were detected and quantified on a triple quadrupole 
mass spectrometer (Quantiva, ThermoScientific, Waltham, MA) coupled to a binary pump 
HPLC (UltiMate 3000, ThermoScientific). MS parameters were optimized for the target 
compound under direct infusion at 5 µL min-1 to identify the SRM transitions (precursor/product 
fragment ion pair) with the highest intensity (Table 14). Samples were maintained at 4°C on an 
autosampler before injection. The injection volume was 10 µL. Chromatographic separation was 
achieved on a hydrophilic interaction column (Luna 5 µm NH2 100 Å 250 × 2 mm, Phenomenex, 
Torrance, CA) using a solvent gradient method (353). Solvent A was an ammonium acetate 
(20 mM) solution in water with 5% acetonitrile (v/v). The pH of solvent A was adjusted to 9.5 
immediately before analysis using ammonium hydroxide. Solvent B was pure acetonitrile. Table 
15 describes the relevant literature information and rationale for the measurement of the 
metabolites of interest. 
 
Statistical analyses 
Diet records, body composition, and glucose and lipid metabolism biomarkers (measured 
by collaborators), were analyzed with a one-way ANOVA with repeated measures. A P-value of 















 Initial analysis of the fecal microbiota and plasma metabolite data revealed no significant 
dose response effects between the two levels of sumac sorghum intervention. For this reason, the 
effect of treatment (i.e., mean change in response to sumac sorghum treatment; 
∆𝐻+∆𝐿
2
 ) was 
assessed for fecal microbes and plasma metabolites and is presented in this dissertation. The 
microbial data represents the proportion of total sequences in the sample that a given OTU was 
assigned. Each microbial taxon was assessed for normality. If the data was normally distributed, 




 ), where p is the proportion of the bacteria. The metabolomics data 
analyzed is ‘scaled imputed’ data provided by Metabolon Inc. and analyzed per their provided 
methods description (253). To generate this data, each biochemical value is normalized in terms 
of raw area counts, re-scaled to have median equal to 1, and any missing values are imputed with 
the minimum (255). If the data were normally distributed, they were analyzed in the ‘scaled 
imputed’ format. If the data were not normally distributed, a log transformation was performed 










Catechol Negative 109.1 91.1 20.0 56.9 
Benzoic acid Negative 121.1 77.1 10.3 34.9 
Trans-cinnamic acid Negative 147.1 103.1 12.7 40.6 
3-phenylpropionic acid Negative 149.1 105.1 10.3 44.3 
3-(3-hydroxyphenol)propionic acid Negative 165.1 121.1 10.3 48.3 
Indole-3-propionic acid Negative 188.1 59.1 15.7 50.3 
Quinic acid Negative 191.1 85.1 21.1 61.4 
Cinnamoylglycine Negative 204.1 160.1 10.3 48.0 




Table 15. Table of relevant literature and rationale supporting the investigation of specific 
metabolites in the human fecal samples. 
Metabolite Rationale References 
Quinic acid 1. Produced from chlorogenic acid by microbiota.  
2. Precursor to benzoic acid production by microbiota.  
3. Quinic acid moiety shown to be the major precursor of 
hippuric acid. 
(354, 355) 
Benzoic acid 1. Gut microbial metabolism of dietary aromatic compounds to 
benzoate is first step in biosynthesis of hippurate.  
2. Benzoate may also be derived from other dietary sources; 
however, we do not have data on dietary intake of benzoate 
and no differences in benzoate observed in plasma samples.  
3. Major microbial metabolite generated which is then absorbed 
and metabolized to form hippuric acid and 3-
hydroxyhippurate.  
(354, 355) 
Cinnamic acid 1. Likely intermediate in the metabolism of phenylalanine to 3-
phenylpropionic acid.  
2. Cinnamic acid is formed from Phe by the enzyme 
phenylalanine ammonia lyase.  
3. Cinnamic acid is converted in the mammalian body primarily 
to hippuric acid and is excreted as such along with benzoic 
acid.  
4. There are many cinnamic acid derivatives found naturally in 
sorghum. 
(356-359) 
Cinnamoylglycine 1. Cinnamoylglycine, a glycine conjugate of cinnamic acid, is 
known as a urinary metabolite in man (PMID: 649712). 
Whether it is formed de novo from plant cinnamate or is a 
plant product excreted unchanged has not been conclusively 
demonstrated. 
2. Not found when small quantities (0. 5-6 g) of cinnamic acid 
are fed to man, but by analogy with animal experiments may 
be produced when much larger quantities are given. (PMID: 
6743769).  
3. Previously shown to be abundant in conventional mice but 
only present in minimal concentrations in germ free mice. 
4. Cinnamoylglycine found to be a potential urinary biomarker 




1. Proanthocyanidin metabolite formed by human colonic 
microflora from phenylalanine and proanthocyanidins 
polymers.  
2. Despite an increase in serum levels of 3-phenylpropionic acid, 
there was no difference in benzoic acid, suggesting its rapid 
conversion into hippuric acid or conversion to alternate 
glycine conjugated forms (i.e. phenylpropionylglycine).  
(190, 356, 357) 
3-(3-hydroxyphenol)propionic acid 1. Metabolite derived from co-incubation of proanthocyanidins 
with human colonic microflora.  
2. Upstream of benzoic acid and 3-hydroxyhippurate. 
(190) 
Indoxyl sulfate 1. Derivative of microbial degradation of tryptophan found 
significantly reduced in plasma of our subjects.  
(361, 362) 
Indole-3-propionic acid 1. Major compound derived from microbial metabolism of 
indole. 
2. Found only in the plasma of conventionally raised mice.  
3. Shown to be a powerful antioxidant.  
4. Shown to be produced by Clostridium sporogenes.  
5. IPA is rapidly cleared from the body, suggesting its presence 







whichever form of the data was closest to a normal distribution was used for analysis.  
 T-tests on the treatment effect variables for microbes and metabolites were conducted and 
the means and standard errors for the variables are presented. Due to many hypotheses being 
tested simultaneously, multiple comparisons adjustments were made to the P-values generated 
from the t-tests. The Q-value is the P-value adjusted using the False Discovery Rate (FDR) 
approach. A Q-value <0.1 was considered significant unless otherwise stated.  
 For analysis of the fecal metabolomics, only subjects with metabolite signatures from 
baseline and post-high time points were included in the paired t-test. If the data was normally 
distributed a parametric t-test was performed. If the data was non-normal, a non-parametric t-test 
was performed. A P-value <0.05 was considered significant unless otherwise stated.     
Results 
Energy and nutrient intake, and body composition 
 Total energy intake was not significantly different between the treatment periods, 
however, there was an increase in fiber intake with each increase in cereal intake, and there was 
a significant increase in the intake of carbohydrate with the 50 and the 100 g of cereal consumed 
(Table 16). Although subject carbohydrate intake was greater during the sorghum intervention, 
body composition and blood biochemistry appeared unaffected by the nearly 30-g increase in 
carbohydrate intake (Table 17). At baseline, the average percent body fat was 28.4 ± 8.2% 
(mean ± SE) and remained unchanged throughout the experiment despite the increase in 








Table 16. Data from 3-day diet records collected at baseline and at the end of each dietary 
intervention period. 
Macronutrient Baseline 50 g Cereal 100 g Cereal 
Energy, kcal 2204.0 ± 72.8 2187.6 ± 126.1 2241.8 ± 95.8 
Fat, g 86.7 ± 3.7 81.2 ± 5.4 82.9 ± 4.8 
Saturated fat, g 30.4 ± 1.7 27.3 ± 2.2 27.5 ± 1.8 
Fiber, g 18.0 ± 1.4a 21.9 ± 1.2b 25.4 ± 1.1c 
Carbohydrate, g 269.0 ± 12.6a 282.6 ± 14.6 b 303.5 ± 12.8c 
Protein, g 80.2 ± 3.3 81.8 ± 4.8 80.2 ± 4.0 
a,b,c  Within a row, data without a common superscript differ (P < 0.05). Data are means ± SE.  
Table 17. Blood glucose and lipid profiles prior to and after consuming the sumac cereal.  
Variable Baseline 50 g Cereal 100 g Cereal 
Body fat, % 28.4 ± 1.7 28.6 ± 1.6 28.5 ± 1.7 
Glucose, mg/dl, (n=23) 89.4 ± 4.1 85.3 ± 3.1 86.4  ± 3.2 
Total cholesterol, mg/dl, (n=23) 169.1 ± 7.6 163.3 ± 7.5 172.8 ± 10.0 
HDL cholesterol, mg/dl, (n=23) 49.4 ± 2.6 46.1 ± 2.6 47.7 ± 2.7 
LDL cholesterol, mg/dl, (n=18) 108.4 ± 6.9 106.2 ± 5.4 114.4 ± 7.1 
Non-HDL, mg/dl, (n=23) 124.0 ± 7.6 117.2 ± 7.0 125.2 ± 9.0 
Total cholesterol/HDL, (n=23) 3.6 ± 0.2 3.7 ± 0.2 3.8 ± 0.3 
Triglycerides, mg/dl, (n=18) 110.8 ± 16.2 102.7 ± 17.7 108.8 ± 19.9 




Immunological marker analysis  
Undesirable microbial populations and/or damage to intestinal barrier integrity can 
elevate circulating levels of lipopolysaccharide binding protein (LBP), which is associated with 
obesity-related insulin resistance (363). In addition, obesity has been linked to increases in other 
pro-inflammatory markers, including high-sensitive C-reactive protein (hs-CRP) and interleukin-
6 (IL-6), hallmarks of subclinical, chronic activation of the immune system. Plasma was 
analyzed to determine the levels of hs-CRP, IL-6, and LBP in plasma. We found no changes in 
the levels of these markers of inflammation in the subjects after consumption of either the 50 or 







Figure 12. Circulating levels of (A) hs-CRP, (B) IL-6 and (C) LBP in subjects prior to and after 





Alterations in fecal microbiota 
To determine the effect of the sumac sorghum puff cereal on the gut microbiota, fecal 
samples taken at each time point were subjected to DNA isolation and microbial amplification 
and sequencing of the bacterial 16S rRNA gene at the V1-V3 regions. In total, there were 
372,186 reads with an average number of reads per sample of 3,877 ± 1,620. The average length 
of reads used in the analyses was 490 ± 14 base pairs. Diversity analyses were calculated based 
on 2,000 sequences per sample to avoid bias in the number of sequences. With respect to alpha 
diversity (i.e., diversity within samples), there were no significant differences observed for 
Chao1, Shannon, or Simpson diversity indices or number of observed OTUs between treatment 
groups (Figure 13). Beta-diversity (i.e., diversity between samples) plots showed no significant 
clustering between treatments (Figure 14).  
Our initial statistical analyses revealed no evidence of a dose response. Therefore, a 
treatment effect was calculated for the microbial taxa which averaged the response to the low 
and high sumac sorghum interventions. Significant alterations in microbes in response to sumac 





Figure 13. Alpha diversity estimates at Pre-Low, Post-Low, Pre-High, and Post-High sampling 





Figure 14. Beta-diversity principal components plot employing Bray Curtis dissimilarity for 
distance calculation between samples. Color coding by treatment: Pre1-red, Pre2-orange, Post 








sorghum intervention reduced the relative abundance of bacteria belonging to Firmicutes (-
3.72±1.3%, Q=0.05030) and increased the relative abundance of bacteria belonging to 
Verrucomicrobia (4.30±1.62%, Q=0.05030). Within the Firmicutes phylum, the largest 
alterations were observed in the genera Lachnospiraceae incertae sedis (-3.92±1.08%, 
Q=0.07560) and Faecalibacterium (3.09±1.08%, Q=0.07560). Decreases, albeit nonsignificant, 
were also observed for the genera Dorea (~1.3%, Q=0.29011) and Blautia (~3.3%, Q=0.36676), 
which contribute to the ~9.7% decrease in the Lachnospiraceae family noted in Table 11. The 
increase in the Verrucomicrobia phylum was primarily due to a 4.29±0.91% increase in the 
genus Akkermansia but this change was not significant after FDR correction (Q=0.28460).      
Short chain fatty acids 
 Baseline fecal short chain fatty acid (SCFA) concentrations exhibited a high degree of 
inter-subject variability, which could be attributed to differences in pre-treatment bacterial 
composition, diet, and/or SCFA transporter expression in the host. Total and individual SCFA 
were not different between baseline and post-washout time points (data not shown). Total fecal 
SCFA concentrations did not change significantly in response to either the high- or lower-level 
sorghum diets (Table 19). Similarly, fecal butyrate concentrations were not affected by 
consumption of the low or higher level of sumac sorghum cereals.  
Plasma metabolomic profiling 
Metabolomic profiles were established for comparisons in human plasma samples to 
determine if sumac sorghum consumption had any impact on the presence of metabolites 






Table 18. Changes in select microbial abundances in response to sumac sorghum intervention.  









Firmicutes Phylum original -3.72 1.30 0.0088 0.0503 
Verrucomicrobia Phylum log((1+p)/(1-p)) 4.30 1.62 0.0144 0.0503 
Clostridia Class original -5.37 0.99 0.0000 0.0003 
Verrucomicrobiae Class log((1+p)/(1-p)) 4.29 1.62 0.0144 0.0880 
Gammaproteobacteria Class log((1+p)/(1-p)) 0.32 0.13 0.0203 0.0880 
Clostridiales Order original -5.33 0.99 0.0000 0.0003 
Lachnospiraceae Family original -9.69 1.34 0.0000 0.0000 
Ruminococcaceae Family original 3.90 1.31 0.0067 0.0872 
Verrucomicrobiaceae Family log((1+p)/(1-p)) 4.29 1.62 0.0144 0.0982 
Micrococcaceae Family log((1+p)/(1-p)) 0.04 0.01 0.0151 0.0982 
Lachnospiracea incertae sedis Genus original -3.92 1.08 0.0014 0.0756 
Faecalibacterium Genus original 3.09 1.08 0.0024 0.0756 
Akkermansia Genus original 4.29 0.91 0.0144 0.2846 
 
Table 19.  Baseline concentrations and changes in response to low, high and the average 
treatment response for total and individual SCFA.   
SCFA 
Baseline conc.  
(µmol/g wet wt.) 
Δ Low Δ High Δ Treatment 
Total SCFA 120.95 ± 9.18 -10.05 ± 14.30 3.89 ± 11.80 -3.08 ± 7.49 
Acetate 44.40 ± 4.09 -3.20 ± 6.00 3.00 ± 4.64 -0.10 ± 3.04 
Propionate 22.50 ± 2.33 -5.57 ± 4.78 0.82 ± 2.05 -2.38 ± 2.69 
Butyrate 29.46 ± 4.12 1.13 ± 3.80 -1.29 ± 3.48 -0.08 ± 1.83 
Valerate 11.36 ± 1.28 -1.50 ± 1.13 0.80 ± 1.67 -0.35 ± 0.96 
Isobutyrate 3.88 ± 0.44 -0.74 ± 0.52 0.15 ± 0.56 -0.30 ± 0.37 
Isovalerate 9.35 ± 0.83 -0.48 ± 1.66 0.40 ± 1.36 -0.04 ± 1.26 




microbial metabolism of dietary phenols, aromatic amino acids were selected for presentation in 
Figure 15 due to their relevance to our stated objective of characterizing metabolites derived 
from microbial-metabolism. These metabolites are presented across all time points, with the 
adjusted P-value (i.e., Q-value) for the treatment effect noted. The complete list of metabolites 
significantly altered by sumac sorghum consumption is presented in Appendix Table 5. Sumac 
sorghum intervention produced increases in a number of metabolites derived from microbial 
metabolism of dietary polyphenols (e.g., proanthocyanidins and chlorogenic acid) and 




hydroxyhippuric acid (Q=0.083), cinnamoylglycine (Q=0.024), and 3-phenylpropionate 
(Q=0.083) (190, 354-356, 358, 360, 364-367). Additionally, sumac sorghum consumption led to 
reduced levels of the gamma-glutamyl amino acids (GGAAs) gamma-glutamylvaline (Q<0.001) 
and gamma-glutamylmethionine (Q=0.019). These and other GGAAs are generated by gamma-
glutamyl transferase (GGT) and elevated GGT is a biomarker for metabolic syndrome and 





Figure 15. Relative concentrations of select plasma metabolites revealed by multi-platform mass 
spectrometry. A-E, metabolites generated from the microbial metabolism of dietary polyphenols 
and phenylalanine; F, derived from microbial metabolism of tryptophan; G-H, gamma-glutamyl 
amino acids involved in recycling oxidized glutathione. * indicates statistical analysis was 





Fecal metabolite profiling 
 As previously mentioned, many of the compounds detected in the plasma of subjects 
following sumac sorghum consumption are of particular interest because of their known 
microbial production. Furthermore, many of these metabolites are catabolites of 
proanthocyanidin polymers (e.g., condensed tannins), which are the major polyphenolic 
compounds in sumac sorghum. Therefore, we sought to determine the concentration of these and 
other associated metabolites in subject fecal samples. Figure 16 illustrates a conceptual pathway 
adapted from Wikoff et al. and Gonthier et al. (355, 356) for the production of the target 
metabolites based on the available literature presented in Table 9. Additionally, microbial 
metabolites of tryptophan such as indole, indoxyl sulfate, and indole-3-propionic acid have 
recently been investigated for their role in colonic health (141, 142, 372-374). Unpublished work 
in our lab demonstrated reductions in fecal indole levels when rats consumed sumac sorghum. 
Although not significantly altered in subject plasma, 3-indoxyl sulfate tended to be lower in 
subjects following sumac sorghum consumption (q=0.14362).  
For this reason, we also investigated the levels of two tryptophan/indole derivatives, 3-
indoxyl sulfate and indole-3-propionic acid, in baseline and post-high (100 g/day) subject fecal 
samples. The compounds of interest included: 3-(3-hydroxyphenol)propionic acid, 3-
phenylpropionic acid (aka hydrocinnamic acid), benzoic acid, quinic acid, indoxyl sulfate, 
indole-3-propionic acid, cinnamoylglycine, and cinnamic acid. Surprisingly, out of the 8 
metabolites analyzed, only 5 were detected in our human fecal methanol:water extracts, with 
others being below the level of detection or quantification (Table 20). Because the statistical 
analysis of the data requires paired samples, only compounds detected in both samples for a 




levels at baseline, following the high level of sumac sorghum consumption subjects had 
increased concentrations of 3-(3-hydroxyphenol)propionic acid (~2.45 fold, n=13, P=0.000), 3-
phenylpropionic acid (~2.25 fold, n=17, p=0.004), and benzoic acid (~2.23 fold, n=9, P=0.001). 
Quinic acid was decreased in subjects following the high sumac intervention period (35% 





Figure 16. Conceptual diagram illustrating the production of metabolites from the dietary 
precursors: phenylalanine, proanthocyanidins, and chlorogenic acid. Adapted from Wikoff et al. 





In this study we have demonstrated that through a minimal dietary change achieved by 
the consumption of extruded sorghum cereal, a source of dietary fiber containing complex 




relative concentrations of aromatic and phenolic compounds produced by microbial metabolism 
in host plasma and the intestinal lumen. Many of the putatively bioactive compounds in the diet 
Table 20. Metabolites selected for targeted quantification in subject fecal samples at baseline 
and post-high time points.  














3-(3-hydroxyphenol)propionic acid 621-54-5 47 34 1 12 13 
3-phenylpropionic acid 501-52-0 47 38 0 9 17 
Benzoic acid 65-85-0 47 27 5 15 9 
Quinic acid 77-95-2 47 17 9 21 5 
Indoxyl sulphate 2642-37-7 47 7 1 39 0 
Indole-3-propionic acid 830-96-6 47 0 0 47 0 
Cinnamoylglycine 16534-24-0 47 0 0 47 0 
Cinnamic acid 140-10-3 47 0 0 47 0 
1Below the Level of Quantification (BLOQ). Refers to when peak is detected but cannot be quantified because the 
signal to noise ratio is <5. 2Below the Level of Detection (BLOD). Refers to when there is no visible peak for the 
sample.  
 
Table 21. Paired t-test results for the targeted fecal metabolite quantification at baseline and 







3-(3-hydroxyphenol)propionic acid 13 13.26 ± 4.35 32.52 ± 11.16 0.000* 
3-phenylpropionic acid 17 10.96 ± 2.76 24.72 ± 3.93 0.004 
Benzoic acid 9 0.39 ± 0.15 0.87 ± 0.36 0.001* 
Quinic acid 5 0.86 ± 0.25 0.30 ± 0.07 0.013* 




have low native bioavailability due to their polymerization and a lack of digestive capability by 
the host (302, 375). Many bioactive compounds are also held within plant fiber matrices and, 
therefore, have reduced bioaccessibility until microbial digestion of the carbohydrate latticework 
releases the compounds for further metabolism (375). Thus, the extent of bioavailability and 
bioaccessibility of bioactives in foods determines when, where, and to what extent a bioactive 
compound can be utilized/metabolized by the host, which can be dependent on the gut 




were able to modify the levels of microbially-derived metabolites in the blood and feces of our 
subjects. Many of the metabolites significantly affected by the dietary intervention have been 
identified as potentially relevant biomarkers for cardiovascular disease risk, impaired glucose 
tolerance, and metabolic syndrome (255, 368-371, 376, 377); however, their exact bioactive 
function(s) and mechanisms of action (if any) have yet to be determined. Experiments utilizing 
the microbially derived and parent compounds detected in our subjects following sumac sorghum 
consumption will be necessary to infer causal relationships beyond the correlative associations 
currently ascribed to these compounds. 
Following sumac sorghum consumption, there was no difference in alpha-or beta-
diversity metrics for fecal microbiota. This observation is not uncommon in human dietary 
intervention studies as large inter-individual variation in microbial populations promotes 
clustering by subject rather than treatment (378). Subjects had decreased bacteria belonging to 
the Firmicutes phylum and increased bacteria belonging to the Verrucomicrobia phylum. The 
decrease in Firmicutes was largely attributed to a decrease in Lachnospiraceae incertae sedis, 
which can be more appropriately classified as bacteria of the Lachnospiraceae family of 
‘uncertain placement.’ Lachnospiraceae bacteria are anaerobic bacteria belonging to the 
Clostridiales order and occur in the human and mammalian gut microbiota (379, 380). These 
bacteria have been linked to obesity and protection of colon cancer in humans, due in part to 
their production of butyrate; however, not all members of this family produce butyrate (381, 
382). Feeding mice with a high fat diet increased the abundance of Lachnospiraceae bacteria, 
which accompanied an increase in β-catenin signaling and inflammation (383). Another study 
determined that intestinal colonization of germ free ob/ob mice by a strain of Lachnospiraceae 




which particular members of the Lachnospiraceae family of bacteria were present in our human 
samples at this depth of sequencing; however, the association with this bacteria and its positive 
association with the aforementioned metabolic disorders suggests that longer term reductions in 
the bacterium could beneficially impact metabolic syndrome risk. 
Conversely, sumac sorghum significantly increased the abundance of Faecalibacterium 
and tended to increase Akkermansia (4% on average in response to sumac consumption). 
Faecalibacterium is a genus of bacteria with the sole known species, Faecalibacterium 
prausnitzii, whose depletion in the gut has been reported in several intestinal disorders (385). 
Faecalibacterium has been described as an anti-inflammatory, commensal bacterium that is 
negatively associated with colitis, and positively associated with maintenance of clinical 
remission in ulcerative colitis (386-389). Butyrate-dependent (390, 391) and –independent (387, 
388) mechanisms have been proposed to explain the role of Faecalibacterium in colitis and in 
the promotion of intestinal barrier function and inflammation suppression. Consequently, 
Faecalibacterium, has been identified as a good candidate for clinical investigation as a probiotic 
(385). Akkermansia, although not statistically significant after FDR correction, displayed a 
tendency for increased abundance in subjects consuming sumac sorghum. There are only two 
known species of Akkermansia, Akkermansia muciniphila, which is found in the human an 
mammalian gut, and Akkermansia glycaniphila recently identified by Ouwerkerk et al. in reptiles 
(392). The former is a gram-negative, strict anaerobe, capable of utilizing mucins as a sole 
source of carbon and nitrogen (303). Similar to Faecalibacterium, Akkermansia muciniphila, has 
been associated with improved glucose tolerance, reduced adipose tissue inflammation, and 
improved gut barrier function (308, 393). Additionally, Akkermansia has been associated with 




there is evidence demonstrating that dietary polyphenols from various sources are able to 
promote the growth and abundance of Akkermansia in the gut (305, 307, 309, 393), which 
supports our finding that sumac sorghum containing polyphenols in the form of condensed 
tannins, can act as a prebiotic to increase the abundance of Akkermansia in the human gut. 
However, it is important to note that many of the associations discussed here have not been 
mechanistically established and more work will be necessary to determine if, and/or to what 
extent alterations in these microbes contribute to the improved host physiology. In experiments 
where dietary polyphenols are being studied, it will be important to dissect direct effects of the 
compounds on the host from those that are facilitated by microbial functions, such as metabolism 
of the native compounds into other bioactive metabolites. Nevertheless, further investigation of 
the mechanisms by which Faecalibacterium and Akkermansia can improve the constellation of 
risk factors related to metabolic syndrome and intestinal disease, especially in combination with 
dietary polyphenols as bioactive microbial substrates, is especially warranted.        
Despite the alterations in putatively beneficial bacteria, we were not able to demonstrate 
significant changes in the risk factors associated with metabolic syndrome (e.g. BMI, cholesterol, 
fasting plasma glucose, etc.) over the short intervention period. It will be necessary to conduct 
longer dietary intervention periods in future experiments to determine if this pattern is retained 
over time, as there remains a potential for long term therapeutic effects. Of course, 
comprehensive studies at the level of the individual will be necessary to determine how lifestyle 
and genetic factors contribute to our endpoints. The microbiome is widely accepted as a major 
contributor to host health and changes in its composition following dietary interventions have 
been recently defined as ‘rapid and reproducible’ (293). However, disease phenotypes associated 




isn’t unreasonable to suggest that complete reprogramming of an unhealthy metabolic phenotype 
may take a similar length of time.  
Although we were not able to show significant changes in fecal SCFA concentrations, it 
is important to note that the dietary fiber provided by sumac sorghum is primarily insoluble and, 
thus, is not as efficiently metabolized by the bacteria (37, 210, 394). Furthermore, fecal 
concentrations of SCFA may not adequately reflect production by the bacteria or uptake by the 
host in vivo. For these reasons, we cannot conclude that the sorghum had any effect on the 
fermentative processes of the microbiota in our human subjects. Prior data in our animal models 
suggest that sumac consumption can reduce the level of excreted fecal butyrate, relative to 
cellulose fed control animals and animals consuming additional sorghum varieties (103, 212, 
245, 348). Indeed, the microbial analyses indicate a significant increase in Faecalibacterium 
prausnitzii, a bacterium associated with relatively high levels of butyrate production as 
previously mentioned. Further work will be needed to determine if the rate of SCFA synthesis, 
utilization by the bacteria, or absorption by the host can be influenced by the sorghum cereal. 
The ability of dietary polyphenols to exert bioactive functions is likely a combination of 
changes to the gut microbiome and direct effects of the native compounds directly on host cells 
and tissues. The former includes both changes to the composition and the metabolism of gut 
bacteria. In this experiment, we sought to characterize the plasma metabolome of subjects before 
and after the dietary intervention in order to identify the metabolic impact of sumac sorghum 
consumption. As anticipated, a number of biochemicals derived from microbial metabolism of 
plant phenols were altered in plasma samples following sumac sorghum consumption. Catechol 
sulfate, a sulfate-conjugated derivative of phenolic compounds, was increased in subject plasma 




after consumption of a mixed fruit/berry puree, reaching concentrations of 5 to 20 µm (395). 
Another recent human experiment employing lean and obese subjects consuming mango 
demonstrated an inverse correlation between plasma concentrations of catechol sulfate with 
BMI, suggesting that increases in BMI are associated with reduced polyphenol absorption (396). 
Furthermore, catechol sulfate was positively associated with IL-10 production in both lean and 
obese subjects, suggesting it could have anti-inflammatory activity. Another compound derived 
from microbial metabolism of dietary phenols, 3-hydroxyhippurate, was increased in subject 
plasma following sumac sorghum consumption. 3-hydroxyhippurate is an aromatic acid found in 
urine and plasma of humans, and is derived from the microbial metabolism of dietary 
polyphenols, such as chlorogenic acid (189, 354, 355, 397-399). Decreased urinary levels of 3-
hydroxyhippurate have been associated with impaired glucose tolerance (376). 4-
hydroxyhippurate was similarly increased in subjects following sumac consumption. 
Two metabolites derived from aromatic amino acids (e.g., phenylalanine), 
cinnamoylglycine and 3-phenylpropionate (aka hydrocinnamate) were increased in subjects 
following sumac consumption. Cinnamoylglycine is a glycine conjugate of cinnamic acid, a 
urinary metabolite in humans (366). Whether it is formed de novo from plant cinnamic acid or is 
a plant product excreted unchanged has not been conclusively demonstrated. Importantly, it is 
suggested to be a biomarker for colonization resistance to Clostridium difficle and, therefore,  
may exert antimicrobial activities in the colonic lumen (360). 3-phenylpropionic acid is a 
metabolite formed by human colonic microflora from both phenylalanine and proanthocyanidin 
polymers (356). Benzoic acid is a known derivative of 3-phenylpropionic acid, but the former 




conversion to alternate glycine-conjugated forms such as phenylpropionylglycine (190, 356, 
357).     
Lastly, several gamma-glutamyl amino acids (GGAA) were decreased in subjects 
following sumac sorghum consumption. GGAA are produced by gamma-glutamyl transferase 
(GGT), a cell surface enzyme, during the transfer of gamma-glutamyl functional groups from 
glutathione to an amino acid acceptor (400). Thus, GGT plays a crucial role in the recycling/re-
synthesis of glutathione and, to a lesser extent, the transport of amino acids into cells. 
Importantly, numerous studies have identified elevated GGT levels as a biomarker for metabolic 
syndrome and cardiovascular disease risk (368-371, 377). Lower levels of gamma-glutamyl 
amino acids were observed in the serum of subjects after consumption of sumac sorghum, which 
suggests increased absorption of these molecules from circulation or reduced production by 
GGT. Previous studies have identified a primary role of GGT in metabolizing extracellular 
reduced glutathione, which generates gamma-glutamyl amino acids that are then transported into 
the cell, where the amino acids are liberated to be reused in the synthesis of glutathione (401). 
Glutathione is responsible for preventing damage to the cell’s components produced by various 
reactive oxygen species such as lipid peroxides, peroxides, free radicals, and heavy metals (402). 
Thus, lower levels of gamma-glutamyl amino acids in the blood could reflect lower levels of 
reduced glutathione (i.e., lower oxidant stress), that could be compensated by antioxidant 
activities afforded by sumac sorghum derived metabolites in circulation. Additionally, 
researchers have proposed that gamma-glutamyl amino acids could be used as a biomarker for 
colonization resistance by bacteria from the Lachnospiraceae and Ruminococcaceae families 
(255). In our experiment, bacteria belonging to the genus Lachnospiraceae incertae sedis 




Following the results of our plasma metabolomics profiling, which revealed several 
microbially-derived compounds increased in response to sumac sorghum consumption, we 
hypothesized that intermediary metabolites which are known or highly suspected to be derived 
from the microbiota would be increased in fecal samples collected at the same time point. 
Additionally, our fecal microbe profiling had demonstrated shifts in the microbiota in response to 
sumac sorghum consumption, which could later be correlated with plasma and fecal metabolites 
to identify potential contributors to the metabolic shifts detected in the feces and in circulation. 
Out of the 8 metabolites chosen for measurement (based on known literature, standard 
availability, and validation), only four were detected and quantifiable in enough subjects to 
conduct statistical analyses. Potential explanations for undetected metabolites include, 1) the 
chemical standard validated by the method is not a form of the metabolite present in vivo, 2) that 
the levels of target metabolites are truly below the level of detection and/or quantification, and 3) 
that the extraction procedures employed were not sufficient and/or appropriate to recover the 
metabolites of interest. 3-(3-hydroxyphenol)propionic acid, 3-phenylpropionic acid, and benzoic 
acid, all derivatives of proanthocyanidin polymers, were increased in subjects following sumac 
sorghum consumption; however, not all subjects had detectable/quantifiable levels of these 
compounds post-consumption. This inconsistency could be due to lack of microbial catabolic 
function necessary to generate these derivatives in all subjects or differences in production, 
absorption, and/or conversion rates. Variability in subject microbial profiles clearly indicate this 
as a possible contributor. Furthermore, although we do not believe that compliance was an issue 
according to the diet records, subjects did not consume the dietary intervention under direct 
supervision by investigative staff and, therefore, must be considered. Nevertheless, the increase 




consumption makes them ideal candidates for future in vivo or in vitro mechanistic studies. More 
work will be necessary to determine to what extent these metabolites can act locally on host 
physiology at the site of production (i.e., the intestinal epithelium), how they can impact the 
microbiota composition, and how they can impact other risk factors related to metabolic 
syndrome. Quinic acid was reduced in subjects following sumac sorghum, despite it being a 
microbial derivative of chlorogenic acid, found in sorghum, and a precursor of benzoic acid 
(179, 209). Furthermore, quinic acid is a major precursor of hippuric acid (354, 355).  
Taken together, our results suggest that a modest intake of sumac sorghum can induce 
putatively beneficial shifts in gut microbiota and microbially-derived metabolites in the intestinal 
lumen and in circulation. Much of the literature linking specific gut microbes and their 
metabolites to positive health outcomes are based on correlative analyses in diseased and 
healthy, or lean and obese subjects or rodent models. It will be necessary to advance the work 
presented in this study and others by conducting highly controlled, mechanistic studies to 
elucidate causal bioactive functions of these microbes and their metabolites. Significant 
variability in nearly all parameters measured prevents our ability to detect smaller and potentially 
relevant changes with our sample size. Statistically, it is incredibly, perhaps impossibly, difficult 
to control for every factor (e.g., genetics, age, diet, etc.) that might contribute to the composition 
and functional repertoire of the gut microbiome. As diet and exercise are significant modifiers of 
the microbiome, future studies would benefit from stricter inclusion and exclusion criteria and 
should seek to control the activity and diet of subjects as much as possible (e.g., exercise 
regimes, and preparation, provision, and supervision of all meals/experimental interventions for 




Some bacteria have been well described in terms of their metabolic activity and 
contribution to host health (e.g., H. pylori, E. coli, etc.); however, the majority of microbiome 
constituents remain to be fully characterized. This lack of information precludes our ability to 
associate the production of the detected metabolites with a given a bacterium. Targeted fecal 
metabolite profiling revealed significant increases in metabolites derived from dietary 
proanthocyanidins contained in sumac sorghum, confirming their presence in the fecal stream. 
These compounds may act locally on the intestinal tissue and systemically before undergoing 
further metabolism by host enzymes, such as conjugation in intestinal and hepatic cells. 
Although we have not yet confirmed the protein levels of GGT, detection of lower levels of 
gamma-glutamyl amino acid metabolites suggests sumac sorghum in the diet may have the 
potential to modulate GGT activity or the availability of its substrate, which may serve to 
mitigate oxidative stress while simultaneously reducing the burden on intrinsic antioxidant 
networks in the host.  
Phenotypes associated with the risk of metabolic disease are strongly correlated with 
unhealthy (i.e., high fat, low fiber, etc.) dietary consumption patterns. Concurrent with this 
observation are functional and compositional changes in the gut microbiota that have the 
potential to promote disease development. Moreover, the functional capabilities of the 
microbiota can affect the nutritional value to the host of a given food. Thus, there is a complex, 
trilateral interaction that exists between the host, diet, and microbiota, whereby the diet can 
directly, via host digestive processes, and indirectly, via microbial digestion, affect host 
metabolism. For this reason, research characterizing the functional potential of a given 
microbiome will be necessary to elucidate the mechanisms that define host-microbial symbiosis. 











RELATING THE MICROBIOME AND THE METABOLOME: A SECONDARY 
ANALYSIS OF THE KANSAS SORGHUM STUDY DATA 
 
Introduction 
Sequencing of the 16S microbial gene permits us to determine whether the incorporation 
of a polyphenol-rich sorghum cereal into the diet had any effect on the composition of the 
microbiota but gives no indication of whether these changes have any effect on the physiology of 
the host. As many microbial metabolites are known to be absorbed and utilized/metabolized by 
the host, plasma metabolomics allows the identification and relative quantification of diet-
induced, microbially-derived compounds that are in circulation. Unfortunately, the physiological 
processes underpinning these observations are highly uncharacterized and further complicated by 
microbial gene redundancy, which allows many different bacteria to perform the same or similar 
functions. For example, there are many species of bacteria known to synthesize butyrate. 
Therefore, our goal was to determine relationships between metabolomic and microbial 
variables, so that future experiments could focus on identifying which bacteria may be 
responsible for the generation of specific metabolites that are absorbed by the host. The analysis 
variables of interest were: 1) dose response (i.e., low vs. high change from baseline); 2) mean 
change across diets (i.e., treatment response); 3) high diet change from baseline; and 4) low diet 







Methods and materials 
Study design and dietary intervention 
 The procedures used in this study were approved by the Institutional Review Boards of 
Texas A&M University, Kansas State University and University of Nebraska and written 
informed consent was obtained from all subjects (n=24) who participated. Males and females 
between the ages of 25-60 years, who were: nonsmokers; not taking medications for weight loss; 
not currently dieting for weight loss (weight had not changed more than 5 kg in either direction 
during the last 3 mo); and had a BMI between 26 and 29 were recruited. Subjects must have been 
able to read, write and understand the English language. Subjects were excluded if they: did not 
regularly eat breakfast or snacks; had food allergies; had cardiovascular disease; were diabetic; 
had cancer in the 5 years prior to the study (except basal cell skin carcinoma); had renal or 
hepatic disease; had weight loss or gain of more than 5 kg in the previous 3 months (intentional 
or unintentional); had a history of drug or alcohol abuse in the previous 6 months; were taking 
weight loss, lipid-lowering, anti-hypertensive or anti-inflammatory steroid medications; had 
Crohn's disease, ulcerative colitis or other digestive disorders that interfere with digestion or 
absorption; women who were pregnant or lactating; women who did not have a regular menstrual 
cycle; were vegetarians; or people that consumed more than 15 grams of fiber per day.   
 The study employed a randomized crossover design with two levels of sumac sorghum 
dietary intervention: low, 50 g/day and high, 100 g/day. The sumac sorghum intervention was an 
extruded cereal puff containing only 95% sumac flour and 5% sumac bran that resembled a 
cocoa puff in texture, color, and bowl life (i.e., how long the cereal retained texture when milk 
was added). Subjects were provided with an optional teaspoon sugar sachet to use if desired. A 




Subjects consumed each level of intervention for 4 weeks, separated by a 3-week washout 
period. Subjects were instructed not to change exercise regimen or diet, aside from the 
intervention. Samples were collected at baseline and washout time points and following each 
intervention period. Samples for metabolite analysis were collected in the morning following a 
10-hour overnight fast. Details of the methods and materials employed for the generation of 
microbial and metabolite data are presented in Chapter IV. 
Statistical methods  
The following analyses were carried out separately for each level of sumac sorghum 
consumption (i.e., Low, 50 g/day and High, 100 g/day).    
Inclusion criteria and summary statistics for microbial and metabolite data analysis 
Due to the variability observed in the microbial and metabolomic data (i.e., not all subject 
samples contained all detected microbes or metabolites) inclusion criteria were established for 
the data prior to statistical analysis. The inclusion criteria for the analyses were as follows: 1) 
subjects with complete data were included (one subject with microbial measurements but no 
metabolite data was excluded), 2) a microbe was included if at least 12 subjects had at least two 
non-zero values of the four measurements (pre and post for the two diets, low and high), referred 
to as the 50% version rule, and 3) a metabolite was analyzed if there were no missing values (i.e., 
N=23 subjects).  
Due to a high dimensional data set (i.e., number of variables), principal component 
(PCA) and canonical correlation (CCA) analyses were performed to attain lower dimensional 
data that were analyzed by metabolite and microbial pair using Pearson correlation (403). 
Statistical conclusions are based on the Pearson correlation results adjusted for multiple 




PCA is a multivariate method used for high-dimensional data reduction that permits the 
extraction of variables which are most important in a highly dimensional data table (404, 405). 
Original variables were standardized and transformed into a set of orthogonal principal 
components with corresponding eigenvalues and eigenvectors. Principal component eigenvalues 
are ordered from highest to lowest proportion of variance explained. PCA was performed 
separately by taxon for microbial variables and by subpathway for metabolite variables. 
Microbiota were included using the 50% rule for zeros (at least 12 subjects have at least two 
non-zero values of the four measurements). All biochemicals with non-missing data were 
included in the analysis. The selection criteria for evaluation of a principal component was: 1) 
cumulative variance <95%; and 2) >5% variance explained. For each evaluated principal 
component, a variable was included if the absolute value of its coefficient was >0.45. For 
principal component analysis of microbial taxon genus with n=32 (greater than subject n=23), 
300 random samples of 22 were analyzed and selection of microbiota was based on frequency 
percent.  
The selected microbiota and metabolites from PCA were analyzed using canonical 
correlation by taxon and subpathway (8x54 analyses). CCA is a multivariate method used to 
analyze relationships between two sets of random variables by optimizing the cross-covariance 
(406). Similar approaches have been used to identify potential relationships between microbes 
and metagenomic gene signatures (407). A canonical variate pair consists of a linear combination 
of each set of variables with maximized correlation between the linear combinations. The 
number of pairs equals the number of variables in each dataset (or in the smaller dataset if 
unequal). The canonical correlation for each canonical pair is tested by row using an F test for 




zero). The inclusion criteria was P-value <0.10. For each canonical pair selected, the correlations 
of the canonical variates (biochemical and microbial) with each variable were evaluated. The 
correlation of a microbial or biochemical variable with its own canonical variate or opposite 
canonical variate was absolute value >0.40 for inclusion. 
For the microbiota and metabolites selected using canonical correlation analysis, Pearson 
correlation was performed for the statistical results and conclusions. Analysis was conducted for 
all microbial and metabolomics pairs by taxon and subpathway with FDR adjustment for 
multiple comparisons.  
Results 
 Pearson correlation of ΔLow and ΔHigh microbiota (i.e., genus level) and plasma 
metabolite data are presented in Tables 22 and 23, respectively. A number of significant 
correlations were identified after dimensional reduction and false discovery rate correction of P-
values. For the low level of consumption, a positive association with Bacteroides was seen for 
the gamma-glutamyl amino acids gamma-glutamylvaline (r=0.582, Q=0.008) and gamma-
glutamylleucine (r=0.537, Q=0.012). Gamma-glutamylvaline was negatively associated with 
Streptococcus (r=-0.441, Q=0.036) and Faecalibacterium (r=-0.465, Q=0.032), and the latter 
with Faecalibacterium (r=-0.577, Q=0.008). Glutamate, an important neurotransmitter and 
necessary molecule for the synthesis of glutathione, was positively associated with Dialister 
(r=0.522, Q=0.025), and negatively associated with Blautia (r=-0.411, Q=0.046) and 
Faecalibacterium (r=-0.481, Q=0.025). 3-hydroxybutyrate was positively associated with 
Dialister (r=0.508, Q=0.020) and Akkermansia (r=0.433, Q=0.034) genera and negatively 




Table 22. Significant correlations between plasma metabolites and microbes (genus level) in response to the low level (50 g/day) 




Low consumption (50 g/day) Pearson Correlation 
Subpathway Biochemical Genus Est. (r) Lower CL Upper CL P-Value Q-value 
Chemical 2-ethylhexanoate Bacteroides 0.614 0.271 0.819 0.001 0.002 
Gamma-glutamyl gamma-glutamylvaline Bacteroides 0.582 0.224 0.802 0.002 0.008 
Carnitine metabolism decanoylcarnitine Blautia 0.573 0.211 0.797 0.003 0.008 
Gamma-glutamyl gamma-glutamylleucine Bacteroides 0.537 0.160 0.777 0.006 0.012 
Glutamate metabolism glutamate Dialister 0.522 0.140 0.769 0.008 0.025 
Ketone bodies 3-hydroxybutyrate  Dialister 0.508 0.122 0.761 0.010 0.020 
Sugar, sugar substitute, starch erythritol Akkermansia 0.502 0.113 0.757 0.012 0.024 
Carnitine metabolism cis-4-decenoyl carnitine Blautia 0.488 0.095 0.750 0.015 0.015 
Fatty acid metabolism  propionylcarnitine Blautia 0.470 0.072 0.739 0.020 0.049 
Ketone bodies 3-hydroxybutyrate  Akkermansia 0.433 0.026 0.717 0.034 0.034 
Glutamate metabolism glutamate Blautia -0.411 -0.704 0.001 0.046 0.046 
Sugar, sugar substitute, starch erythritol Bacteroides -0.423 -0.711 -0.013 0.039 0.039 
Gamma-glutamyl gamma-glutamylvaline Streptococcus -0.441 -0.722 -0.036 0.030 0.036 
Chemical iminodiacetate  Bacteroides -0.446 -0.725 -0.042 0.028 0.028 
Fatty acid metabolism  propionylcarnitine Dialister -0.457 -0.731 -0.055 0.024 0.049 
Gamma-glutamyl gamma-glutamylvaline Faecalibacterium -0.465 -0.736 -0.066 0.021 0.032 
Glutamate metabolism glutamate Faecalibacterium -0.481 -0.745 -0.085 0.017 0.025 
Ketone bodies 3-hydroxybutyrate  Blautia -0.489 -0.750 -0.096 0.015 0.020 
Ketone bodies 3-hydroxybutyrate  Streptococcus -0.513 -0.764 -0.128 0.010 0.020 
Carnitine metabolism decanoylcarnitine Dialister -0.514 -0.764 -0.129 0.010 0.013 
Krebs cycle citrate Bacteroides -0.518 -0.767 -0.135 0.009 0.035 
Cys, Met, SAM, Tau metabolism 2-hydroxybutyrate  Streptococcus -0.526 -0.771 -0.146 0.008 0.008 
Carnitine metabolism cis-4-decenoyl carnitine Dialister -0.556 -0.787 -0.186 0.004 0.008 
Long chain fatty acid palmitate (16:0) Ruminococcus -0.557 -0.788 -0.188 0.004 0.004 




Table 23. Significant correlations between plasma metabolites and microbes (genus level) in response to the high level (100 g/day) 
consumption of dietary sumac sorghum in human subjects. 
High consumption (100 g/day) Pearson Correlation 






Benzoate metabolism hippurate Akkermansia 0.697 0.400 0.862 0.000 0.000 
Fatty acid metabolism isovalerate Bifidobacterium 0.694 0.396 0.860 0.000 0.000 
Inositol metabolism myo-inositol Akkermansia 0.635 0.302 0.830 0.001 0.001 
Tocopherol metabolism alpha-tocopherol Blautia 0.549 0.177 0.784 0.005 0.010 
Fruf, man, gal, starch, and sucrose metabolism fructose Akkermansia 0.543 0.168 0.780 0.006 0.011 
Cysteine, methionine, SAM, taurine metabolism 2-hydroxybutyrate Blautia 0.447 0.043 0.726 0.028 0.028 
Ketone bodies 3-hydroxybutyrate Dialister 0.447 0.043 0.726 0.028 0.028 
Inositol metabolism myo-inositol Bifidobacterium 0.435 0.028 0.718 0.033 0.033 
Tocopherol metabolism alpha-tocopherol Ruminococcus -0.447 -0.725 -0.042 0.028 0.028 
Glycine, serine and threonine metabolism glycine Blautia -0.479 -0.744 -0.083 0.017 0.035 
Valine, leucine and isoleucine metabolism isoleucine Dialister -0.488 -0.749 -0.094 0.015 0.015 
Aminosugars metabolism erythronate* Blautia -0.502 -0.757 -0.113 0.012 0.012 
Guanidino and acetamido metabolism 4-acetamidobutanoate Faecalibacterium -0.515 -0.765 -0.131 0.009 0.009 
Purine metabolism, adenine containing N1-methyladenosine Ruminococcus -0.640 -0.832 -0.309 0.001 0.001 







Interestingly, correlation analysis of data sets for the high level of sumac sorghum 
consumption, revealed, for the most part, relationships for different metabolites, than was 
observed for the low level of consumption. No associations were seen for gamma-glutamyl 
amino acids and glutamate; however, 3-hydroxybutyrate remained positively correlated with 
Dialister bacteria (r=0.447, Q=0.028). Most intriguingly, the microbially-associated metabolite 
hippurate was positively correlated with the presence of Akkermansia (r=0.697, Q=0.000). 
Akkermansia was also found to correlate positively with myo-inositol (r=0.635, Q=0.001), 
which was also positively associated with Bifidobacterium (r=0.435, Q=0.033). Isovalerate, a 
branched chain isomer of the SCFA valerate, was positively correlated with the presence of 
Bifidobacterium (r=0.694, Q=0.000). 
Discussion 
The gut microbiome and its metabolism is highly integrated with the physiology of the 
host and novel associations of microbial contribution on multiple host systems is being 
discovered by research at an accelerating pace (408-411). The ability of the intestinal 
microbiome to metabolize dietary compounds, along with substrate produced by the host (e.g., 
bile acids, mucins, etc.), into metabolites that can affect host tissues is a fascinating and complex 
system that will take many years to fully decrypt. Just as host organs work in symphony to 
generate energy, circulate metabolites, and detoxify waste and unwanted biochemicals, so too 
does the microbiome. Increasingly, the microbiome is referred to as a host ‘organ system’ (412-
417). However, unlike other mammalian organ systems which may exhibit alterations in 
gene/protein/epigenetic profiles, changes in composition of the microbiome can result in 
alterations to the metagenome. This ‘plasticity’ of the microbiome, especially in free living 




bacteria. Furthermore, given the extent of interactions possible between different bacterial 
species, it is more likely that the collective profile of the microbiome contributes to the 
phenotypic response observed at the time of scientific investigation. The exceptions are 
bacterium which have been abundantly characterized and rigorously investigated for their 
functions in vivo (e.g., E. coli and H. pylori) (418-422). Furthermore, it has been suggested that 
the functional profile (i.e., metagenome, metatranscriptome, and metaproteome) of the 
microbiota is better for classifying microbial communities, particularly in the context of disease 
and metabolism (215).  For example, although certain bacterial species are known to be 
producers of SCFA, the abundance of critical genes involved in SCFA production, their 
expression, and translation would provide a much better characterization of the metabolic 
activity for a given microbiome sample.    
 The sumac sorghum intervention contains dietary polyphenols which are known to 
impact, and undergo metabolism by, bacteria in the large intestine. Unfortunately, due to the 
extremely large amount of variables (i.e., high dimensionality) in each data set (i.e., microbe and 
metabolite), dimensional reduction analyses and inclusion criteria were imposed on the raw data 
in order to make the correlation analyses more manageable. The trade-off with employing such 
procedures is that not all variables are utilized in the final analyses. For example, some of the 
plasma metabolites that were significantly increased in subjects following consumption of the 
sumac sorghum were not included in the analysis due to their low proportion of variance as 
revealed by principal component analysis, or due to missing data. However, these compounds are 
of particular interest due to their identification as microbially- or polyphenol-derived 




analyses aimed at identifying and including metabolites and bacteria with known or suspected 
association.  
Gamma-glutamyl amino acids are the byproduct of gamma-glutamyl transferase (GGT), 
an enzyme involved in the synthesis and degradation of glutathione and drug and xenobiotic 
degradation (423). Elevated GGT is a biomarker for cardiovascular disease risk (368, 370, 371, 
377). Lower levels of gamma-glutamyl amino acids were observed in the serum of subjects after 
consumption of sumac sorghum, which suggests increased absorption of these molecules from 
circulation or reduced production by GGT. Previous studies have identified a primary role of 
GGT in metabolizing extracellular reduced glutathione, which generates gamma-glutamyl amino 
acids that are then transported into the cell, where the amino acids are liberated to be reused in 
the synthesis of glutathione (401). Glutathione is responsible for preventing damage to the cell’s 
components produced by various reactive oxygen species such as lipid peroxides, peroxides, free 
radicals, and heavy metals (402). Thus, lower levels of gamma-glutamyl amino acids in the 
blood could reflect lower levels of reduced glutathione (i.e., lower oxidant stress), that could be 
compensated by antioxidant activities afforded by sumac sorghum derived metabolites in 
circulation. The results of our correlative work suggest that an increased abundance of 
Bacteroides genera in the gut is associated with increased gamma-glutamyl amino acid levels in 
the blood, and therefore the possibility of elevated oxidative stress. Conversely, a negative 
relationship between Faecalibacterium, and perhaps to a similar extent Streptococcus, and 
gamma glutamyl-amino acid levels suggests that these bacteria could be associated with 
decreased oxidative stress. Importantly, Faecalibacterium has been described as an anti-
inflammatory, commensal bacterium that is negatively associated with colitis, and positively 




dependent (390, 391) and –independent (387, 388) mechanisms have been proposed to explain 
the role of Faecalibacterium in colitis and in the promotion of intestinal barrier function and 
inflammation suppression. Although glutamate is involved in the synthesis of glutathione, a 
relationship linking circulating levels of glutamate and the microbiome has not been fully 
described. There are species of anaerobic bacteria that are known to ferment glutamate to 
produce acetate, butyrate, carbon dioxide, and ammonia (424) and others that are known to 
produce it (425); however, none of these species were implicated by our analyses. In our 
subjects, plasma glutamate levels were decreased following sumac sorghum consumption and its 
precursor molecule, glutamine, was decreased (data not shown).   
3-hydroxybutyrate levels were not significantly affected by sumac sorghum consumption, 
but were correlated with various genera in the low and high consumption data sets. 3-
hydroxybutyrate (aka β-hydroxybutyrate, BHB), a ketone body and histone deactylase inhibitor 
(HDAC), has been shown to increase in various tissues including the brain following exercise, 
calorie restriction, fasting, and ketogenic diets, and is thought to promote improvements in 
cognition, depression and anxiety via increases in brain derived neurotropic factor (BDNF) 
(426). BHB is synthesized in the liver via metabolism of fatty acids such as butyrate, a histone 
deacetylase inhibitor (HDAC) (427, 428). Butyrate, a SCFA produced by microbial fermentation 
of dietary fiber in the gut, is a highly regarded molecule for its role in intestinal health, 
metabolism, and immunity (28, 77, 148, 156, 158, 332, 429, 430). Recently, potential synergies 
of BHB and butyrate on the modulation of metabolism, inflammation, cognition, and overall 
health have been reviewed (428). Dialister, which was positively associated with plasma BHB 
levels in our experiment, was increased in humans consuming 60 g of whole-grain barley and 




physiologic effects of whole grains (350). Furthermore, Akkermansia, which was also positively 
associated with BHB levels, has been shown to improve negative metabolic outcomes of a high 
fat diet in mice, including: weight gain, epithelial integrity, and lipopolysaccharide endotoxemia 
(431). In clinical studies, negative associations between metabolic disorders and Akkermansia 
have been observed; however, more work is needed to clarify contrasting observations in some 
studies (304). Nevertheless, our correlative work suggests a potential relationship between these 
species and systemic levels of BHB.  
  Interestingly, many of the significant correlations that were observed for the low level 
(50 g/day) of sumac sorghum consumption were not observed in our analyses of the high level 
(100 g/day) of sumac sorghum consumption. This is possibly a dose-response effect of the 
dietary intervention affecting which metabolites and microbes contribute the greatest variability 
in the data set, and are therefore selected for correlation analysis by PCA. Furthermore, as these 
data were obtained from samples taken at different time points, and our subjects were free living 
humans, it is likely that other unaccounted factors may have contributed.  
Most intriguingly in the high sumac data analysis, is the positive association between 
hippurate and Akkermansia. Hippurate is the glycine conjugate of benzoic acid, and was 
increased in our subjects’ plasma following sumac sorghum consumption. Hippurate has long 
been associated with the microbial catabolism of dietary phenolic and polyphenolic compounds 
(432) and is negatively associated with impaired glucose tolerance (376). In fact, germ free 
animals fed a polyphenolic diet are unable to secrete hippurate or related metabolites, which 
implicates the microbiota as the source of these compounds (433, 434). Furthermore, there is 
substantial evidence demonstrating that dietary polyphenols from a variety of sources are able to 




together, our findings and others’ support the identity of Akkermansia as a significant contributor 
to host health and metabolism, particularly in response to diets high in polyphenolic compounds. 
For this reason, Akkermansia warrants greater investigation in future studies aimed at elucidating 
the beneficial effects of dietary polyphenols on host health and metabolism.     
    In these analyses, we have attempted to identify potential associations between 
metabolites found in the plasma of human subjects consuming a sumac sorghum dietary 
intervention and the various microbial genera in fecal samples. Indeed, our data demonstrate that 
bacteria suggested in the literature to be promotive of intestinal and metabolic health (i.e., 
Faecalibacterium and Akkermansia) are correlated with metabolites identified as potential 
contributors to these host responses (i.e., polyphenolic derivatives and gamma-glutamyl amino 
acids).  However, we want to emphasize that the correlations discussed, while significant, are not 
particularly strong and their interpretation here is merely suggestive of a potential relationship. In 
other words, these data do not confirm that a change in one variable (microbe or metabolite) 
definitively causes a change in the other. Nevertheless, these correlative associations provide 
useful preliminary data for further investigation of physiologically relevant host-microbe 
interactions.  
  









SUMMARY AND CONCLUSIONS 
 
According to a 2017 published review of cancer statistics (435), colon and rectal cancer 
is the third most commonly diagnosed cancer type in men and women in the United States and 
the second and third leading cause of cancer related death, in men and women, respectively, in 
the United States. Despite significant improvements in screening and treatment and an overall 
decline in incidence and mortality of colorectal cancer in individuals over the age of 50, 
incidence and death rates have continued to increase (22% and 34%, respectively) in individuals 
under the age of 50 and is driven solely by cancers of the distal colon and rectum (239). This fact 
has influenced the American Cancer Society (cancer.org) to update its guidelines for colorectal 
cancer screening to begin at age 45 for average risk individuals. For the scientific community, 
this has brought significant attention to the biological differences in cancer between that of the 
distal colon/rectum and the proximal colon and understanding the processes that contribute to the 
unique microenvironments that exist throughout the large intestine. Most notable are differences 
in the gene expression, epigenetic profile, and molecular signature of the tumor, as well as the 
composition of the microbiome at the disease site.  
Microbiota are capable of significantly impacting host physiology at a localized and 
systemic level, and additional interactions between microbe activity and host processes are being 
uncovered by research at an astonishing rate. The magnitude of host-microbe interaction and 
ability for diet and other factors to impact the composition and metabolism of the microbiome 
further supports the classification of the microbiome as an organ system, which may arguably 




dietary interventions in the context of disease and analyzed with ‘omics-style profiling stimulate 
hypotheses for targeted, mechanistic basic research. The experiments presented in this 
dissertation have demonstrated the ability of foods containing bioactive polyphenols to impact 
the host and gut microbiome, with implications for disease prevention and treatment. Dietary 
bioactives (e.g., polyphenols) are extra-nutritional components of fruits, vegetables, and grains 
with the ability to impact colitis, cancer, bone loss, cardiovascular risk, and diabetes (436). These 
effects are thought to be due in large part to their anti-oxidant and anti-inflammatory properties, 
but research has demonstrated that the bioactivity and bioavailability is largely dependent on the 
capacity of the microbiome to metabolize and generate secondary metabolites which may be 
responsible for the observed effects in vivo. Alterations in gut microbe composition, increases in 
microbially-derived metabolites in feces and circulation, and absence of the latter in germ free 
(aka gnotobiotic) animal models following polyphenol consumption strongly implicate the 
microbiome as a significant contributor to the host response to diet. A greater understanding of 
the extent and capacity of the diet-host-microbe trilateral relationship will ultimately 
revolutionize medicine as the world enters the era of personalized, genome-based healthcare and 
nutrition. 
To our knowledge this is the first study employing a plum based dietary intervention at a 
level directly translatable to the recommended consumption of dried plums for humans (i.e., a 40 
g serving providing 5% of calories in a standard 2000 calorie per day diet). Previous experiments 
have used individual bioactive compounds found in dried plum (e.g., chlorogenic acid and 
quercetin) or a dried plum powder to investigate protective mechanisms of dried plum in the 
context of colon cancer and inflammation (196, 205, 437). Our results indicate that by feeding 




to reduce the number and multiplicity of preneoplastic lesions and reduce the expression of genes 
contributing to inflammation. Specifically, dried plum reduced the expression of iNOS 
throughout the colon, which was increased during carcinogenesis, and decreased the expression 
of Tlr2 and Tlr4 microbial recognition transcripts in the proximal colon in carcinogen treated 
animals. The translation of the iNOS transcript into the iNOS protein (inducible nitric oxide 
synthase) results in the subsequent generation of the potent signaling molecule and free radical 
immune response effector, nitric oxide (438). Although it is regarded as a host defense against 
pathogen infection, its lack of specificity can lead to DNA damage and mutation, 
neovascularization, and nitrosylation of proteins (e.g., p53, caspase, etc.) which can promote 
carcinogenesis (266). TLR signaling following microbial pattern recognition activates a 
signaling cascade via NF-κB which leads to expression of inflammatory cytokine gene, thereby 
regulating the immune response to infection. Abnormal regulation of NF-κB signaling is 
implicated in colitis and cancer (439). Therefore, there is potential for dried plum to protect 
against colon carcinogenesis at initiation and promotion stages; however, the design of our 
experiment precludes our ability to assess the former, but supports the identity of dried plums as 
a mitigator of the pro-inflammatory immune response characteristic of early carcinogenesis. Part 
of these effects could be due to alterations in SCFA production or absorption; however, we did 
not observe a significant effect of dried plum on SCFA transporter expression, which was 
reduced in the distal colon of carcinogen treated animals. Increases in excreted SCFA following 
carcinogen treatment in basal diet animals, but not in plum diet animals, suggests dried plum is 
able to support a steadier pattern of SCFA metabolism following cancer initiation. Dried plum 
animals had lower levels of several SCFA in feces compared to basal diet animals, and the same 




that dried plum consumption alters the SCFA profile compared to a basal diet, but also enables 
the steady-state maintenance of that profile during colon cancer initiation, when SCFA such as 
butyrate can act early to initiate apoptosis in DNA damaged stem cells (77, 270, 440). This could 
explain, in part, the reduction in pre-neoplastic lesion incidence and multiplicity observed 8 
weeks later at termination. 
 Dried plum induced substantial alterations in the composition of the microbiota and 
colonic metabolome, particularly in the distal colon of rats in the first experiment. However, 
exposure to the chemical carcinogen (Chapter II) or radiation (Chapter III) had minimal impact 
on the composition of the microbiota. Despite no changes in alpha diversity in either experiment, 
rats from Chapter II clustered significantly based on diet in estimates of diversity between 
samples. In mice exposed to radiation and consuming dried plum a significant increase in 
Enterobacteriaceae and Akkermansia bacteria was observed, but only in 40% of animals 
belonging to that treatment group. Taken together, these observations confirm that dried plum 
significantly impacts the composition of the colon microbiota including dramatic shifts in 
dominant bacterial groups; however, it is inappropriate to draw any conclusions regarding the 
mechanism of protection of dried plum consumption on the formation of ACF (Chapter II) solely 
based on the observed changes in microbe composition. Furthermore, differences in the 
composition of gut bacteria between the Sprague Dawley rat (Rattus norvegicus, Chapter II) and 
C57BL/6 (Mus musculus, Chapter III), make comparisons between these experiments difficult as 
the bacteria that dominate their guts belong to different groups in the lower taxonomy.      
 Our analysis of the predicted metagenome and fecal metabolome in Chapter II suggests 
that dried plum consumption results in changes to the functional capacity and metabolism of the 




the microbiome can impact the profile and metabolic potential of the gut microbiome as an organ 
system, with implications for affecting cancer and disease risk. Pathway analysis of the 
metabolomic changes implicate several pathway nodes implicated in colon cancer, that can be 
investigated in greater focus in future experiments. 
Sorghum is an extremely versatile grain containing a good source of nutrients and 
bioactive compounds (e.g., 3-deoxyanthocyanins and tannins), and is the fifth most produced 
cereal in the world (441). Like the bioactive compounds found in dried plums, those in sorghum 
have been associated with improvements in parameters related to obesity, inflammation, 
diabetes, and cancer (179, 209, 211, 442, 443). Consumption of sorghum results in changes to 
the composition of the microbiome and microbial-derivatives of sorghum bioactives have been 
detected in urine, feces, and plasma in both humans and animal models (103, 211, 245, 442, 
444). In our experiment, we fed two levels of a bran enriched sumac sorghum puff cereal to 
human subjects predisposed to metabolic syndrome to see if a low or modest level of sorghum 
consumption could impact biomarkers related to lipid and glucose metabolism, and 
inflammation, which are relevant to cardiovascular disease risk, diabetes, obesity, and cancer. 
 Despite no significant changes in these parameters over the relatively short intervention 
periods, significant alterations in gut microbe composition and microbially-derived metabolites 
in feces and plasma were observed. Faecalibacterium was significantly increased and 
Akkermansia displayed a tendency to increase in subjects after consuming sumac sorghum. Both 
of these bacteria are associated with beneficial effects on host health. F. prausnitzii, the sole 
known species of the genus Faecalibacterium, represents more than 5% of the bacteria in a 
healthy human intestine (385, 386). Prior to beginning the experiment, our subjects averaged 




sequences increased to 7.2% following sumac sorghum consumption. F. prausnitzii is one of the 
most abundant butyrate producing bacterium in the gastrointestinal tract, and likely contributes 
to the anti-inflammatory properties ascribed to F. prausnitzii (386). In this experiment, no 
significant changes were observed in fecal SCFA levels in response to sumac sorghum 
consumption, although previous work in our lab has indicated that sumac fed animals had the 
lowest concentration of butyrate compared to Black and Hi Tannin sorghum brans, and cellulose 
controls (445). Akkermansia is being studied for its impact on human metabolism and has shown 
protection in against obesity and diabetes (303-305, 307-309, 393, 431). A recent study 
employing twin cohorts reported that a decrease in Akkermansia was associated with an 
increased risk of type 2 diabetes and obesity (446). In our experiment, only a trend for increased 
Akkermansia was observed in response to sumac sorghum consumption (4% average increase in 
sequences), and no improvements were documented in fasting blood glucose levels or plasma 
lipid profiles.           
A major limitation of this experiment was the relatively small sample size, and lack of 
controlled diet and exercise patterns among the subjects. Although subjects were instructed not 
to change their exercise or dietary regimes aside from the dietary intervention, we can only 
assume that subjects complied with these restrictions and that they consumed the dietary 
intervention as prescribed. As subjects were free living, we had no control over the remainder of 
their diet, which can greatly confound our ability to detect changes because diet is such a potent 
modifier of the microbiome. Nevertheless, the changes in microbes and microbial-derived 
metabolites in the plasma and feces, suggest that a longer study and/or one with greater control 
over subject behavior could yield stronger results. Our final analysis of microbiome and plasma 




related in some capacity to the changes observed in the plasma metabolome. Targeted 
experiments focused on fully characterizing the metabolic profile of these bacteria, perhaps in 
animal models where the microbiome can be controlled by inoculation of specific bacteria or 
groups of bacteria, will be necessary to elucidate their unique contributions to the 
aforementioned observations.       
Taken together, these experiments suggest that dried plum and sumac sorghum, both 
sources of bioactive polyphenols, are modifiers of the microbiome and its metabolism, with 
important implications for multiple diseases, including cancer, obesity, and diabetes. 
Future Studies 
Each experiment demonstrated that modest modifications to the diet, which should be 
easily achievable for humans to incorporate routinely, can alter the microbiota, mucosal 
environment, and systemic metabolome. Further studies are warranted to better characterize the 
mechanisms by which dried plums and sumac sorghum exert their effects on gut and systemic 
health. In the case of dried plum as a mitigator of azoxymethane-induced colon carcinogenesis, it 
will be important to determine 1) if dried plum interferes with the ability of the carcinogen to 
initiate colon carcinogenesis, and 2) if the protection observed at the ACF stage translates into 
protection at the tumor stage (i.e., reduced tumor size and abundance). The former could easily 
be tested by introducing the experimental diets after treatment with the chemical carcinogen 
rather than before. All animals could begin the study consuming a basal diet until the second 
AOM exposure when then half of the animals would switch to the dried plum diet until 
termination. The ability of dried plum to prevent the induction of colon carcinogenesis by AOM 
should not be taken negatively, however, as the mechanisms of its protection in this regard could 




explored in additional studies. Therefore, it will depend ultimately on the hypothesis being tested 
by the experiment with careful consideration of the limitations of the model and experimental 
paradigm. Interestingly, Lactobacillus acidophilus has been shown to reduce ACF formation in 
AOM treated Sprague Dawley rats (447); however, in our experiment, bacteria of the genus 
Lactobacillus were reduced in plum diet fed animals, which had lower ACF number and 
multiplicity. 
Although we did not detect many alterations in SCFA or microbe composition in mice 
exposed to an acute dose of HZE radiation, we know that space relevant doses of HZE can 
induce shifts in gut microbial populations (104). The most important hurdle of ground-based 
radiation research for the study of spaceflight, is the difficulty of protracted, low dose-rate 
exposures that more closely mimic spaceflight, versus acute exposures observed in solar flares, 
nuclear reactor incidents or nuclear weapon detonations. Therefore, it will be necessary to 
develop these exposure methodologies to better study the radiation impacts on microbiota and 
the intestinal environment as they occur over time frames similar to an actual mission duration.   
Both dried plum and sumac sorghum require cell culture work to probe for potential 
mechanisms of bioactivity for the polyphenols contained in them. This work should include both 
native compounds and those derived from microbial metabolism. It is known that smaller 
polyphenolic compounds (e.g., monomers and dimers of flavan-3ols) can enter systemic 
circulation; however, these compounds are often modified by enterocytes/colonocytes during 
uptake and transport to the liver where they can be further modified (38). Therefore, distinct 
bioactive profiles are necessary for metabolized and unmetabolized forms of native (i.e., 
occurring naturally in the foodstuff) bioactive molecules and for their microbial-derivatives, 




distinguish these bioactivities independently of the presence of the microbiota, which is made 
possible by the use of germ-free animals. As an alternative to traditional cell culture work, recent 
advances in cell-microbe co-culture, termed “Gut-On-A-Chip,” present an fruitful opportunity to 
study infinite combinations of cell populations/profiles, substrates, and microbes ex vivo. 
Studies employing germ-free animals and animals with discrete microbial populations, in 
addition to traditional cell culture and co-culture experimentation, will be necessary to dissect the 
mechanisms and co-dependencies of specific diet-host-microbe interactions. The correlation, or 
often lack of correlation, between data from stool versus healthy or diseased tissue samples adds 
enormous complexity to the host-microbe relationship. Therefore, to improve our understanding 
of these relationships, ’omics’ studies should be used to interrogate concomitant changes in the 
diseased mucosa and the stool to maximize the information gathered from passive fecal 
sampling. Experiments should use multiple ’omics’ approaches to identify those biomarkers that 
most accurately and robustly characterize the disease state. Furthermore, it will be necessary to 
assess these relationships throughout the disease process to improve the sensitivity and 
specificity of diagnostic screening approaches for CRC prevention and treatment. 
Future studies attempting to define causal relationships between specific microbiota and 
disease processes would greatly benefit from more precise sampling techniques, such as laser 
capture microdissection (LCM). Application of site-specific sampling techniques in combination 
with more sensitive analytical approaches in future experiments will improve the ability to detect 
diet-induced modifications of host-microbe interactions in colon cancer models. Targeted 
quantification of microbial butyrate producing genes, and protein expression of SCFA 




in this study. Furthermore, true metagenome sequencing would give insight on the function of 





1. Seidel DV, Azcarate-Peril MA, Chapkin RS, Turner ND. Shaping functional gut 
microbiota using dietary bioactives to reduce colon cancer risk. Semin Cancer Biol. 2017 
Oct;46:191-204. 
2. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic 
syndrome and risk of incident colorectal cancer. Cancer. 2006 Jul 1;107:28-36. 
3. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. 
Gastroenterology. 2010 Jun;138:2101-14 e5. 
4. Datta K, Suman S, Kallakury BV, Fornace AJ, Jr. Heavy ion radiation exposure triggered 
higher intestinal tumor frequency and greater beta-catenin activation than gamma radiation in 
APC(Min/+) mice. PLoS One. 2013;8:e59295. 
5. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, et al. Is 
metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev. 
2007 Aug;16:1543-6. 
6. Kim SB, Bozeman RG, Kaisani A, Kim W, Zhang L, Richardson JA, Wright WE, Shay 
JW. Radiation promotes colorectal cancer initiation and progression by inducing senescence-
associated inflammatory responses. Oncogene. 2016 Jun 30;35:3365-75. 
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100:57-70. 
8. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, 
Arreola A, Arzumanyan A. Designing a broad-spectrum integrative approach for cancer 
prevention and treatment. Semin Cancer Biol. 2015;S276-S304. 
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 
4;144:646-74. 
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the 
metabolic requirements of cell proliferation. Science. 2009 May 22;324:1029-33. 
11. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy 
fuel exchange in cancer cells. Radiother Oncol. 2009 Sep;92:329-33. 
12. Xie J, Wu H, Dai C, Pan Q, Ding Z, Hu D, Ji B, Luo Y, Hu X. Beyond Warburg effect--
dual metabolic nature of cancer cells. Sci Rep. 2014 May 13;4:4927. 
13. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal 
stem cells. Curr Opin Cell Biol. 2013 Apr;25:177-83. 




15. Moody CS, Hassan HM. Mutagenicity of oxygen free radicals. Proc Natl Acad Sci U S 
A. 1982 May;79:2855-9. 
16. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000 Mar;21:497-503. 
17. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and 
resilience of the human gut microbiota. Nature. 2012 Sep 13;489:220-30. 
18. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, 
Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science. 2005 Jun 
10;308:1635-8. 
19. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, 
Levenez F, et al. A human gut microbial gene catalogue established by metagenomic sequencing. 
Nature. 2010 Mar 4;464:59-65. 
20. Kanauchi O, Matsumoto Y, Matsumura M, Fukuoka M, Bamba T. The Beneficial Effects 
of Microflora, Especially Obligate Anaerobes, and Their Products on the Colonic Environment 
in Inflammatory Bowel Disease. Curr Pharm Des. 2005;11:1047-53. 
21. Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, Tjalsma H. Towards 
the human colorectal cancer microbiome. PLoS One. 2011;6:e20447. 
22. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, et al. A 
metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012 Oct 
4;490:55-60. 
23. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran 
Van Nhieu J, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 2011 
Jan 27;6:e16393. 
24. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel 
disease. Gut. 2004 Jan;53:1-4. 
25. Turner ND, Ritchie LE, Bresalier RS, Chapkin RS. The microbiome and colorectal 
neoplasia: environmental modifiers of dysbiosis. Curr Gastroenterol Rep. 2013 Sep;15:346. 
26. Irrazábal T, Belcheva A, Girardin SE, Martin A, Philpott DJ. The multifaceted role of the 
intestinal microbiota in colon cancer. Mol Cell. 2014;54:309-20. 
27. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and 
cancer: how are they linked? Free Radic Biol Med. 2010 Dec 1;49:1603-16. 
28. Greer JB, O'Keefe SJ. Microbial induction of immunity, inflammation, and cancer. Front 




29. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections 
to chronic inflammation and cancer. Cell. 2006 Feb 24;124:823-35. 
30. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 
Mar 19;140:883-99. 
31. O'Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev 
Gastroenterol Hepatol. 2016 Dec;13:691-706. 
32. Salonen A, de Vos WM. Impact of diet on human intestinal microbiota and health. Annu 
Rev Food Sci Technol. 2014;5:239-62. 
33. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables 
on cancer risk. Am J Clin Nutr. 2003 Sep;78:559S-69S. 
34. Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L, Wolk A. 
Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst. 2001 Apr 
4;93:525-33. 
35. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: critical 
review and meta-analyses of the epidemiologic evidence. J Natl Cancer Inst. 1990 Apr 
18;82:650-61. 
36. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel 
AE, Etherton TD. Bioactive compounds in foods: their role in the prevention of cardiovascular 
disease and cancer. The American Journal of Medicine. 2002 Dec 30;113:71-88. 
37. Papandreou D, Noor ZT, Rashed M. The role of soluble, insoluble fibers and their 
bioactive compounds in cancer: a mini review. Food and Nutrition Sciences. 2015;6:1. 
38. Monagas M, Urpi-Sarda M, Sanchez-Patan F, Llorach R, Garrido I, Gomez-Cordoves C, 
Andres-Lacueva C, Bartolome B. Insights into the metabolism and microbial biotransformation 
of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct. 2010 Dec;1:233-53. 
39. Aura AM, Martin-Lopez P, O'Leary KA, Williamson G, Oksman-Caldentey KM, 
Poutanen K, Santos-Buelga C. In vitro metabolism of anthocyanins by human gut microflora. 
Eur J Nutr. 2005 Mar;44:133-42. 
40. Aura A-M. Microbial metabolism of dietary phenolic compounds in the colon. 
Phytochemistry Reviews. 2008;7:407-29. 
41. Clavel T, Henderson G, Alpert CA, Philippe C, Rigottier-Gois L, Dore J, Blaut M. 
Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and 




42. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, 
Korving J, Begthel H, et al. Identification of stem cells in small intestine and colon by marker 
gene Lgr5. Nature. 2007 Oct 25;449:1003-7. 
43. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, 
Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of 
intestinal cancer. Nature. 2009 Jan 29;457:608-11. 
44. Potten CS, Wilson JW, Booth C. Regulation and significance of apoptosis in the stem 
cells of the gastrointestinal epithelium. Stem Cells. 1997;15:82-93. 
45. Ruthig DJ, Meckling-Gill KA. Both (n-3) and (n-6) fatty acids stimulate wound healing 
in the rat intestinal epithelial cell line, IEC-6. J Nutr. 1999 Oct;129:1791-8. 
46. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011 
Mar;17:313-9. 
47. Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, Huch M, Boymans S, 
Kuijk E, et al. Tissue-specific mutation accumulation in human adult stem cells during life. 
Nature. 2016 Oct 13;538:260-4. 
48. Huels DJ, Sansom OJ. Stem vs non-stem cell origin of colorectal cancer. Br J Cancer. 
2015 Jun 30;113:1-5. 
49. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000 Oct 
13;103:311-20. 
50. Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I, Silver A. 
Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer. 
2006 Oct 15;119:1837-42. 
51. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012 May 
1;4:a008052. 
52. Rycaj K, Tang DG. Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and 
Interpretations. Cancer Res. 2015 Oct 1;75:4003-11. 
53. Davidson LA, Callaway ES, Kim E, Weeks BR, Fan YY, Allred CD, Chapkin RS. 
Targeted Deletion of p53 in Lgr5-Expressing Intestinal Stem Cells Promotes Colon 
Tumorigenesis in a Preclinical Model of Colitis-Associated Cancer. Cancer Res. 2015 Dec 
15;75:5392-7. 
54. Chaffer CL, Weinberg RA. How does multistep tumorigenesis really proceed? Cancer 
Discov. 2015 Jan;5:22-4. 





56. Wu S, Powers S, Zhu W, Hannun YA. Substantial contribution of extrinsic risk factors to 
cancer development. Nature. 2016 Jan 7;529:43-7. 
57. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can 
be explained by the number of stem cell divisions. Science. 2015 Jan 2;347:78-81. 
58. Tetteh PW, Basak O, Farin HF, Wiebrands K, Kretzschmar K, Begthel H, van den Born 
M, Korving J, de Sauvage F, et al. Replacement of Lost Lgr5-Positive Stem Cells through 
Plasticity of Their Enterocyte-Lineage Daughters. Cell Stem Cell. 2016 Feb 4;18:203-13. 
59. Tetteh PW, Farin HF, Clevers H. Plasticity within stem cell hierarchies in mammalian 
epithelia. Trends Cell Biol. 2015 Feb;25:100-8. 
60. Beyaz S, Mana MD, Roper J, Kedrin D, Saadatpour A, Hong SJ, Bauer-Rowe KE, 
Xifaras ME, Akkad A, et al. High-fat diet enhances stemness and tumorigenicity of intestinal 
progenitors. Nature. 2016 Mar 3;531:53-8. 
61. DeClercq V, McMurray DN, Chapkin RS. Obesity promotes colonic stem cell expansion 
during cancer initiation. Cancer Lett. 2015 Dec 28;369:336-43. 
62. Igarashi M, Guarente L. mTORC1 and SIRT1 Cooperate to Foster Expansion of Gut 
Adult Stem Cells during Calorie Restriction. Cell. 2016 Jul 14;166:436-50. 
63. Kim E, Davidson LA, Zoh RS, Hensel ME, Salinas ML, Patil BS, Jayaprakasha GK, 
Callaway ES, Allred CD, et al. Rapidly cycling Lgr5(+) stem cells are exquisitely sensitive to 
extrinsic dietary factors that modulate colon cancer risk. Cell Death Dis. 2016 Nov 10;7:e2460. 
64. Chang WCL, Chapkin RS, Lupton JR. Predictive value of proliferation, differentiation 
and apoptosis as intermediate markers for colon tumorigenesis. Carcinogenesis. 1997 
Apr;18:721-30. 
65. Ward JM, Uno H, Kurata Y, Weghorst CM, Jang JJ. Cell proliferation not associated 
with carcinogenesis in rodents and humans. Environ Health Perspect. 1993;101:125-35. 
66. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000 Nov;157:1415-30. 
67. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer 
chemotherapy. Oncogene. 2006 Aug 7;25:4798-811. 
68. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic 
proteins released from mitochondria in cell death. Oncogene. 2004 Apr 12;23:2861-74. 
69. Ichim G, Tait SW. A fate worse than death: apoptosis as an oncogenic process. Nature 
Reviews Cancer. 2016;16:539. 





71. Ng Y, Barhoumi R, Tjalkens RB, Fan YY, Kolar S, Wang N, Lupton JR, Chapkin RS. 
The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and 
apoptosis in colonocytes. Carcinogenesis. 2005 Nov;26:1914-21. 
72. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 
mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990 Oct;87:7555-9. 
73. Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ, Lupton JR. A 
chemoprotective fish oil/pectin diet enhances apoptosis via Bcl-2 promoter methylation in rat 
azoxymethane-induced carcinomas. Exp Biol Med (Maywood). 2012 Dec;237:1387-93. 
74. Hong MY, Chapkin RS, Davidson LA, Turner ND, Morris JS, Carroll RJ, Lupton JR. 
Fish oil enhances targeted apoptosis during colon tumor initiation in part by downregulating Bcl-
2. Nutr Cancer. 2003;46:44-51. 
75. Wright SC, Zhong J, Larrick JW. Inhibition of Apoptosis as a Mechanism of Tumor 
Promotion. FASEB J. 1994 Jun;8:654-60. 
76. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, 
Hamilton SR, et al. Incidence and functional consequences of hMLH1 promoter 
hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998 Jun 9;95:6870-5. 
77. Cho Y, Turner ND, Davidson LA, Chapkin RS, Carroll RJ, Lupton JR. Colon cancer cell 
apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and 
butyrate through promoter methylation. Exp Biol Med (Maywood). 2014 Mar;239:302-10. 
78. Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, 
Soballe P, Simon R, et al. Distinguishing right from left colon by the pattern of gene expression. 
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12:755-62. 
79. Barnicle A, Seoighe C, Golden A, Greally JM, Egan LJ. Differential DNA methylation 
patterns of homeobox genes in proximal and distal colon epithelial cells. Physiol Genomics. 
2016 Apr;48:257-73. 
80. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, 
proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. 
Int J Oncol. 2010 Sep;37:707-18. 
81. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, 
Waldron L, Hoshida Y, et al. Assessment of colorectal cancer molecular features along bowel 
subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. 
Gut. 2012 Jun;61:847-54. 
82. Watanabe T, Kobunai T, Toda E, Yamamoto Y, Kanazawa T, Kazama Y, Tanaka J, 
Tanaka T, Konishi T, et al. Distal colorectal cancers with microsatellite instability (MSI) display 





83. Hong MY, Chang WCL, Chapkin RS, Lupton JR. Relationship among colonocyte 
proliferation, differentiation, and apoptosis as a function of diet and carcinogen. Nutrition and 
Cancer-an International Journal. 1997;28:20-9. 
84. Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. 
Nat Rev Microbiol. 2016 Jan;14:20-32. 
85. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role 
in inflammatory disease and progression to cancer. Biochem J. 1996 Jan 1;313 ( Pt 1):17-29. 
86. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers 
AB, Moroski-Erkul CA, et al. DNA damage induced by chronic inflammation contributes to 
colon carcinogenesis in mice. J Clin Invest. 2008 Jul;118:2516-25. 
87. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, Chu FF, Pfeifer GP. 
Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer 
Res. 2008 Dec 15;68:10280-9. 
88. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 
and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to 
cancer. Mol Cell. 2010 Aug 27;39:493-506. 
89. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, 
the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009 Jul;30:1073-81. 
90. Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, Birnbaumer L, Lipkin SM. 
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory 
bowel disease-associated colorectal cancer. Cancer Res. 2009 Aug 15;69:6423-9. 
91. Vannucci L, Stepankova R, Kozakova H, Fiserova A, Rossmann P, Tlaskalova-
Hogenova H. Colorectal carcinogenesis in germ-free and conventionally reared rats: different 
intestinal environments affect the systemic immunity. Int J Oncol. 2008 Mar;32:609-17. 
92. Sacksteder MR. Occurrence of spontaneous tumors in the germfree F344 rat. J Natl 
Cancer Inst. 1976 Dec;57:1371-3. 
93. Reddy BS, Weisburger JH, Narisawa T, Wynder EL. Colon carcinogenesis in germ-free 
rats with 1,2-dimethylhydrazine and N-methyl-n'-nitro-N-nitrosoguanidine. Cancer Res. 1974 
Sep;34:2368-72. 
94. Reddy BS, Narisawa T, Wright P, Vukusich D, Weisburger JH, Wynder EL. Colon 
carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res. 1975 
Feb;35:287-90. 
95. Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of 
the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One. 




96. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu 
GY, Osterreicher CH, et al. Adenoma-linked barrier defects and microbial products drive IL-
23/IL-17-mediated tumour growth. Nature. 2012 Nov 8;491:254-8. 
97. Klimesova K, Kverka M, Zakostelska Z, Hudcovic T, Hrncir T, Stepankova R, Rossmann 
P, Ridl J, Kostovcik M, et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 
receptor-associated kinase M-deficient mice. Inflamm Bowel Dis. 2013 May;19:1266-77. 
98. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll- and nod-
like receptors induces effective tumor-specific immune responses. Sci Transl Med. 2012 Feb 
8;4:120ra16. 
99. Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. 
Oncogene. 2014 Jul 3;33:3485-95. 
100. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, 
Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in 
patients with active inflammatory bowel disease. Gut. 2004 May;53:685-93. 
101. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, 
Jarrin C, Chardon P, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by 
a metagenomic approach. Gut. 2006 Feb;55:205-11. 
102. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and 
noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis. 2007 
Jun;13:675-83. 
103. Ritchie LE, Sturino JM, Carroll RJ, Rooney LW, Azcarate-Peril MA, Turner ND. 
Polyphenol-rich sorghum brans alter colon microbiota and impact species diversity and species 
richness after multiple bouts of dextran sodium sulfate-induced colitis. FEMS Microbiol Ecol. 
2015 Mar;91:fiv008. 
104. Ritchie LE, Taddeo SS, Weeks BR, Lima F, Bloomfield SA, Azcarate-Peril MA, Zwart 
SR, Smith SM, Turner ND. Space Environmental Factor Impacts upon Murine Colon Microbiota 
and Mucosal Homeostasis. PLoS One. 2015 Jun 17;10:e0125792. 
105. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural 
segregation of gut microbiota between colorectal cancer patients and healthy volunteers. The 
ISME journal. 2012;6:320. 
106. Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, Chen Y, Yang F, Lu N, et al. Dysbiosis 
signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013 Aug;66:462-70. 
107. Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, Moris F, 
Rodrigo L, Mira A, Collado MC. Microbial mucosal colonic shifts associated with the 
development of colorectal cancer reveal the presence of different bacterial and archaeal 




108. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-
associated microbiota in patients with colorectal cancer. PLoS One. 2012;7:e39743. 
109. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool 
microbiome and metabolome differences between colorectal cancer patients and healthy adults. 
PLoS One. 2013;8:e70803. 
110. Sanchez-Espiridion B, White L, Mishra L, Raju GS, Kopetz S, Gu J, Ye Y, Wu X, Liang 
D. Abstract 8: Global and targeted metabolomic profiling of colorectal cancer progression. 
Cancer Res. 2016;76:8-. 
111. Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP. Metabolomics 
and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. 
Cancer Metab. 2016;4:11. 
112. Gagnaire A, Nadel B, Raoult D, Neefjes J, Gorvel JP. Collateral damage: insights into 
bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol. 2017 Feb;15:109-
28. 
113. Vizcaino MI, Crawford JM. The colibactin warhead crosslinks DNA. Nat Chem. 2015 
May;7:411-7. 
114. Wu S, Powell J, Mathioudakis N, Kane S, Fernandez E, Sears CL. Bacteroides fragilis 
enterotoxin induces intestinal epithelial cell secretion of interleukin-8 through mitogen-activated 
protein kinases and a tyrosine kinase-regulated nuclear factor-κB pathway. Infect Immun. 
2004;72:5832-9. 
115. Wu S, Shin J, Zhang G, Cohen M, Franco A, Sears CL. The Bacteroides fragilis toxin 
binds to a specific intestinal epithelial cell receptor. Infect Immun. 2006 Sep;74:5382-90. 
116. Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, 
Hacker-Prietz A, Rabizadeh S, Woster PM, et al. Polyamine catabolism contributes to 
enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A. 
2011 Sep 13;108:15354-9. 
117. Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, 
Carroll KC, Albesiano E, et al. The Bacteroides fragilis toxin gene is prevalent in the colon 
mucosa of colorectal cancer patients. Clin Infect Dis. 2015 Jan 15;60:208-15. 
118. Lu R, Wu S, Zhang YG, Xia Y, Zhou Z, Kato I, Dong H, Bissonnette M, Sun J. 
Salmonella Protein AvrA Activates the STAT3 Signaling Pathway in Colon Cancer. Neoplasia. 
2016 May;18:307-16. 
119. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufman 
R, Huber LA, et al. Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced 




120. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. STAT3 is necessary for proliferation 
and survival in colon cancer-initiating cells. Cancer Res. 2011 Dec 1;71:7226-37. 
121. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, 
Rose-John S, Cheroutre H, et al. IL-6 and Stat3 are required for survival of intestinal epithelial 
cells and development of colitis-associated cancer. Cancer Cell. 2009 Feb 3;15:103-13. 
122. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. 
Cancer Cell. 2009 Feb 3;15:79-80. 
123. Raisch J, Rolhion N, Dubois A, Darfeuille-Michaud A, Bringer MA. Intracellular colon 
cancer-associated Escherichia coli promote protumoral activities of human macrophages by 
inducing sustained COX-2 expression. Lab Invest. 2015 Mar;95:296-307. 
124. Wang X, Huycke MM. Colorectal cancer: role of commensal bacteria and bystander 
effects. Gut Microbes. 2015 Nov 2;6:370-6. 
125. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist: Lippincott Williams & Wilkins 
Philadelphia; 2006. 
126. Task Group on Radiation Protection in Space IC, Dietze G, Bartlett DT, Cool DA, 
Cucinotta FA, Jia X, McAulay IR, Pelliccioni M, Petrov V, et al. ICRP, 123. Assessment of 
radiation exposure of astronauts in space. ICRP Publication 123. Ann ICRP. 2013 Aug;42:1-339. 
127. Riley P. Free radicals in biology: oxidative stress and the effects of ionizing radiation. 
International journal of radiation biology. 1994;65:27-33. 
128. Pouget J-P, Mather SJ. General aspects of the cellular response to low- and high-LET 
radiation. European Journal of Nuclear Medicine. 2001;28:541-61. 
129. Zeitlin C, Hassler DM, Cucinotta FA, Ehresmann B, Wimmer-Schweingruber RF, Brinza 
DE, Kang S, Weigle G, Bottcher S, et al. Measurements of energetic particle radiation in transit 
to Mars on the Mars Science Laboratory. Science. 2013 May 31;340:1080-4. 
130. Cucinotta FA, Kim M-HY, Chappell LJ. Probability of causation for space radiation 
carcinogenesis following international space station, near Earth asteroid, and Mars missions. 
2012. 
131. Anson NM, Selinheimo E, Havenaar R, Aura AM, Mattila I, Lehtinen P, Bast A, 
Poutanen K, Haenen GR. Bioprocessing of wheat bran improves in vitro bioaccessibility and 
colonic metabolism of phenolic compounds. J Agric Food Chem. 2009 Jul 22;57:6148-55. 
132. Hemery YM, Anson NM, Havenaar R, Haenen GR, Noort MW, Rouau X. Dry-
fractionation of wheat bran increases the bioaccessibility of phenolic acids in breads made from 




133. Maciorowski KG, Turner ND, Lupton JR, Chapkin RS, Shermer CL, Ha SD, Ricke SC. 
Diet and carcinogen alter the fecal microbial populations of rats. J Nutr. 1997 Mar;127:449-57. 
134. Taguri T, Tanaka T, Kouno I. Antimicrobial activity of 10 different plant polyphenols 
against bacteria causing food-borne disease. Biol Pharm Bull. 2004 Dec;27:1965-9. 
135. Sójka M, Kołodziejczyk K, Milala J, Abadias M, Viñas I, Guyot S, Baron A. 
Composition and properties of the polyphenolic extracts obtained from industrial plum pomaces. 
J Funct Foods. 2015 Jan;12:168-78. 
136. O’Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, Posma JM, Kinross J, 
Wahl E, Ruder E. Fat, fibre and cancer risk in African Americans and rural Africans. Nature 
communications. 2015;6. 
137. Zhang Z, Geng J, Tang X, Fan H, Xu J, Wen X, Ma ZS, Shi P. Spatial heterogeneity and 
co-occurrence patterns of human mucosal-associated intestinal microbiota. ISME J. 2014 
Apr;8:881-93. 
138. Consortium HMP. Structure, function and diversity of the healthy human microbiome. 
Nature. 2012;486:207-14. 
139. Clifford M. Diet-derived phenols in plasma and tissues and their implications for health. 
Planta Med. 2004;70:1103-14. 
140. Williamson G, Clifford MN. Colonic metabolites of berry polyphenols: the missing link 
to biological activity? Br J Nutr. 2010 Oct;104 Suppl 3:S48-66. 
141. Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive 
metabolites: opportunities for new therapeutic interventions. Genome Med. 2016 Apr 21;8:46. 
142. Cheng Y, Jin UH, Allred CD, Jayaraman A, Chapkin RS, Safe S. Aryl Hydrocarbon 
Receptor Activity of Tryptophan Metabolites in Young Adult Mouse Colonocytes. Drug Metab 
Dispos. 2015 Oct;43:1536-43. 
143. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal 
cancer. Nat Rev Microbiol. 2014 Oct;12:661-72. 
144. Turner ND, Lupton JR. Dietary fiber. Adv Nutr. 2011 Mar;2:151-2. 
145. Macfarlane GT, Macfarlane S. Human colonic microbiota: ecology, physiology and 
metabolic potential of intestinal bacteria. Scand J Gastroenterol Suppl. 1997;222:3-9. 
146. Lupton JR, Kurtz PP. Relationship of colonic luminal short-chain fatty acids and pH to in 
vivo cell proliferation in rats. J Nutr. 1993 Sep;123:1522-30. 
147. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty 




148. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review 
article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008 Jan 15;27:104-
19. 
149. Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate 
controversy. J Nutr. 2004 Feb;134:479-82. 
150. Lupton JR, Turner ND. Potential protective mechanisms of wheat bran fiber. Am J Med. 
1999 Jan 25;106:24S-7S. 
151. Gazzaniga JM, Lupton JR. Dilution effect of dietary fiber sources: an in vivo study in the 
rat. Nutr Res. 1987;7:1261-8. 
152. Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by 
accelerating intestinal transit. Gut. 1997 Aug;41:245-51. 
153. Zoran DL, Turner ND, Taddeo SS, Chapkin RS, Lupton JR. Wheat bran diet reduces 
tumor incidence in a rat model of colon cancer independent of effects on distal luminal butyrate 
concentrations. J Nutr. 1997 Nov;127:2217-25. 
154. Tudela CV, Boudry C, Stumpff F, Aschenbach JR, Vahjen W, Zentek J, Pieper R. Down-
regulation of monocarboxylate transporter 1 (MCT1) gene expression in the colon of piglets is 
linked to bacterial protein fermentation and pro-inflammatory cytokine-mediated signalling. Br J 
Nutr. 2015;113:610-7. 
155. Liu X, Blouin J-M, Santacruz A, Lan A, Andriamihaja M, Wilkanowicz S, Benetti P-H, 
Tomé D, Sanz Y, Blachier F. High-protein diet modifies colonic microbiota and luminal 
environment but not colonocyte metabolism in the rat model: the increased luminal bulk 
connection. American Journal of Physiology-Gastrointestinal and Liver Physiology. 
2014;307:G459-G70. 
156. Donohoe DR, Curry KP, Bultman SJ. Microbial oncotarget: bacterial-produced butyrate, 
chemoprevention and Warburg effect. Oncotarget. 2013 Feb;4:182-3. 
157. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by 
analyzing (meta)genomic data. MBio. 2014 Apr 22;5:e00889. 
158. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect 
dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 
2012 Nov 30;48:612-26. 
159. Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, 
Robertson KD, Munn DH, Liu K. Butyrate suppresses colonic inflammation through HDAC1-
dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest 




160. Ganapathy V, Gurav A, Singh N. The butyrate transporter SLC5A8 is a tumor suppressor 
in colon linked to dietary fiber content. AACR; 2015. 
161. Gurav A, Sivaprakasam S, Bhutia YD, Boettger T, Singh N, Ganapathy V. Slc5a8, a 
Na+-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour 
suppressor in colon that protects against colitis and colon cancer under low-fibre dietary 
conditions. Biochem J. 2015;469:267-78. 
162. Gurav A, Singh N, Ganapathy V. A critical role for Slc5a8 in the suppression of colonic 
inflammation by commensal bacteria-derived metabolites (MUC9P. 821). The Journal of 
Immunology. 2014;192:199.8. 
163. Fan YY, Zhang J, Barhoumi R, Burghardt RC, Turner ND, Lupton JR, Chapkin RS. 
Antagonism of CD95 signaling blocks butyrate induction of apoptosis in young adult mouse 
colonic cells. Am J Physiol. 1999 Aug;277:C310-9. 
164. Chapkin RS, Fan Y-Y, Lupton JR. Effect of diet on colonic-programmed cell death: 
molecular mechanism of action. Toxicol Lett. 2000;112:411-4. 
165. Kim M, Qie Y, Park J, Kim CH. Gut Microbial Metabolites Fuel Host Antibody 
Responses. Cell Host Microbe. 2016 Aug 10;20:202-14. 
166. Furusawa Y, Obata Y, Hase K. Commensal microbiota regulates T cell fate decision in 
the gut. Semin Immunopathol; 2015: Springer; 2015. p. 17-25. 
167. Crim KC, Sanders LM, Hong MY, Taddeo SS, Turner ND, Chapkin RS, Lupton JR. 
Upregulation of p21Waf1/Cip1 expression in vivo by butyrate administration can be 
chemoprotective or chemopromotive depending on the lipid component of the diet. 
Carcinogenesis. 2008 Jul;29:1415-20. 
168. Belcheva A, Irrazabal T, Martin A. Gut microbial metabolism and colon cancer: can 
manipulations of the microbiota be useful in the management of gastrointestinal health? 
Bioessays. 2015 Apr;37:403-12. 
169. Belcheva A, Irrazabal T, Robertson SJ, Streutker C, Maughan H, Rubino S, Moriyama 
EH, Copeland JK, Surendra A, et al. Gut microbial metabolism drives transformation of MSH2-
deficient colon epithelial cells. Cell. 2014 Jul 17;158:288-99. 
170. Liu RH. Health benefits of fruit and vegetables are from additive and synergistic 
combinations of phytochemicals. Am J Clin Nutr. 2003 Sep;78:517S-20S. 
171. Tsao R, Yang R, Young JC, Zhu H. Polyphenolic profiles in eight apple cultivars using 
high-performance liquid chromatography (HPLC). J Agric Food Chem. 2003;51:6347-53. 
172. Vanamala J, Cobb G, Turner ND, Lupton JR, Yoo KS, Pike LM, Patil BS. Bioactive 
compounds of grapefruit (Citrus paradisi Cv. Rio Red) respond differently to postharvest 




173. Dinkova-Kostova AT. Phytochemicals as protectors against ultraviolet radiation: 
versatility of effects and mechanisms. Planta Med. 2008;74:1548-59. 
174. Alothman M, Bhat R, Karim A. Effects of radiation processing on phytochemicals and 
antioxidants in plant produce. Trends in Food Science & Technology. 2009;20:201-12. 
175. Holt EM, Steffen LM, Moran A, Basu S, Steinberger J, Ross JA, Hong CP, Sinaiko AR. 
Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress 
in adolescents. J Am Diet Assoc. 2009 Mar;109:414-21. 
176. Siriwardhana N, Kalupahana NS, Cekanova M, LeMieux M, Greer B, Moustaid-Moussa 
N. Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem. 
2013 Apr;24:613-23. 
177. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999;12:564-
82. 
178. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000 
Aug;130:2073S-85S. 
179. Dykes. Phenolic Compounds in Cereal Grains and Their Health Benefits. Cereal Foods 
World. 2007 May-Jun;52:105-11. 
180. Vanamala J, Leonardi T, Patil BS, Taddeo SS, Murphy ME, Pike LM, Chapkin RS, 
Lupton JR, Turner ND. Suppression of colon carcinogenesis by bioactive compounds in 
grapefruit. Carcinogenesis. 2006 Jun;27:1257-65. 
181. Leonardi T, Vanamala J, Taddeo SS, Davidson LA, Murphy ME, Patil BS, Wang N, 
Carroll RJ, Chapkin RS, et al. Apigenin and naringenin suppress colon carcinogenesis through 
the aberrant crypt stage in azoxymethane-treated rats. Exp Biol Med (Maywood). 2010 
Jun;235:710-7. 
182. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary 
polyphenolic compounds. Annu Rev Nutr. 2001;21:381-406. 
183. Lea MA, Ibeh C, desBordes C, Vizzotto M, Cisneros-Zevallos L, Byrne DH, Okie WR, 
Moyer MP. Inhibition of growth and induction of differentiation of colon cancer cells by peach 
and plum phenolic compounds. Anticancer Res. 2008 Jul-Aug;28:2067-76. 
184. Lea MA, Ibeh C, Han L, Desbordes C. Inhibition of growth and induction of 
differentiation markers by polyphenolic molecules and histone deacetylase inhibitors in colon 
cancer cells. Anticancer Res. 2010 Feb;30:311-8. 
185. Miene C, Weise A, Glei M. Impact of polyphenol metabolites produced by colonic 





186. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising 
role for epigenetics. Biochem Pharmacol. 2010 Dec 15;80:1771-92. 
187. Banerjee N, Kim H, Talcott ST, Turner ND, Byrne DH, Mertens-Talcott SU. Plum 
polyphenols inhibit colorectal aberrant crypt foci formation in rats: potential role of the miR-
143/protein kinase B/mammalian target of rapamycin axis. Nutr Res. 2016 Oct;36:1105-13. 
188. Shankar E, Kanwal R, Candamo M, Gupta S. Dietary phytochemicals as epigenetic 
modifiers in cancer: promise and challenges. Semin Cancer Biol. 2016;40:82-99. 
189. Rechner AR, Smith MA, Kuhnle G, Gibson GR, Debnam ES, Srai SK, Moore KP, Rice-
Evans CA. Colonic metabolism of dietary polyphenols: influence of structure on microbial 
fermentation products. Free Radic Biol Med. 2004 Jan 15;36:212-25. 
190. Déprez S, Brezillon C, Rabot S, Philippe C, Mila I, Lapierre C, Scalbert A. Polymeric 
Proanthocyanidins Are Catabolized by Human Colonic Microflora into Low-Molecular-Weight 
Phenolic Acids. The Journal of Nutrition. 2000 Nov 1;130:2733-8. 
191. Cardona F, Andres-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuno MI. Benefits of 
polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013 
Aug;24:1415-22. 
192. Duenas M, Munoz-Gonzalez I, Cueva C, Jimenez-Giron A, Sanchez-Patan F, Santos-
Buelga C, Moreno-Arribas MV, Bartolome B. A survey of modulation of gut microbiota by 
dietary polyphenols. Biomed Res Int. 2015;850902. 
193. Etxeberria U, Fernandez-Quintela A, Milagro FI, Aguirre L, Martinez JA, Portillo MP. 
Impact of polyphenols and polyphenol-rich dietary sources on gut microbiota composition. J 
Agric Food Chem. 2013 Oct 9;61:9517-33. 
194. Stacewicz-Sapuntzakis M, Bowen PE, Hussain EA, Damayanti-Wood BI, Farnsworth 
NR. Chemical composition and potential health effects of prunes: a functional food? Crit Rev 
Food Sci Nutr. 2001 May;41:251-86. 
195. Fang N, Yu S, Prior RL. LC/MS/MS characterization of phenolic constituents in dried 
plums. J Agric Food Chem. 2002 Jun 5;50:3579-85. 
196. Piefer LA, Weeks B, Carroll R, Byrne D, Ambrus A, Turner N. Quercetin and 
chlorogenic acid affect butyrate excretion, NF-κB activity, and cell proliferation in DSS treated 
rats. The FASEB Journal. 2012;26:263.6-.6. 
197. Turner N, Paulhill K, Warren C, Davidson L, Chapkin R, Lupton J, Carroll R, Wang N. 
Quercetin suppresses early colon carcinogenesis partly through inhibition of inflammatory 





198. Warren CA, Paulhill KJ, Davidson LA, Lupton JR, Taddeo SS, Hong MY, Carroll RJ, 
Chapkin RS, Turner ND. Quercetin may suppress rat aberrant crypt foci formation by 
suppressing inflammatory mediators that influence proliferation and apoptosis. The Journal of 
nutrition. 2009;139:101-5. 
199. Zhang XA, Zhang S, Yin Q, Zhang J. Quercetin induces human colon cancer cells 
apoptosis by inhibiting the nuclear factor-kappa B Pathway. Pharmacogn Mag. 2015 
Apr;11:404-9. 
200. Refolo MG, D'Alessandro R, Malerba N, Laezza C, Bifulco M, Messa C, Caruso MG, 
Notarnicola M, Tutino V. Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin 
Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines. J Cell Physiol. 2015 
Dec;230:2973-80. 
201. Han M, Song Y, Zhang X. Quercetin Suppresses the Migration and Invasion in Human 
Colon Cancer Caco-2 Cells Through Regulating Toll-like Receptor 4/Nuclear Factor-kappa B 
Pathway. Pharmacogn Mag. 2016 May;12:S237-44. 
202. Dihal AA, de Boer VC, van der Woude H, Tilburgs C, Bruijntjes JP, Alink GM, Rietjens 
IM, Woutersen RA, Stierum RH. Quercetin, but not its glycosidated conjugate rutin, inhibits 
azoxymethane-induced colorectal carcinogenesis in F344 rats. The Journal of nutrition. 
2006;136:2862-7. 
203. Peters R, Lock RH. Laxative effect of sorbitol. Br Med J. 1958 Sep 13;2:677-8. 
204. Lu X, Li C, Wang YK, Jiang K, Gai XD. Sorbitol induces apoptosis of human colorectal 
cancer cells via p38 MAPK signal transduction. Oncol Lett. 2014 Jun;7:1992-6. 
205. Yang Y, Gallaher DD. Effect of dried plums on colon cancer risk factors in rats. Nutr 
Cancer. 2005 2005/09/01;53:117-25. 
206. Glinghammar B, Inoue H, Rafter JJ. Deoxycholic acid causes DNA damage in colonic 
cells with subsequent induction of caspases, COX-2 promoter activity and the transcription 
factors NF-kB and AP-1. Carcinogenesis. 2002 May;23:839-45. 
207. Baijal PK, Clow EP, Fitzpatrick DW, Bird RP. Tumor-enhancing effects of cholic acid 
are exerted on the early stages of colon carcinogenesis via induction of aberrant crypt foci with 
an enhanced growth phenotype. Can J Physiol Pharmacol. 1998 Dec;76:1095-102. 
208. Liu RH. Whole grain phytochemicals and health. Journal of Cereal Science. 2007 
Nov;46:207-19. 
209. Dykes L, Rooney LW. Sorghum and millet phenols and antioxidants. Journal of Cereal 
Science. 2006 Nov;44:236-51. 
210. Awika JM, McDonough CM, Rooney LW. Decorticating sorghum to concentrate healthy 




211. Ritchie L, Taddeo S, Weeks B, Carroll R, Dykes L, Rooney L, Turner N. Impact of 
Novel Sorghum Bran Diets on DSS-Induced Colitis. Nutrients. 2017;9:330. 
212. Ritchie LE, Sturino JM, Azcarate-Peril MA, Turner ND. Novel sorghum brans containing 
bioactive compounds alter colon microbiota in response to a DSS-induced chronic inflammatory 
state. FASEB J. 2013 Apr;27:247.2. 
213. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, Creasy 
HH, Earl AM, FitzGerald MG, Fulton RS. Structure, function and diversity of the healthy human 
microbiome. Nature. 2012;486:207. 
214. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, 
Jones WJ, Roe BA, et al. A core gut microbiome in obese and lean twins. Nature. 2009 Jan 
22;457:480-4. 
215. Xu Z, Malmer D, Langille MG, Way SF, Knight R. Which is more important for 
classifying microbial communities: who's there or what they can do? ISME J. 2014 Dec;8:2357-
9. 
216. Integrative HMPRNC. The Integrative Human Microbiome Project: dynamic analysis of 
microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 
2014 Sep 10;16:276-89. 
217. O'toole PW, Flemer B. Studying the Microbiome:“Omics” Made Accessible. Semin 
Liver Dis; 2016 Sep;36:306-11. 
218. Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012 
Sep 13;489:250-6. 
219. Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. Using 
QIIME to Analyze 16S rRNA Gene Sequences from Microbial Communities. Curr Protoc 
Microbiol. 2012 Nov;27:1E-5. 
220. Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente 
JC, Burkepile DE, Vega Thurber RL, et al. Predictive functional profiling of microbial 
communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013 Sep;31:814-21. 
221. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids 
Res. 2000 Jan 1;28:27-30. 
222. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski 
K, Dwight SS, et al. Gene ontology: tool for the unification of biology. The Gene Ontology 
Consortium. Nat Genet. 2000 May;25:25-9. 





224. Boursi B, Arber N. Current and future clinical strategies in colon cancer prevention and 
the emerging role of chemoprevention. Curr Pharm Des. 2007;13:2274-82. 
225. Yazici C, Wolf PG, Liu T-W, Vermillion K, Carroll T, Mutlu E, Tussing-Humphreys L, 
Braunschweig C, Xicola RM, Jung B. Abstract B31: Sulfidogenic bacteria are an important diet-
driven exposure promoting colorectal cancer in African Americans. AACR; 2017. 
226. Cao X, Ding l, Xie Z-Z, Yang Y, Whiteman M, Moore PK, Bian J-S. A review of 
hydrogen sulfide synthesis, metabolism and measurement: Is modulation of hydrogen sulfide a 
novel therapeutic for cancer? Antioxidants and Redox Signaling. 2018. 
227. Hale VL, Jeraldo P, Mundy M, Yao J, Keeney G, Scott N, Cheek EH, Davidson J, Green 
M, Martinez C. Synthesis of multi-omic data and community metabolic models reveals insights 
into the role of hydrogen sulfide in colon cancer. Methods. 2018. 
228. Phillips CM. Nutrigenetics and metabolic disease: current status and implications for 
personalised nutrition. Nutrients. 2013 Jan 10;5:32-57. 
229. Ordovas JM, Corella D. Nutritional genomics. Annu Rev Genomics Hum Genet. 
2004;5:71-118. 
230. Stover PJ. Nutritional genomics. Physiol Genomics. 2004 Jan 15;16:161-5. 
231. Elliott R, Ong TJ. Nutritional genomics. BMJ. 2002 Jun 15;324:1438-42. 
232. Trujillo E, Davis C, Milner J. Nutrigenomics, proteomics, metabolomics, and the practice 
of dietetics. J Am Diet Assoc. 2006 Mar;106:403-13. 
233. Breton J, Tennoune N, Lucas N, Francois M, Legrand R, Jacquemot J, Goichon A, 
Guerin C, Peltier J, et al. Gut Commensal E. coli Proteins Activate Host Satiety Pathways 
following Nutrient-Induced Bacterial Growth. Cell Metab. 2016 Feb 9;23:324-34. 
234. Khan MJ, Gerasimidis K, Edwards CA, Shaikh MG. Role of Gut Microbiota in the 
Aetiology of Obesity: Proposed Mechanisms and Review of the Literature. J Obes. 
2016;2016:7353642. 
235. Fuentes CT, Schellekens H, Hoevenaars N, Ross P, Roy B, Stanton C, Dinan TG, Cryan 
JF. Identification of Novel Probiotics to Modify Appetite and Satiety Directly Targeting the 
Ghrelin Receptor. The FASEB Journal. 2016;30:717.2. 
236. Burcelin R. When gut fermentation controls satiety: A PYY story. Molecular 
Metabolism. 2017;6:10-1. 
237. Fetissov SO. Role of the gut microbiota in host appetite control: bacterial growth to 




238. Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, Brim H, Ashktorab H, Ng 
SC, et al. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal 
Cancer. Clin Cancer Res. 2017 Apr 15;23:2061-70. 
239. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. 
Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 6;67:177-93. 
240. Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-
Albuquerque R, Jr., Soares JB, Cardoso E, Henrique R, et al. Decreased Toll-interacting protein 
and peroxisome proliferator-activated receptor gamma are associated with increased expression 
of Toll-like receptors in colon carcinogenesis. J Clin Pathol. 2012 Apr;65:302-8. 
241. Shamsuddin AM. 2 - Normal and Pathological Anatomy of the Large Intestine. Colon 
Cancer Cells: Academic Press; 1990;15-40. 
242. Chang WCL, Chapkin RS, Lupton JR. Fish oil blocks azoxymethane-induced rat colon 
tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell 
proliferation. J Nutr. 1998 Mar;128:491-7. 
243. Davidson LA, Nguyen DV, Hokanson RM, Callaway ES, Isett RB, Turner ND, 
Dougherty ER, Wang N, Lupton JR, et al. Chemopreventive n-3 polyunsaturated fatty acids 
reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer 
Res. 2004 Sep 15;64:6797-804. 
244. Cho Y, Kim H, Turner ND, Mann JC, Wei J, Taddeo SS, Davidson LA, Wang N, 
Vannucci M, et al. A chemoprotective fish oil- and pectin-containing diet temporally alters gene 
expression profiles in exfoliated rat colonocytes throughout oncogenesis. J Nutr. 2011 
Jun;141:1029-35. 
245. Ritchie LE, Taddeo SS, Weeks BR, Carroll RJ, Dykes L, Rooney LW, Turner ND. 
Impact of Novel Sorghum Bran Diets on DSS-Induced Colitis. Nutrients. 2017 Mar 27;9:330. 
246. Fierer N, Hamady M, Lauber CL, Knight R. The influence of sex, handedness, and 
washing on the diversity of hand surface bacteria. Proc Natl Acad Sci U S A. 2008 Nov 
18;105:17994-9. 
247. Liu Z, Lozupone C, Hamady M, Bushman FD, Knight R. Short pyrosequencing reads 
suffice for accurate microbial community analysis. Nucleic Acids Res. 2007;35:e120. 
248. Wu GD, Lewis JD, Hoffmann C, Chen YY, Knight R, Bittinger K, Hwang J, Chen J, 
Berkowsky R, et al. Sampling and pyrosequencing methods for characterizing bacterial 
communities in the human gut using 16S sequence tags. BMC Microbiol. 2010 Jul 30;10:206. 
249. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer 
N, Pena AG, Goodrich JK, et al. QIIME allows analysis of high-throughput community 




250. Reeder J, Knight R. Rapid denoising of pyrosequencing amplicon data: exploiting the 
rank-abundance distribution. Nature methods. 2010;7:668. 
251. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 
2010 Oct 1;26:2460-1. 
252. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe 
KD, Guo L. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced 
toxicology in Fischer 344 male rats. Toxicol Pathol. 2009 Jun;37:521-35. 
253. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted 
ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry 
platform for the identification and relative quantification of the small-molecule complement of 
biological systems. Anal Chem. 2009 Aug 15;81:6656-67. 
254. DeHaven CD, Evans AM, Dai H, Lawton KA. Organization of GC/MS and LC/MS 
metabolomics data into chemical libraries. J Cheminform. 2010;2:9. 
255. Jump RL, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M, Deshpande A, 
Nerandzic MM, Donskey CJ. Metabolomics analysis identifies intestinal microbiota-derived 
biomarkers of colonization resistance in clindamycin-treated mice. PLoS One. 2014;9:e101267. 
256. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad 
Sci U S A. 2003 Aug 5;100:9440-5. 
257. Cheng L, Lai M-D. Aberrant crypt foci as microscopic precursors of colorectal cancer. 
World journal of gastroenterology: WJG. 2003;9:2642. 
258. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, 
Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N 
Engl J Med. 1998;339:1277-84. 
259. Stacewicz-Sapuntzakis M. Dried plums and their products: composition and health 
effects--an updated review. Crit Rev Food Sci Nutr. 2013 Jan 1;53:1277-302. 
260. Husoy T, Haugen M, Murkovic M, Jobstl D, Stolen LH, Bjellaas T, Ronningborg C, 
Glatt H, Alexander J. Dietary exposure to 5-hydroxymethylfurfural from Norwegian food and 
correlations with urine metabolites of short-term exposure. Food Chem Toxicol. 2008 
Dec;46:3697-702. 
261. Podda R, Delli Castelli D, Digilio G, Gullino ML, Aime S. Asparagine in plums detected 
by CEST-MRI. Food Chem. 2015 Feb 15;169:1-4. 
262. Heinonen S, Nurmi T, Liukkonen K, Poutanen K, Wahala K, Deyama T, Nishibe S, 
Adlercreutz H. In vitro metabolism of plant lignans: new precursors of mammalian lignans 




263. Collett ED, Davidson LA, Fan YY, Lupton JR, Chapkin RS. n-6 and n-3 polyunsaturated 
fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell 
Physiol. 2001 May;280:C1066-75. 
264. Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in 
Ingenuity Pathway Analysis. Bioinformatics. 2014 Feb 15;30:523-30. 
265. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol. 2006 
Nov 14;12:6741-6. 
266. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in 
azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 2004 Jun;95:475-80. 
267. Kim DO, Lee KW, Chun OK, Leer HJ, Lee CY. Antiproliferative activity of 
polyphenolics in plums. Food Sci Biotechnol. 2003 Aug;12:399-402. 
268. Chun OK, Kim DO, Lee CY. Superoxide radical scavenging activity of the major 
polyphenols in fresh plums. J Agric Food Chem. 2003 Dec 31;51:8067-72. 
269. Yang L, Seki E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. 
Front Physiol. 2012 May 22;3:138. 
270. Fung KY, Cosgrove L, Lockett T, Head R, Topping DL. A review of the potential 
mechanisms for the lowering of colorectal oncogenesis by butyrate. Br J Nutr. 2012 
Sep;108:820-31. 
271. Wei H, Dong L, Wang T, Zhang M, Hua W, Zhang C, Pang X, Chen M, Su M, et al. 
Structural shifts of gut microbiota as surrogate endpoints for monitoring host health changes 
induced by carcinogen exposure. FEMS Microbiol Ecol. 2010 Sep;73:577-86. 
272. Kaakoush NO. Insights into the Role of Erysipelotrichaceae in the Human Host. Front 
Cell Infect Microbiol. 2015 Nov 20;5:84. 
273. Cai WJ, Wang MJ, Ju LH, Wang C, Zhu YC. Hydrogen sulfide induces human colon 
cancer cell proliferation: role of Akt, ERK and p21. Cell Biol Int. 2010 Apr 14;34:565-72. 
274. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, 
Magris M, Hidalgo G, Baldassano RN, et al. Human gut microbiome viewed across age and 
geography. Nature. 2012 May 9;486:222-7. 
275. Zhao L, Chen J, Su J, Li L, Hu S, Li B, Zhang X, Xu Z, Chen T. In vitro antioxidant and 
antiproliferative activities of 5-hydroxymethylfurfural. J Agric Food Chem. 2013 Nov 
6;61:10604-11. 
276. Kowalski S, Lukasiewicz M, Duda-Chodak A, Zięć G. 5-Hydroxymethyl-2-Furfural 
(HMF) – Heat-Induced Formation, Occurrence in Food and Biotransformation – a Review. 




277. Hedelin M, Lof M, Sandin S, Adami HO, Weiderpass E. Prospective Study of Dietary 
Phytoestrogen Intake and the Risk of Colorectal Cancer. Nutr Cancer. 2016 Apr 2;68:388-95. 
278. Jiang R, Botma A, Rudolph A, Husing A, Chang-Claude J. Phyto-oestrogens and 
colorectal cancer risk: a systematic review and dose-response meta-analysis of observational 
studies. Br J Nutr. 2016 Dec;116:2115-28. 
279. Triff K, Kim E, Chapkin RS. Chemoprotective epigenetic mechanisms in a colorectal 
cancer model: Modulation by n-3 PUFA in combination with fermentable fiber. Curr Pharmacol 
Rep. 2015 Feb;1:11-20. 
280. Chapkin RS, Hong MY, Fan YY, Davidson LA, Sanders LM, Henderson CE, Barhoumi 
R, Burghardt RC, Turner ND, Lupton JR. Dietary n-3 PUFA alter colonocyte mitochondrial 
membrane composition and function. Lipids. 2002 Feb;37:193-9. 
281. Kim E, Davidson LA, Patil BS, Jayaprakasha GK, Callaway ES, Turner ND, Chapkin 
RS. Effects of chemoprotective diets on crypt adult stem cells: the cells of origin of colon cancer 
(819.1). The FASEB Journal. 2014 April 1;28. 
282. Chapkin RS, Davidson LA, Ly L, Weeks BR, Lupton JR, McMurray DN. 
Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer. J 
Nutr. 2007 Jan;137:200S-4S. 
283. Turk HF, Kolar SS, Fan YY, Cozby CA, Lupton JR, Chapkin RS. Linoleic acid and 
butyrate synergize to increase Bcl-2 levels in colonocytes. Int J Cancer. 2011 Jan 1;128:63-71. 
284. Chapkin RS, Seo J, McMurray DN, Lupton JR. Mechanisms by which docosahexaenoic 
acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. 
Chem Phys Lipids. 2008 May;153:14-23. 
285. Chapkin RS, DeClercq V, Kim E, Fuentes NR, Fan YY. Mechanisms by Which 
Pleiotropic Amphiphilic n-3 PUFA Reduce Colon Cancer Risk. Curr Colorectal Cancer Rep. 
2014 Dec 1;10:442-52. 
286. Davidson LA, Brown RE, Chang WC, Morris JS, Wang N, Carroll RJ, Turner ND, 
Lupton JR, Chapkin RS. Morphodensitometric analysis of protein kinase C beta(II) expression in 
rat colon: modulation by diet and relation to in situ cell proliferation and apoptosis. 
Carcinogenesis. 2000 Aug;21:1513-9. 
287. Turner ND, Zhang J, Davidson LA, Lupton JR, Chapkin RS. Oncogenic ras alters 
sensitivity of mouse colonocytes to butyrate and fatty acid mediated growth arrest and apoptosis. 
Cancer Lett. 2002 Dec 1;186:29-35. 
288. Fan YY, Zhan Y, Aukema HM, Davidson LA, Zhou L, Callaway E, Tian Y, Weeks BR, 
Lupton JR, et al. Proapoptotic effects of dietary (n-3) fatty acids are enhanced in colonocytes of 




289. Steen EJ, Kang Y, Bokinsky G, Hu Z, Schirmer A, McClure A, Del Cardayre SB, 
Keasling JD. Microbial production of fatty-acid-derived fuels and chemicals from plant biomass. 
Nature. 2010 Jan 28;463:559-62. 
290. Certik M, Shimizu S. Biosynthesis and regulation of microbial polyunsaturated fatty acid 
production. J Biosci Bioeng. 1999;87:1-14. 
291. Zargar A, Bailey CB, Haushalter RW, Eiben CB, Katz L, Keasling JD. Leveraging 
microbial biosynthetic pathways for the generation of ‘drop-in’biofuels. Curr Opin Biotechnol. 
2017;45:156-63. 
292. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel 
syndrome: present state and perspectives. Microbiology. 2010 Nov;156:3205-15. 
293. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, 
Devlin AS, Varma Y, et al. Diet rapidly and reproducibly alters the human gut microbiome. 
Nature. 2014 Jan 23;505:559-63. 
294. Thompson AL, Monteagudo-Mera A, Cadenas MB, Lampl ML, Azcarate-Peril MA. 
Milk- and solid-feeding practices and daycare attendance are associated with differences in 
bacterial diversity, predominant communities, and metabolic and immune function of the infant 
gut microbiome. Frontiers in cellular and infection microbiology. 2015;5:3. 
295. Allali I, Delgado S, Marron PI, Astudillo A, Yeh JJ, Ghazal H, Amzazi S, Keku T, 
Azcarate-Peril MA. Gut microbiome compositional and functional differences between tumor 
and non-tumor adjacent tissues from cohorts from the US and Spain. Gut Microbes. 2015 Apr 
15;6:161-72. 
296. Devine AA, Gonzalez A, Speck KE, Knight R, Helmrath MA, Lund PK, Azcarate Peril 
MA. Impact of ileocecal resection and concomitant antibiotics on the microbiome of the murine 
jejunum and colon. PLoS One. 2013;8(8): e73140.  
297. Allali I, Arnold JW, Roach J, Cadenas MB, Butz N, Hassan HM, Koci M, Ballou A, 
Mendoza M, et al. A comparison of sequencing platforms and bioinformatics pipelines for 
compositional analysis of the gut microbiome. BMC Microbiol. 2017 Sep 13;17:194. 
298. Monteagudo-Mera A, Arthur JC, Jobin C, Keku TO, Bruno Barcena JM, Azcarate-Peril 
MA. High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their 
metabolic activity in the mouse gut microbiome. Beneficial microbes. 2016;3:1-18. 
299. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for 
large alignments. PLoS One. 2010;5:e9490. 
300. Lozupone C, Hamady M, Knight R. UniFrac--an online tool for comparing microbial 




301. Tuohy KM, Conterno L, Gasperotti M, Viola R. Up-regulating the human intestinal 
microbiome using whole plant foods, polyphenols, and/or fiber. J Agric Food Chem. 2012 Sep 
12;60:8776-82. 
302. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and 
bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. The American 
journal of clinical nutrition. 2005;81:230S-42S. 
303. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., 
sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004 
Sep;54:1469-76. 
304. Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating 
host functions. Microb Pathog. 2017 May;106:171-81. 
305. Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, Raskin 
I. Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and 
Attenuate High-Fat Diet-Induced Metabolic Syndrome. Diabetes. 2015 Aug;64:2847-58. 
306. Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, Gershovich K, Sabo E, Nevelsky A, Daniel 
S, Dahan A, Ziv O, et al. Radiation induces proinflammatory dysbiosis: transmission of 
inflammatory susceptibility by host cytokine induction. Gut. 2018 Jan;67:97-107. 
307. Anhê FF, Roy D, Pilon G, Dudonné S, Matamoros S, Varin TV, Garofalo C, Moine Q, 
Desjardins Y, Levy E. A polyphenol-rich cranberry extract protects from diet-induced obesity, 
insulin resistance and intestinal inflammation in association with increased Akkermansia spp. 
population in the gut microbiota of mice. Gut. 2015;64:872-83. 
308. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An increase in the 
Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in 
diet-induced obese mice. Gut. 2014 May;63:727-35. 
309. Zhang Z, Wu X, Cao S, Wang L, Wang D, Yang H, Feng Y, Wang S, Li L. Caffeic acid 
ameliorates colitis in association with increased Akkermansia population in the gut microbiota of 
mice. Oncotarget. 2016 May 31;7:31790-9. 
310. Alam A, Leoni G, Quiros M, Wu H, Desai C, Nishio H, Jones RM, Nusrat A, Neish AS. 
The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. Nat 
Microbiol. 2016 Jan 27;1:15021. 
311. Seidel DV, Hicks KK, Taddeo SS, Azcarate-Peril MA, Carroll RJ, Turner ND. Dried 
plums modify fecal short chain fatty acid concentrations and gene expression in a rat model of 
colon carcinogenesis. The FASEB Journal. 2016;30:147.3-.3. 
312. Seidel DV, Taddeo SS, Azcarate-Peril MA, Carroll RJ, Turner ND. Dried Plums Modify 





313. Datta K, Suman S, Kallakury BV, Fornace AJ, Jr. Exposure to heavy ion radiation 
induces persistent oxidative stress in mouse intestine. PLoS One. 2012;7:e42224. 
314. Arjmandi BH, Khalil DA, Lucas EA, Georgis A, Stoecker BJ, Hardin C, Payton ME, 
Wild RA. Dried plums improve indices of bone formation in postmenopausal women. J Womens 
Health Gend Based Med. 2002 Jan-Feb;11:61-8. 
315. Deyhim F, Stoecker BJ, Brusewitz GH, Devareddy L, Arjmandi BH. Dried plum reverses 
bone loss in an osteopenic rat model of osteoporosis. Menopause. 2005 Nov-Dec;12:755-62. 
316. Franklin M, Bu SY, Lerner MR, Lancaster EA, Bellmer D, Marlow D, Lightfoot SA, 
Arjmandi BH, Brackett DJ, et al. Dried plum prevents bone loss in a male osteoporosis model 
via IGF-I and the RANK pathway. Bone. 2006 Dec;39:1331-42. 
317. Halloran BP, Wronski TJ, VonHerzen DC, Chu V, Xia X, Pingel JE, Williams AA, 
Smith BJ. Dietary Dried Plum Increases Bone Mass in Adult and Aged Male Mice–3. The 
Journal of nutrition. 2010;140:1781-7. 
318. Hooshmand S, Kern M, Metti D, Shamloufard P, Chai SC, Johnson SA, Payton ME, 
Arjmandi BH. The effect of two doses of dried plum on bone density and bone biomarkers in 
osteopenic postmenopausal women: a randomized, controlled trial. Osteoporos Int. 2016 
Jul;27:2271-9. 
319. Rendina E, Lim YF, Marlow D, Wang Y, Clarke SL, Kuvibidila S, Lucas EA, Smith BJ. 
Dietary supplementation with dried plum prevents ovariectomy-induced bone loss while 
modulating the immune response in C57BL/6J mice. J Nutr Biochem. 2012;23:60-8. 
320. Schreurs A-S, Shirazi Y, Shahnazari M, S Alwood J, A Truong T, G T Tahimic C, Limoli 
C, Turner N, Halloran B, Globus R. Dried plum diet protects from bone loss caused by ionizing 
radiation; 2016. 
321. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with 
radioresponsiveness of human tumors: Analysis of 101 published survival curves. International 
Journal of Radiation Oncology*Biology*Physics. 1985 Sep 1;11:1699-707. 
322. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. 
Nat Rev Cancer. 2008 Jul;8:545-54. 
323. Chen MF, Lin CT, Chen WC, Yang CT, Chen CC, Liao SK, Liu JM, Lu CH, Lee KD. 
The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol 
Phys. 2006 Sep 1;66:244-53. 
324. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat 
Oncol Biol Phys. 1996 Jan 1;34:251-66. 
325. T. James P, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future 




326. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am 
J Clin Nutr. 2007 Sep;86:s836-42. 
327. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J 
Pathol. 2006 Nov;169:1505-22. 
328. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the 
development of low-grade inflammation and type 2 diabetes associated with obesity. Gut 
Microbes. 2012 Jul;3:279-88. 
329. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and 
insulin resistance in human obesity. Curr Pharm Des. 2008;14:1225-30. 
330. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard J. 
Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin 
and IL-6 levels in obese women. Int J Obes. 2004;28:993. 
331. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut 
microbiome and the immune system. Nature. 2011 Jun 15;474:327-36. 
332. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate 
improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009 
Jul;58:1509-17. 
333. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-
associated gut microbiome with increased capacity for energy harvest. Nature. 2006 Dec 
21;444:1027-31. 
334. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, 
Arumugam M, Batto JM, et al. Richness of human gut microbiome correlates with metabolic 
markers. Nature. 2013 Aug 29;500:541-6. 
335. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-
Thie GM, Ackermans MT, Serlie MJ, et al. Transfer of intestinal microbiota from lean donors 
increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 
Oct;143:913-6. 
336. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, 
Henrissat B, et al. Gut microbiota from twins discordant for obesity modulate metabolism in 
mice. Science. 2013 Sep 6;341:1241214. 
337. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes 
associated with obesity. Nature. 2006 Dec 21;444:1022-3. 
338. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for 




339. Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, Clarke SF, 
O'Toole PW, Quigley EM, et al. Composition and energy harvesting capacity of the gut 
microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010 Dec;59:1635-42. 
340. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos 
WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients 
with irritable bowel syndrome. Gastroenterology. 2011 Nov;141:1792-801. 
341. Hagerman AE, Riedl KM, Jones GA, Sovik KN, Ritchard NT, Hartzfeld PW, Riechel 
TL. High Molecular Weight Plant Polyphenolics (Tannins) as Biological Antioxidants. J Agric 
Food Chem. 1998 May;46:1887-92. 
342. Serrano J, Puupponen-Pimia R, Dauer A, Aura AM, Saura-Calixto F. Tannins: current 
knowledge of food sources, intake, bioavailability and biological effects. Mol Nutr Food Res. 
2009 Sep;53 Suppl 2:S310-29. 
343. Bhat TK, Singh B, Sharma OP. Microbial degradation of tannins--a current perspective. 
Biodegradation. 1998;9:343-57. 
344. Heider J, Fuchs G. Microbial anaerobic aromatic metabolism. Anaerobe. 1997 Feb;3:1-
22. 
345. Smith AH, Mackie RI. Effect of condensed tannins on bacterial diversity and metabolic 
activity in the rat gastrointestinal tract. Appl Environ Microbiol. 2004 Feb;70:1104-15. 
346. Lemlioglu-Austin D, Turner ND, McDonough CM, Rooney LW. Effects of sorghum 
[Sorghum bicolor (L.) Moench] crude extracts on starch digestibility, Estimated Glycemic Index 
(EGI), and Resistant Starch (Rs) contents of porridges. Molecules. 2012 Sep 17;17:11124-38. 
347. Austin DL, Turner ND, McDonough CM, Rooney LW. Effects of brans from specialty 
sorghum varieties on in vitro starch digestibility of soft and hard sorghum endosperm porridges. 
Cereal Chem. 2012;89:190-7. 
348. Ritchie LE, Carroll R, Weeks B, Rooney L, Turner N. Novel sorghum brans containing 
bioactive compounds alter the production of microbial secondary metabolites in response to a 
DSS-induced chronic inflammatory state. The FASEB Journal. 2012;26:823.36. 
349. Center NC. NDS-R software. Minneapolis: Regents of the University of Minnesota. 
2003. 
350. Martinez I, Lattimer JM, Hubach KL, Case JA, Yang J, Weber CG, Louk JA, Rose DJ, 
Kyureghian G, et al. Gut microbiome composition is linked to whole grain-induced 
immunological improvements. ISME J. 2013 Feb;7:269-80. 
351. Martinez I, Kim J, Duffy PR, Schlegel VL, Walter J. Resistant starches types 2 and 4 
have differential effects on the composition of the fecal microbiota in human subjects. PLoS 




352. Sridharan GV, Choi K, Klemashevich C, Wu C, Prabakaran D, Pan LB, Steinmeyer S, 
Mueller C, Yousofshahi M, et al. Prediction and quantification of bioactive microbiota 
metabolites in the mouse gut. Nat Commun. 2014 Nov 20;5:5492. 
353. Bajad SU, Lu W, Kimball EH, Yuan J, Peterson C, Rabinowitz JD. Separation and 
quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-
tandem mass spectrometry. J Chromatogr A. 2006 Aug 25;1125:76-88. 
354. Gonthier MP, Remesy C, Scalbert A, Cheynier V, Souquet JM, Poutanen K, Aura AM. 
Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human 
faecal microbiota in vitro. Biomed Pharmacother. 2006 Nov;60:536-40. 
355. Gonthier MP, Verny MA, Besson C, Remesy C, Scalbert A. Chlorogenic acid 
bioavailability largely depends on its metabolism by the gut microflora in rats. J Nutr. 2003 
Jun;133:1853-9. 
356. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. 
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. 
Proc Natl Acad Sci U S A. 2009 Mar 10;106:3698-703. 
357. Moss CW, Lambert M, Goldsmith D. Production of hydrocinnamic acid by clostridia. 
Appl Microbiol. 1970;19:375-8. 
358. Hoskins JA, Holliday SB, Greenway AM. The metabolism of cinnamic acid by healthy 
and phenylketonuric adults: a kinetic study. Biomed Mass Spectrom. 1984 Jun;11:296-300. 
359. Pekkinen J, Rosa NN, Savolainen OI, Keski-Rahkonen P, Mykkanen H, Poutanen K, 
Micard V, Hanhineva K. Disintegration of wheat aleurone structure has an impact on the 
bioavailability of phenolic compounds and other phytochemicals as evidenced by altered urinary 
metabolite profile of diet-induced obese mice. Nutr Metab (Lond). 2014 Jan 2;11:1. 
360. Obrenovich ME, Tima M, Polinkovsky A, Zhang R, Emancipator SN, Donskey CJ. 
Targeted Metabolomics Analysis Identifies Intestinal Microbiota-Derived Urinary Biomarkers of 
Colonization Resistance in Antibiotic-Treated Mice. Antimicrob Agents Chemother. 2017 
Aug;61. 
361. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J 
Clin Invest. 2014 Oct;124:4204-11. 
362. Fujii H, Nakai K, Fukagawa M. Role of oxidative stress and indoxyl sulfate in 
progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial. 2011 
Apr;15:125-8. 
363. Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, Salvador J, 
Ricart W, Fruhbeck G, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker 




364. Selma MV, Espin JC, Tomas-Barberan FA. Interaction between phenolics and gut 
microbiota: role in human health. J Agric Food Chem. 2009 Aug 12;57:6485-501. 
365. Jacobs DM, Spiesser L, Garnier M, de Roo N, van Dorsten F, Hollebrands B, van Velzen 
E, Draijer R, van Duynhoven J. SPE-NMR metabolite sub-profiling of urine. Anal Bioanal 
Chem. 2012 Nov;404:2349-61. 
366. Brown GK, Stokke O, Jellum E. Chromatographic profile of high boiling point organic 
acids in human urine. J Chromatogr. 1978 Mar 1;145:177-84. 
367. Moss CW, Lambert MA, Goldsmith DJ. Production of hydrocinnamic acid by clostridia. 
Appl Microbiol. 1970 Feb;19:375-8. 
368. Bo S, Gambino R, Durazzo M, Guidi S, Tiozzo E, Ghione F, Gentile L, Cassader M, 
Pagano GF. Associations between gamma-glutamyl transferase, metabolic abnormalities and 
inflammation in healthy subjects from a population-based cohort: a possible implication for 
oxidative stress. World J Gastroenterol. 2005 Dec 7;11:7109-17. 
369. Fornaciari I, Fierabracci V, Corti A, Aziz Elawadi H, Lorenzini E, Emdin M, Paolicchi 
A, Franzini M. Gamma-glutamyltransferase fractions in human plasma and bile: characteristic 
and biogenesis. PLoS One. 2014;9:e88532. 
370. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, 
D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, 
cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb 
Vasc Biol. 2007 Jan;27:127-33. 
371. Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular 
risk biomarker. Prev Cardiol. 2010 Winter;13:36-41. 
372. Whitfield-Cargile CM, Cohen ND, Chapkin RS, Weeks BR, Davidson LA, Goldsby JS, 
Hunt CL, Steinmeyer SH, Menon R, et al. The microbiota-derived metabolite indole decreases 
mucosal inflammation and injury in a murine model of NSAID enteropathy. Gut Microbes. 2016 
May 3;7:246-61. 
373. Diaz-Diaz CJ, Ronnekleiv-Kelly SM, Nukaya M, Geiger PG, Balbo S, Dator R, Megna 
BW, Carney PR, Bradfield CA, Kennedy GD. The Aryl Hydrocarbon Receptor is a Repressor of 
Inflammation-associated Colorectal Tumorigenesis in Mouse. Ann Surg. 2016 Sep;264:429-36. 
374. Jin UH, Lee SO, Sridharan G, Lee K, Davidson LA, Jayaraman A, Chapkin RS, Alaniz 
R, Safe S. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-
dependent agonist and antagonist activities. Mol Pharmacol. 2014 May;85:777-88. 
375. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and 




376. Zhao X, Fritsche J, Wang J, Chen J, Rittig K, Schmitt-Kopplin P, Fritsche A, Haring HU, 
Schleicher ED, et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human 
pre-diabetic metabolic traits. Metabolomics. 2010 Sep;6:362-74. 
377. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its 
implications for health. J Nutr. 2004 Mar;134:489-92. 
378. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights 
D, Walters WA, et al. Linking long-term dietary patterns with gut microbial enterotypes. 
Science. 2011 Oct 7;334:105-8. 
379. Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the 
Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol. 2014 
Mar;6:703-13. 
380. Dworkin M, Falkow S. Prokaryotes: Delta and Epsilon Subclasses, Deeply Rooting 
Bacteria: a Handbook on the Biology of Bacteria: Springer; 2006. 
381. Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, et al. 
Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012 Aug 
30;488:621-6. 
382. Duncan SH, Barcenilla A, Stewart CS, Pryde SE, Flint HJ. Acetate utilization and butyryl 
coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large 
intestine. Appl Environ Microbiol. 2002 Oct;68:5186-90. 
383. Zeng H, Ishaq SL, Zhao FQ, Wright AG. Colonic inflammation accompanies an increase 
of beta-catenin signaling and Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-
fat diet-fed mice. J Nutr Biochem. 2016 Sep;35:30-6. 
384. Kameyama K, Itoh K. Intestinal colonization by a Lachnospiraceae bacterium contributes 
to the development of diabetes in obese mice. Microbes Environ. 2014;29:427-30. 
385. Martin R, Miquel S, Benevides L, Bridonneau C, Robert V, Hudault S, Chain F, Berteau 
O, Azevedo V, et al. Functional Characterization of Novel Faecalibacterium prausnitzii Strains 
Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-
Generation Probiotic. Front Microbiol. 2017;8:1226. 
386. Miquel S, Martin R, Rossi O, Bermudez-Humaran LG, Chatel JM, Sokol H, Thomas M, 
Wells JM, Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr Opin 
Microbiol. 2013 Jun;16:255-61. 
387. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, 
Blugeon S, Bridonneau C, Furet JP, et al. Faecalibacterium prausnitzii is an anti-inflammatory 
commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl 




388. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, 
Corthier G, Marteau P, Dore J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. 
Inflamm Bowel Dis. 2009 Aug;15:1183-9. 
389. Varela E, Manichanh C, Gallart M, Torrejon A, Borruel N, Casellas F, Guarner F, 
Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission 
in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013 Jul;38:151-61. 
390. Van Immerseel F, Ducatelle R, De Vos M, Boon N, Van De Wiele T, Verbeke K, 
Rutgeerts P, Sas B, Louis P, Flint HJ. Butyric acid-producing anaerobic bacteria as a novel 
probiotic treatment approach for inflammatory bowel disease. J Med Microbiol. 2010;59:141-3. 
391. Benus RF, van der Werf TS, Welling GW, Judd PA, Taylor MA, Harmsen HJ, Whelan 
K. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in 
healthy human subjects. Br J Nutr. 2010;104:693-700. 
392. Ouwerkerk JP, Aalvink S, Belzer C, de Vos WM. Akkermansia glycaniphila sp. nov., an 
anaerobic mucin-degrading bacterium isolated from reticulated python faeces. Int J Syst Evol 
Microbiol. 2016 Nov;66:4614-20. 
393. Anhê FF, Pilon G, Roy D, Desjardins Y, Levy E, Marette A. Triggering Akkermansia 
with dietary polyphenols: A new weapon to combat the metabolic syndrome? Gut microbes. 
2016;7:146-53. 
394. Picolli da Silva L, de Lourdes Santorio Ciocca M. Total, insoluble and soluble dietary 
fiber values measured by enzymatic–gravimetric method in cereal grains. J Food Compost Anal. 
2005 Feb 1;18:113-20. 
395. Pimpao RC, Ventura MR, Ferreira RB, Williamson G, Santos CN. Phenolic sulfates as 
new and highly abundant metabolites in human plasma after ingestion of a mixed berry fruit 
puree. Br J Nutr. 2015 Feb 14;113:454-63. 
396. Fang C, Kim H, Barnes RC, Talcott ST, Mertens-Talcott SU. Obesity-Associated 
Diseases Biomarkers Are Differently Modulated in Lean and Obese Individuals and Inversely 
Correlated to Plasma Polyphenolic Metabolites After 6 Weeks of Mango (Mangifera indica L.) 
Consumption. Mol Nutr Food Res. 2018 May 24;62:e1800129. 
397. Rechner AR, Kuhnle G, Hu H, Roedig-Penman A, van den Braak MH, Moore KP, Rice-
Evans CA. The metabolism of dietary polyphenols and the relevance to circulating levels of 
conjugated metabolites. Free Radic Res. 2002 Nov;36:1229-41. 
398. Rechner AR, Kuhnle G, Bremner P, Hubbard GP, Moore KP, Rice-Evans CA. The 
metabolic fate of dietary polyphenols in humans. Free Radic Biol Med. 2002 Jul 15;33:220-35. 
399. Gonthier M-P, Rios LY, Verny M-A, Rémésy C, Scalbert A. Novel liquid 




human urine of microbial aromatic acid metabolites derived from dietary polyphenols. Journal of 
Chromatography B. 2003 Jun 15;789:247-55. 
400. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001 Aug;38:263-
355. 
401. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR, Jr., Lee DH. Is serum gamma-
glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? 
Free Radic Biol Med. 2004 Oct 1;37:1018-23. 
402. Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF. The changing faces of 
glutathione, a cellular protagonist. Biochem Pharmacol. 2003 Oct 15;66:1499-503. 
403. Garcia TC, Steffey MA, Zwingenberger AL, Daniel L, Stover SM. CT-derived indices of 
canine osteosarcoma-affected antebrachial strength. Vet Surg. 2017 May;46:549-58. 
404. Abdi H, Williams LJ. Principal component analysis. Wiley interdisciplinary reviews: 
computational statistics. 2010;2:433-59. 
405. Bro R, Smilde AK. Principal component analysis. Analytical Methods. 2014;6:2812-31. 
406. Thompson B. Canonical correlation analysis. Encyclopedia of statistics in behavioral 
science. 2005. 
407. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley 
RE. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad 
Sci U S A. 2011 Mar 15;108 Suppl 1:4578-85. 
408. Cani PD, Everard A. Talking microbes: when gut bacteria interact with diet and host 
organs. Mol Nutr Food Res. 2016;60:58-66. 
409. Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in 
physiology and disease. Nat Med. 2016 Oct 6;22:1079-89. 
410. Sommer F, Backhed F. Know your neighbor: Microbiota and host epithelial cells interact 
locally to control intestinal function and physiology. Bioessays. 2016 May;38:455-64. 
411. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, 
Kinross J, Smidt H, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016 
Feb;65:330-9. 
412. Ochoa-Repáraz J, Kirby TO, Kasper LH. The gut microbiome and multiple sclerosis. 
Cold Spring Harb Perspect Med. 2018;8:a029017. 
413. Kitsios GD, Morowitz MJ, Dickson RP, Huffnagle GB, McVerry BJ, Morris A. 





414. Dinan TG, Borre YE, Cryan JF. Genomics of schizophrenia: time to consider the gut 
microbiome? Mol Psychiatry. 2014 Dec;19:1252-7. 
415. Bi Y, Qin N, Yang R. Human microbiota: a neglected “organ” in precision medicine. 
Infectious Diseases and Translational Medicine. 2015;1:63-72. 
416. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut 
microbiota: the neglected endocrine organ. Mol Endocrinol. 2014 Aug;28:1221-38. 
417. Marteau P, Doré J. Gut microbiota: An organ all its own. 2017. 
418. Wroblewski LE, Shen L, Ogden S, Romero-Gallo J, Lapierre LA, Israel DA, Turner JR, 
Peek RM, Jr. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-
mediated myosin II activation. Gastroenterology. 2009 Jan;136:236-46. 
419. Roper J, Francois F, Shue PL, Mourad MS, Pei Z, Olivares de Perez AZ, Perez-Perez GI, 
Tseng CH, Blaser MJ. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. 
J Clin Endocrinol Metab. 2008 Jun;93:2350-7. 
420. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JE, 
McColl KE. Helicobacter pylori infection and chronic gastric acid hyposecretion. 
Gastroenterology. 1997 Jul;113:15-24. 
421. Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal 
adenocarcinoma. Cancer Prev Res (Phila). 2008 Oct;1:308-11. 
422. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption 
of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science. 2003 May 
30;300:1430-4. 
423. Courtay C, Oster T, Michelet F, Visvikis A, Diederich M, Wellman M, Siest G. Gamma-
glutamyltransferase: nucleotide sequence of the human pancreatic cDNA. Evidence for a 
ubiquitous gamma-glutamyltransferase polypeptide in human tissues. Biochem Pharmacol. 1992 
Jun 23;43:2527-33. 
424. Buckel W, Barker HA. Two pathways of glutamate fermentation by anaerobic bacteria. J 
Bacteriol. 1974 Mar;117:1248-60. 
425. Liu Q, Zhang J, Wei XX, Ouyang SP, Wu Q, Chen GQ. Microbial production of L -
glutamate and L -glutamine by recombinant Corynebacterium glutamicum harboring Vitreoscilla 
hemoglobin gene vgb. Appl Microbiol Biotechnol. 2008 Jan;77:1297-304. 
426. Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T, Ulja D, 
Karuppagounder SS, Holson EB, et al. Exercise promotes the expression of brain derived 
neurotrophic factor (BDNF) through the action of the ketone body beta-hydroxybutyrate. Elife. 




427. Stipanuk MH, Caudill MA. Biochemical, Physiological, and Molecular Aspects of 
Human Nutrition-E-Book: Elsevier health sciences; 2013. 
428. Cavaleri F, Bashar E. Potential Synergies of beta-Hydroxybutyrate and Butyrate on the 
Modulation of Metabolism, Inflammation, Cognition, and General Health. J Nutr Metab. 
2018;2018:7195760. 
429. Hu S, Dong TS, Dalal SR, Wu F, Bissonnette M, Kwon JH, Chang EB. The microbe-
derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human 
colon cancer. PLoS One. 2011 Jan 20;6:e16221. 
430. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin 
Clin Nutr Metab Care. 2012 Sep;15:474-9. 
431. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien 
M, Muccioli GG, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium 
controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013 May 28;110:9066-71. 
432. Lees HJ, Swann JR, Wilson ID, Nicholson JK, Holmes E. Hippurate: the natural history 
of a mammalian–microbial cometabolite. J Proteome Res. 2013;12:1527-46. 
433. Scheline RR, Midtvedt T. Absence of dehydroxylation of caffeic acid in germ-free rats. 
Experientia. 1970 Oct 15;26:1068-9. 
434. Peppercorn MA, Goldman P. Caffeic acid metabolism by gnotobiotic rats and their 
intestinal bacteria. Proceedings of the National Academy of Sciences. 1972;69:1413-5. 
435. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 
Jan;67:7-30. 
436. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. Dietary polyphenols and the 
prevention of diseases. Crit Rev Food Sci Nutr. 2005 Jun 1;45:287-306. 
437. Matsunaga K, Katayama M, Sakata K, Kuno T, Yoshida K, Yamada Y, Hirose Y, 
Yoshimi N, Mori H. Inhibitory Effects of Chlorogenic Acid on Azoxymethane-induced Colon 
Carcinogenesis in Male F344 Rats. Asian Pac J Cancer Prev. 2002;3:163-6. 
438. Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol. 2015 
Dec;6:334-43. 
439. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol. 2005 Oct;5:749-59. 
440. Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, Munjal U, 
Stein K, Glei M. Mechanisms of primary cancer prevention by butyrate and other products 




441. Woo SS, Jiang J, Gill BS, Paterson AH, Wing RA. Construction and characterization of a 
bacterial artificial chromosome library of Sorghum bicolor. Nucleic Acids Res. 1994 Nov 
25;22:4922-31. 
442. de Morais Cardoso L, Pinheiro SS, Martino HS, Pinheiro-Sant'Ana HM. Sorghum 
(Sorghum bicolor L.): Nutrients, bioactive compounds, and potential impact on human health. 
Crit Rev Food Sci Nutr. 2017 Jan 22;57:372-90. 
443. Awika JM, Rooney LW, Waniska RD. Properties of 3-deoxyanthocyanins from sorghum. 
J Agric Food Chem. 2004 Jul 14;52:4388-94. 
444. Iwei LGU, Ouse SUEH, Ooney LLR, Rior ROLP. Sorghum Bran in the Diet Dose 
Dependently Increased the Excretion of Catechins and Microbial-Derived Phenolic Acids in 
Female Rats. 2007:5326-34. 
445. Ritchie LE. Diet, Disease State, and the Space Environment Modify the Intestinal 
Microbiota and Mucosal Environment via Microbiota-directed Alterations in Colonocyte 
Signalling. Doctoral dissertation, Texas A&M University. 2013. 
446. Yassour M, Lim MY, Yun HS, Tickle TL, Sung J, Song YM, Lee K, Franzosa EA, 
Morgan XC, et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 
diabetes. Genome Med. 2016 Feb 17;8:17. 
447. Arimochi H, Kinouchi T, Kataoka K, Kuwahara T, Ohnishi Y. Effect of intestinal 
bacteria on formation of azoxymethane-induced aberrant crypt foci in the rat colon. Biochem 
Biophys Res Commun. 1997 Sep 29;238:753-7. 
448. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, 
Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity 






TABLES AND FIGURES OF RESULTS 
 






Dextrose2 484.8 436.8 
Casein2 221.6 220.4 
DL-methionine2 3.4 3.4 
AIN-76 mineral mix2 38.8 38.8 
AIN-76A vitamin mix2 11.1 11.1 
Choline bitartrate2 2.2 2.2 
Pectin2 71.9 65.4 
Cellulose2 17.2 15.6 
Corn oil3 149.0 148.9 
Dried plum puree4 0.0 92.3 
Nutrient composition  (g/100 g) 
Total Carbohydrate 57.06 
        Dietary Fiber 6.00 
                      Soluble 4.27 




1Dried plum puree contains water and micronutrients, which causes the Plum (g/kg) column to sum to 1.034 kg. 
2Manufactured by Harlan (CA.160190, CA.160030, CA10850, CA.170915.PWD, CA.40077.PWD, CA.30190, 
CA.160390, SS-62)  
3Provided by Dyets, Inc. (401150) 



















Table A-2. Assay ID for selected gene targets in Chapter II. 
Gene Symbol(s) Gene Alias(es) Assay ID Species Amplicon 
Length 
Tlr2 - Rn02133647_s1 Rat 109 
Tlr4 - Rn00569848_m1 Rat 127 
Tollip - Rn01479669_m1 Rat 64 
18s rRNA - Hs99999901_s1 Human 0 
Slc5a8 RGD1564146 Rn01503812_m1 Rat 60 
Slc16a1 MCT1;RATMCT1;RNMCT1 Rn00562332_m1 Rat 77 
Nfkb1 EBP-1;NF-kB Rn01399583_m1 Rat 63 
Nfkbia RL/IF-1 Rn01473657_g1 Rat 71 
Ptgs2 COX-2;Cox2 Rn01483828_m1 Rat 112 
Acads Scad Rn00574634_m1 Rat 87 
Acadm MCAD Rn00566390_m1 Rat 73 
Gapdh BARS-38;Gapd Rn01775763_g1 Rat 174 
Muc2 HH-Muc Rn01498196_g1 Rat 77 
Nos2 Nos2a;iNos Rn00561646_m1 Rat 77 
Muc4 ASGP-1;Psmc Rn01475265_m1 Rat 63 






























































Corynebacterium 6.75E-04 ± 7.60E-04 3.12E-03 ± 6.34E-04 0.0172 1.86E-03 ± 8.63E-04 2.52E-03 ± 7.06E-04 0.5558 
Rikenellaceae; g 2.30E-01 ± 5.94E-02 2.70E-01 ± 4.96E-02 0.6003 2.44E-01 ± 5.02E-02 3.94E-01 ± 4.11E-02 0.0255 
Odoribacter 1.76E-04 ± 5.24E-04 7.35E-04 ± 4.38E-04 0.4166 2.46E-04 ± 9.36E-05 0.00 ± 7.66E-05 0.0477 
Elusimicrobiaceae; g 2.75E-02 ± 1.26E-02 6.25E-02 ± 1.05E-02 0.0387 3.84E-02 ± 1.47E-02 6.15E-02± 1.20E-02 0.2295 
Lachnospiraceae; Other 1.68 ± 7.18E-01 3.53 ± 5.99E-01 0.0536 1.20 ± 8.45E-01 4.12 ± 6.91E-01 0.0103 
Ruminococcaceae; Other 4.67E-01 ± 9.32E-02 3.50E-01  ± 7.78E-02 0.3410 5.24E-01 ± 8.66E-02 2.77E-01± 7.09E-02 0.0324 
OPB54; f; g 3.92E-04 ± 1.48E-04 0.00 ± 1.24E-04 0.0482 1.45E-04 ± 1.09E-04 6.80E-05 ± 8.92E-05 0.5873 




Table A-4. Percent abundances of select genera organized by proximal and distal colon and experimental diet.  
















CoriobacteriaceaeG 3.60E-03 ± 3.65E-02 4.54E-01 ± 3.49E-02 <.0001 4.32E-03 ± 4.64E-02 4.22E-01 ± 4.52E-02 <.0001 
Adlercreutzia 9.02E-02 ± 9.91E-03 6.53E-02 ± 9.50E-03 0.0759 1.22E-01 ± 1.20E-02 7.59E-02 ± 1.17E-02 0.0092 
Bacteroides 2.01E+01 ± 1.66E+00 1.99E+01 ± 1.59E+00 0.9393 1.58E+01 ± 1.92E+00 2.59E+01 ± 1.87E+00 0.0005 
Parabacteroides 6.46E-01 ± 1.01E-01 9.33E-01 ± 9.67E-02 0.0459 6.79E-01 ± 1.98E-01 1.57 ± 1.93E-01 0.0024 
Porphyromonas n.d. n.d. -- 0.00 ± 2.56E-04 7.44E-04 ± 2.49E-04 0.043 
RikenellaceaeG 2.45E-01 ± 5.59E-02 2.55E-01 ± 5.36E-02 0.8912 1.96E-01 ± 4.64E-02 4.42E-01 ± 4.52E-02 0.0004 
S247G 3.89 ± 3.71E-01 4.79 ± 3.55E-01 0.0895 3.63 ± 3.81E-01 4.85 ± 3.71E-01 0.0268 
BarnesiellaceaeG 1.87E-01 ± 5.22E-02 2.53E-01 ± 5.01E-02  1.42E-01 ± 6.46E-02 3.91E-01 ± 6.29E-02 0.0082 
Butyricimonas 4.51E-02 ± 1.06E-02 7.16E-02 ± 1.02E-02 0.0797 4.11E-02 ± 1.96E-02 1.29E-01 ± 1.91E-02 0.0025 
Paraprevotella 6.55E-02 ± 3.02E-02 3.48E-01 ± 2.89E-02 <.0001 3.40E-02 ± 3.76E-02 4.20E-01 ± 3.66E-02 <.0001 
Mucispirillum 3.17E-02 ± 6.72E-03 9.60E-04 ± 6.44E-03 0.0019 4.24E-02 ± 1.33E-02 0.00 ± 1.29E-02 0.0266 
Lactobacillus 1.58E+01 ± 1.69 1.04E+01 ± 1.62 0.0264 1.54E+01 ± 1.67 7.34 ± 1.63 0.0011 
ClostridialesFG 9.25 ± 1.15 9.81 ± 1.10 0.7288 1.11E+01 ± 8.54E-01 8.63 ± 8.31E-01 0.0429 
ChristensenellaceaeG 1.22E-02 ± 3.74E-03 2.47E-02 ± 3.58E-03 0.0195 1.21E-02 ± 3.10E-03 2.70E-02 ± 3.02E-03 0.0013 
ClostridiaceaeG 3.24 ± 3.23E-01 1.67 ± 3.09E-01 0.001 2.13 ± 1.93E-01 9.71E-01 ± 1.87E-01 <.0001 
LachnospiraceaeOther 9.20E-01 ± 6.75E-01 4.29 ± 6.47E-01 0.0008 7.04E-01 ± 7.82E-01 4.62 ± 7.61E-01 0.0008 
LachnospiraceaeG 2.02 ± 3.82E-01 3.71 ± 3.66E-01 0.0026 1.96 ± 3.98E-01 3.25 ± 3.88E-01 0.0255 
Dorea 5.97E-02 ± 1.68E-01 6.63E-01 ± 1.61E-01 0.0128 1.98E-01 ± 9.24E-02 3.87E-01 ± 9.00E-02 0.1502 
Peptococcaceaerc44G 3.52E-01 ± 5.34E-02 4.68E-01 ± 5.12E-02 0.1238 2.01E-01 ± 5.12E-02 3.62E-01 ± 4.99E-02 0.0299 
ErysipelotrichaceaeOther 9.00E-04 ± 4.25E-04 9.61E-04 ± 4.07E-04 0.9178 1.09E-03 ± 2.56E-04 1.34E-04 ± 2.49E-04 0.0104 
ErysipelotrichaceaeG 1.11E-02 ± 3.77E-03 5.89E-03 ± 3.62E-03 0.3251 2.43E-02 ± 6.14E-03 3.59E-03 ± 5.98E-03 0.0198 
Allobaculum 1.46E+01 ± 2.25 9.74 ± 2.16 0.1227 1.63E+01 ± 2.34 8.49 ± 2.28 0.021 
Coprobacillus 6.20E-04 ± 2.08E-03 7.26E-03 ± 2.00E-03 0.0262 1.50E-03 ± 3.31E-03 1.16E-02 ± 3.22E-03 0.0342 
Holdemania 3.73E-04 ± 4.73E-03 1.48E-02 ± 4.53E-03 0.0332 4.01E-03 ± 5.09E-03 1.89E-02 ± 4.95E-03 0.0416 




Table A-5. Significantly altered metabolites in plasma of human subjects consuming sumac 
sorghum. 
Metabolite Transform Estimate Std. Err. P-value Q-value 
Gamma-glutamylvaline original -0.46956 0.06848 0 0 
Threonate original -0.40669 0.07337 1.00E-05 0.00177 
Catechol sulfate log 0.37786 0.07154 3.00E-05 0.00354 
Gamma-glutamylisoleucine* original -0.37044 0.07652 8.00E-05 0.00708 
Gamma-glutamylmethionine original -0.222 0.05215 0.00032 0.01888 
HWESASXX* log 0.65837 0.1546 0.00032 0.01888 
3-hydroxyhippurate original 1.03108 0.24635 0.00038 0.01922 
Cinnamoylglycine log 0.38459 0.09533 0.00055 0.02434 
Cysteine original -0.24734 0.06412 0.00085 0.03009 
Glutamine original 0.05121 0.01323 0.00083 0.03009 
3-phenylpropionate (hydrocinnamate) log 0.32909 0.09755 0.00274 0.08290 
P- and Q-values, estimates, and standard errors are statistics of the treatment effect (i.e., the average of the response 









Figure A-1 Apoptotic cells/crypt column in rats fed a basal diet (BD) or dried plum diet (DP) 











Figure A-2 Proportion of apoptotic cells/crypt column in rats fed a basal diet (BD) or dried plum 
diet (DP) and exposed to saline (+S) or AOM (+A). No significant differences were observed 







Chapter II Animals and Diets 
 Fifty-one male Sprague-Dawley rats (21 d old) were stratified by body weight and 
assigned to one of 2 experimental diets (basal diet n=25, plum diet n=26). The plum diet was a 
slightly modified basal diet containing a dried plum puree incorporated at a level that would 
provide 5% of the total calories in the diet. The contribution of lipid, protein, and carbohydrate, 
as well as the ratio and amount of soluble to insoluble fiber were made equivalent between the 
diets based on the proximate analysis of the plum puree. The calculation for the final diet 
formulation is seen below. The macronutrients contained in the dried plum puree used in the 
experiment was adjusted for in the diet by balancing the inclusion of dextrose, casein and pectin 
added to the diet. The diets were mixed according to the following protocol:    
 
INGREDIENT %/100 g kg 1-Basal Plum
Dextrose 51.06% 100077.60 100.07760 47.84011 43.07847
Casein 22.35% 43806.00 43.80600 21.86754 21.73326
DL-methionine 0.34% 666.40 0.66640 0.33320 0.33320
Mineral mix 3.91% 7663.60 7.66360 3.83180 3.83180
Vitamin mix 1.12% 2195.20 2.19520 1.09760 1.09760
Choline bitartrate 0.22% 431.20 0.43120 0.21560 0.21560
Pectin 4.27% 8369.20 8.36920 7.09250 6.45050
Cellulose 1.73% 3390.80 3.39080 1.69540 1.54152
Lipid - Corn oil 15.00% 29400.00 29.40000 14.70000 14.68179
Test Compounds 0.0000 N/A N/A 0.00000 9.10548
Water




Total Kcal: 411.1306 411.939552




PLUM Diet Mixing Protocol: Preparation Checklist 
 Adequate diet components 
 Plum (thoroughly mixed) 
 Clean and labeled Ziploc bags for diet components 
 Lab personnel 
 Weighing scales (2): 50 g – 5 kg and <50g 
 Measuring tubs and scoops (spatulas) 
 Stirring tool 
 Labeled diet bags and outer bags 
 Colored tapes 
 Sharpies 
 Aluminum foil 
 5L jugs for oil (2-3) 
 Cart, tub for ice and ice 
 Gloves, bench papers, towels, and 70% ethanol 
 Diet specification sheets 
 Mixing bowl and mixer (2) 
 Labeled specimen cups for diet sample 
Note: Each mixing bowl can only contain up to 20kg of diet, thus the total weight of each diet needs to be divided 
up into ~5 portions (referred to as bowls). 
Diet Bowl 1 Bowl 2 Bowl 3 Bowl 4 Bowl 5 
Basal 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Plum 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 3 tubs + 1 ziplock 
Total 6 tubs + 2 ziplock 6 tubs + 2 ziplock 6 tubs + 2 ziplock 6 tubs + 2 ziplock 6 tubs + 2 ziplock 
 
Diet mixing protocol (BASAL) 
1. Bring diet ingredients and items from previous checklist to basement from lab 
2. Measure out small components (Vitamin/mineral/choline/methionine) as necessary 
per bowl 
3. Measure out corn oil per bowl.  





4. Casein  
5. Dextrose 




6. Still at #1 setting, start mixer for 10 minutes. During this time, pour oil into mix 3 
separate quantities and times. To get it all out from jug, use diet to mop it up. 
7. Scrape sides of bowl and blade. Mix for 5 minutes more.  
8. Lower bowl, scrape sides of bowl and blade, put bowl back into position, and mix for 
another 10 minutes at #2 setting. 
9. Scrape diet off blade, lower and remove bowl. Take a sample from 4 locations in 
bowl and place into 50 mL conical tube w/ appropriate label.  
10. Scoop diet into labeled bags and double bag. Store in freezer. 
11. Repeat the above process for all diets/bowls. 
12. Clean up thoroughly.  
Diet mixing protocol (PLUM) 
1. Bring diet ingredients and items from previous checklist to basement from lab 
2. Measure out small components (Vitamin/mineral/choline/methionine) as necessary 
per bowl 
3. Measure out corn oil per bowl.  
4. Start with Bowl 1 of a diet group. Mix by hand in large container (tub) diet 




4. Casein  
5. Dextrose 
5. Weigh out plum (1 bowl) into small mixer bowl. Add corn oil (1 bowl) to plum in 
small mixer bowl. 
6. Mix Plum/Oil for 3 minutes on power level 1 with small mixer. 
7. Transfer Plum/Oil mixture into large mixing bowl. 
8. Fit large mixing bowl onto electric mixer. Set timer to 10 minutes and start mixing at 
power level 1. Over this time, slowly add dry ingredients into Plum/Oil mixture. 
9. After all dry ingredients have been added (10 minutes) lower bowl and scrape mixer 
and sides of bowl with spatula/gloved hand. 
10. Still at #1 setting, start mixer for another 10 minutes.  
11. Scrape sides of bowl and blade. Mix for 5 minutes more at #2 setting.  
12. Scrape diet off blade, lower and remove bowl. Take a sample from 4 locations in 
bowl and place into 50 mL conical tube w/ appropriate label.  
13. Scoop diet into labeled bags and double bag. Store in freezer. 
14. Repeat the above process for all diets/bowls. 




Prior to beginning the experimental diet, animals were maintained on a standard chow 
diet for 7 d in order to overcome shipping stress. After 21 d of experimental diets, 15 animals 
from the basal diet group and 16 animals from the plum diet group received an injection of 
azoxymethane (15 mg/kg body weight). The remaining 10 animals from each diet group received 
an equivalent volume of saline. These treatments were administered a second time, 7 d after the 
initial injection. During the 48 hr following injection, animals were stored in isolation rooms 
with adequate ventilation to exhaust the metabolized (exhaled) carcinogen. Saline animals were 
kept in a separate isolation room from AOM animals to avoid any exposure to the carcinogen. 
Animals were provided 2 d worth of food to last the duration of the isolation period. At the end 
of the isolation period, animals were returned to their normal husbandry room at the animal 
facility. After the second injection, animals continued to consume their experimental diets for 8 
additional weeks until their termination.   
Body weight and food intake was routinely monitored. Animals were weighed (48 h 
average) upon arrival, prior to beginning experimental diets, before each injection, 4 w after the 
second injection, and at termination. Experimental diet intake was averaged over a 48 h period at 
experimental day 20, 55, and 82. On experimental day 91, animals were euthanized by CO2 
asphyxiation and cervical dislocation. The colon was resected, and two 1 cm sections were 
removed from the proximal and distal colon for histological preparations. The contents of the 
colon were collected separately from the proximal and distal colon for microbial and 
metabolomic analyses. The remaining colon was cut in half longitudinally: ½ was used for ACF 
analysis and the other ½ was separated into proximal and distal segments for scraped mucosa 





Chapter II Tissue Collection and Processing 
Tissue fixation for immunohistological processing 
The two, 1 cm segments removed from the distal end of the colon were fixed in either a 
4% PFA (PFA solution was mixed a day before the killing. Fifty ml of 10X PBS was diluted to 
400 ml with ddH2O, and then 100 ml of 20% PFA was added. PFA solution was refrigerated 
overnight.) or 70% EtOH solution prior to embedding in paraffin. Tissue fixed in 70% EtOH was 
stored at room temperature until embedded in paraffin. Tissue fixed in PFA was incubated on ice 
for 4 h in a 4% PFA solution, then rinsed in successive washes of ice cold 50% EtOH ( 1x dip,  4 
x 20 minutes), 70% EtOH (4 x 20 minutes), and stored at 4°C in 70% EtOH until embedded in 
paraffin. 
Luminal contents collection and processing 
 Luminal contents were expressed from the proximal and distal colon separately. Samples 
from each location were aliquoted into tubes for microbial sequencing and metabolomics and 
then placed into liquid nitrogen. At the end of the termination, samples were transferred to the     
-80°C freezer until further processing.  
Scraped mucosa 
After the luminal material was removed from the colon, the colon was washed twice in 
RNase free Phosphate-Buffered Saline (PBS) and opened lengthwise to expose the luminal 
surface. The opened colon was then cut in half longitudinally again to separate it into two pieces. 
One piece was cut into proximal and distal segments for mucosal scraping. The segments were 
scraped on a chilled RNase free surface, and transferred to an RNase free homogenization tube 
along with 300 µl of Denaturation Solution (Ambion, Austin, TX) or 200 µl of protein buffer 




7 strokes and then transferred to a 2 ml epitube for storage at -80°C. Scraped mucosa was placed 
into a homogenizer along with 200 µl of buffer. Protein buffer (10 ml) was mixed on the day of 
the kill, just prior to use. The protein buffer contained: 1 ml of 500 mM Tris-HCl (pH 7.2) 
(Sigma, T1503), 2.5 ml of 1.0 M Sucrose (Sigma, S9378), 100 µl of 200 mM EDTA (pH 7.6) 
(Sigma, ED4SS), 100 µl of 100 mM EGTA (pH 7.5) (Aldrich, 23453-2), 4.793 ml of water, 1 ml 
of 10% Triton X-100 (Sigma, T6878), 7 µl of -mercaptoethanol (Bio-Rad, 161-0710), 400 µl of 
Protease Inhibitor (Sigma), and 100 µl Phosphatase Inhibitor (Pierce). Mucosa and protein buffer 
was homogenized for at least 7 strokes (on ice) and transferred into a 2 ml eppietube. The sample 
was aspirated through a 12 gauge needle twice and then incubated on ice for 30 minutes prior to 
centrifugation at 15,000 g for 20 minutes. The supernatant was transferred, and the volume was 
split amongst the aliquot tubes and then placed into a -80°C freezer for storage. 
ACF fixation 
 The remaining longitudinal half section was laid out flat on a piece of Whatman filter 
paper that had been moistened with PBS. The filter paper was then folded over to ‘sandwich’ the 
colon segment and the ‘sandwich’ was placed into a Tupperware container filled with 70% 
ethanol. A glass (¼ inch thick) plate was placed on top of the ‘sandwich’ so that the colon would 
fix flat. After 48 h in the Tupperware container, each colon was removed and placed into a 50 ml 
scintillation vial filled with fresh 70% ethanol, until processing for ACF measurement.    
Chapter II fecal collections and processing 
Fresh fecal samples were collected for SCFA analysis 3 w post-diet start, 48 h post-AOM 
#2, and for 48 h prior to termination. Luminal contents collected at termination were not used for 




appropriately labeled cryotubes and flash frozen in liquid nitrogen. At the end of the collection 
period, samples were transferred into the -80°C freezer until further processing.     
Dry matter analysis 
Fecal samples were thawed and placed into a weighed dry pan prior to drying in a 60°C 
oven for 72 h. Samples were cooled in a vacuum desiccator for 24 h before being weighed. This 
procedure was repeated until weight became static.  
Short chain fatty acid (SCFA) analysis 
Fresh fecal samples were collected immediately following defecation. Samples were 
transferred to sterile cryotubes, snap-frozen in liquid nitrogen, and stored at -80°C. Fecal samples 
were prepared for analysis by grinding in a mortar and pestle chilled by immersion in liquid 
nitrogen. The powdered sample (~0.30 g) was weighed into a 1.5 mL centrifuge tube containing 
750 mL of the internal standard, 2-ethylbutyric acid (Sigma-Aldrich, St. Louis, MO), in 70% 
ethanol. Samples were vigorously vortexed and incubated overnight at 47°C to extract the SCFA. 
To prepare the extracted samples for gas-liquid chromatography, samples were first shaken 
vigorously for 20 min and then centrifuged at 11,500 g for 20 min at 47°C. A 200 µl aliquot of 
the supernatant was removed and combined with 200 µl of the second internal standard, 3 mM 
heptanoic acid prepared in 70% ethanol. Immediately before injection into the gas 
chromatograph (GC), 20 µL of 10% orthophosphoric acid (H3PO4) was added to the sample and 
vortexed. One microliter of sample containing the phosphoric acid was then injected into a 
Varian 3900 gas chromatograph (Walnut Creek, CA) with a splitless capillary inlet and flame 
ionization detector equipped with a 30 m, 0.53 mm internal diameter deactivated glass capillary 
pre-column (Supelco, Bellfonte, PA). Data were integrated and plotted with a Hewlett Packard 




detector temperature, 220°C; column flow, 2.21 mL/min He; make-up flow, 28 mL/min 
nitrogen; and oven temperature, 185°C (gradient). Samples are concentrated on the column head 
at 60°C for 30 sec. The temperature is increased at 50°C/min to a temperature of 145°C for 5 
minutes. A temperature gradient of 5°C/min is continued until a final temperature of 185°C.  
After the analysis, the column is allowed to regenerate at 220°C for 5 minutes before the 
temperature is reduced for the next run. Standards and a blank were run before and after the daily 
sample runs to facilitate calibration and data calculations.  
Identification and quantification of SCFA 
Short chain fatty acid standards containing 2-ETBA, heptanoic acid and H3PO4 are made 
fresh, stored at -70°C, and chromatographed at the beginning and end of daily sample runs. 
Blanks containing only internal standard solutions in 70% ethanol are also chromatographed 
daily. Response factors and retention times for the individual fatty acids are determined from the 
results of the daily standard runs and fatty acid composition of samples are calculated based on 
the appropriate daily standard response factor. 
Chapter II ACF analysis 
ACF scoring protocol 
I. Staining 
1. Cover sample ID upon retrieval of sample to remain blind to sample  
2. Place transparent grid sheet on microscope plate. Grids make it easier to read and score 
samples. 
3. Remove colon from scintillation vial with forceps. Scooping is preferred over pinching so 
that the tissue isn’t damaged. 
4. Stain the colon with 0.5% methylene blue. Staining time depends on sample thickness, 
but should be as uniform across samples as possible. (~1 minute) 
5. Remove sample from stain, and allow excess stain to drip off. Sample will likely be 
darker than desired—if so place sample in cup containing 70% ethanol until desired 
staining intensity is achieved. 




7. Verify sample is mucosal side up. Striations in many directions will be visible and the 
resolution of crypts poor if mucosal side is down. 
8. Keep the sample moist with cold PBS on a q-tip. 
9. If mucin is present, remove with EXTREME CARE using a moist (PBS) q-tip. 
II. Morphological characteristics of ACF/AC 
 Are characteristically larger (~2-4 times) and are stained darker than normal crypts 
 Have enlarged/elongated lumens  
 May appear to be raised above the surrounding mucosa 
 May have an enlarged pericryptal zone 
III. Scoring 
1. Establish criteria for determining aberrant crypts (e.g. photo of AC/ACF for which a 
consensus has been reached). 
2. Aberrant crypts are found as single crypts (AC) or multiples (ACF) and should be 
diagramed and tallied accordingly. 
3. Begin at the distal end of the colon (should be to the observers right) and continue pattern 
(described in step 4 below) until the proximal end is reached. 
4. Begin at the top of the distal colon (far edge, right end). Move from top to bottom. When 
done with this field, find a point of reference on the left edge of the field of view. Adjust 
the field of view proximally (left) until point of reference is on the right edge of the field 
of view. Proceed to score the crypt from bottom to top. When top is reached adjust field 






5. Once sample is completely scored, reveal and record the sample ID on the scoring sheet.  
 
Protocol for Setup of ACF Microscope (Chapkin) 
1. Turn on Computer and Monitor (Right side) 
2. Turn on black box (Left side) 
3. White box on top of black box (Left side) 
4. Camera on top of microscope 












Chapter II measurement of apoptosis using TUNEL 
Kit: ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (S7101) 
Manufacturer: EMD Millipore 
Updated: 10/19/2017 
Reagents required: 
Reagent/Kit Manufacturer Catalog # #samples/kit, Qty $ per kit 
ApopTag Plus Kit EMD Millipore S7101 40 Samples (order 6) 551.00 
Proteinase K EMD Millipore 21627 15 ml, 200 ug/ml 102.00 
Filters EMD Millipore SCGP00525 25 each 160.00 
30% H2O2 Sigma-Aldrich H1009-100ML 100 mL 113.00 
Xylene Sigma-Aldrich 534056-4X4L 4 x 4 Liters 323.00 
100% n-butanol Sigma-Aldrich B7906-500ML 500 mL 49.40 
DTT Sigma-Aldrich 43815-1G 1 g 92.30 
DNase I Sigma-Aldrich D7291-.5MG .5 mg 181.00 
Sodium acetate Sigma-Aldrich 71188-1KG 1 kg 98.10 
Acetic acid Sigma-Aldrich 338826-100ML 100 mL 119.00 




17986-05 500 mL 80.00 
100% Ethanol Bio/Bio Unknown Unknown Unknown 
Methyl Green (no 
crystal violet) 
In House    
NaH2PO4 In House    
Na2HPO4 In House    
dH2O In House N/A N/A N/A 
Reagent Preparation: 
1) 10X Phosphate Buffered Saline, pH 7.4 (PBS) 
To make 1 L, dissolve the following in 800 mL dH2O: 
 Na2HPO4 55.0 g 
 NaH2PO4 13.5 g 
 NaCl  117.0 g 
Adjust the pH to 7.4 using NaOH or HCl and add dH2O to a final volume of 1000 mL. 
2) 0.1% (w:v) Methyl Green 
a. Prepare 0.1 M sodium acetate, pH 4.0  
1. Dissolve 1.36 g C2H3O2Na●3H2O in 80 mL of dH2O. 
2. Adjust pH to 4.0 with acetic acid. Add dH2O to a final volume of 100 mL 
3. Dissolve 0.1 g of methyl green in 100 mL of 0.1 M sodium acetate, pH 4.0 (last step). 
4. Filter through a 0.45 or 0.2-micron filter prior to use. 
3) Proteinase K 
a. Dilute the 200 ug/mL stock of Proteinase K (21627) to 20 ug/mL in PBS just before use. 
1. Direct slide application- 100 ul test of diluted stock is required per section. 
4) Working Strength Hydrogen Peroxide (H2O2) 




1. Direct slide application- 100 ul is required per 5 cm2 specimen (section). 
5) DN Buffer (30 mM Tris Base, pH 7.2, 4 mM MgCl2, 0.1 mM DTT) 
a. Prepare 1 M Tris Base, pH 7.2 
1. Dissolve 12.1 g of Tris base in 80 mL of dH2O. Adjust the pH to 7.2 with concentrated 
HCl and add dH2O to a final volume of 100 mL. 
b. Prepare 1 M MgCl2  
1. Dissolve 20.3 g of MgCl2●6H2O in sufficient dH2O for a final volume of 100 mL. 
c. Prepare DN buffer 
1. Combine 3 mL of 1.0 M Tris, pH 7.2, 400 uL of 1.0 M MgCl2, 1.54 mg of DTT and 
sufficient dH2O for a final volume of 100 mL.  
Kit Supplied Reagent Preparation 
Reagent Vol/cm2 Vol/5 cm2 
Equilibration Buffer 13 ul 65 ul 
Working Strength TdT 11 ul 55 ul 
Anti-digoxigenin-Peroxidase 13 ul 65 ul 
DAB Peroxidase Substrate 15 ul 75 ul 
1) Working Strength TdT Enzyme 
The concentrated TdT Enzyme provided in the kit is supplied in a stabilization buffer to preserve activity. 
It must be diluted with Reaction Buffer prior to use. Use 1:80 dilution of TdT enzyme in Reaction Buffer. 
To prepare, add in a fresh microcentrifuge tube: 
1. _____ # Sections x 45 uL = _____Total uL  
2. _____ Total uL *.9875 = _____uL REACTION BUFFER 
3. _____ Total uL *.0125 = _____uL TdT ENZYME 
Mix well by vortexing. This reagent may be prepared in advance and stored on ice for no more than 6 
hours. This amount is sufficient to treat two 5 cm2 tissue specimens. 
2) Working Strength Stop/Wash Buffer 
Prepare by adding: 
 1 mL Stop/Wash Buffer (90419) 
 34 mL dH2O 
 35 mL Total 
This amount is sufficient to treat 5 slides in a coplin jar. This reagent may be prepared in advance and 
stored in a glass or plastic container at 4ºC for up to 1 year. Use a fresh aliquot for each experiment. 
3) Working Strength Peroxidase Substrate 
Prepare working strength DAB by mixing in a clean tube: 
 147 uL DAB Dilution Buffer (90424) 
     3 uL DAB Substrate (90423)   
 150 uL Total 
After dilution, warm the mixture to room temperature and store in the dark until use. This amount is 
sufficient to treat two 5 cm2 tissue specimens. After mixing, the solution is stable for 7 days at room 
temperature or up to 14 days at 4°C. 




This step is to be performed on a deparaffinized, rehydrated tissue (Primary protocol step 1), which has 
been treated with Proteinase K (Primary protocol step 2), but prior to Peroxidase quenching (Primary 
protocol step 3). 
1. Pretreat section with DN Buffer (30 mM Trizma base, pH 7.2, 4 mM MgCl2, 0.1 mM DTT) at 
room temperature for 5 minutes. 
2. Dissolve DNase I in DN Buffer to a final concentration of 1.0-0.1 ug/mL (specific activity is 
10,000 U/mL – 1,000 U/mL). 
3.  Apply DNase solution and incubate for 10 minutes at room temperature. 
4.  Rinse with 5 changes of dH2O for 3 minutes each change. 
 
ApopTag Protocol 
***DO NOT ALLOW SAMPLES TO DRY OUT DURING PROCESSING*** 
1) Deparaffinize Tissue Section (in a coplin jar) 
a. ____  ____  ____ XYLENE; 5 min ea. (1-3) 
b. ____ Let XYLENE just dry and circle sections with PAP Pen, dry 1 min. 
c. ____  ____ ABSOLUTE ETOH; 5 min ea. (4-5) 
d. ____ 95% ETOH; 3 min (6) 
e. ____ 70% ETOH; 3 min (7) 
f. ____ 1X PBS; 5 min (8) 
2) Pretreat Tissue 
a. ____ Apply freshly diluted PROTEINASE K (20 ug/mL) to the specimen for 15 min. at 
RT directly on the slide (50 ul/section). 
i. 100 ul/section______(#sections+1) x 100 ul = ______Total Prot. K needed 
ii. Total Prot. K ______ x .1 = ______Prot K stock needed 
iii. Total Prot. K ______ x .9 = ______PBS needed 
b. ____  ____ dH2O; 2 min ea. (9-10) 
3) Perform DNase I treatment if sample is to be used as positive control (Page 3) 
4) Quench Endogenous Peroxidase 
a. ____ Quench in 3% hydrogen peroxide in PBS (Page 2) for 5 min. 
i. 100 ul/section______ (# sections+1) x 100 ul = ______Total ul 3% needed 
ii. Total ul 3% (_______) *.1 =______ul 30% H2O2   
iii. Total ul 3% (_______) *.9 =______ul 1X PBS 
b.  ____  ____ 1X PBS; 5 min ea. (11-12)  
5) Apply Equilibration Buffer 
a. ____ Gently tap off excess liquid and carefully blot or aspirate around section. (Do this 
step and next together, 1 slide at a time, to avoid drying sample) 
b. ____ Apply 60 ul/section of EQUILIBRATION BUFFER directly onto specimen. 
i. ______# sections x 60 ul/section = ______ul total 
c. ____ Incubate for at least 10 seconds at RT. _________Seconds incubated 
6) Apply Working Strength TdT Enzyme 
a. ____ Gently tap off excess liquid and carefully blot or aspirate around section. 
b. ____ Immediately pipette:  




1. _____ # Sections x 45 uL = _____Total uL  
2. _____ Total uL *.9875 = _____uL REACTION BUFFER 
3. _____ Total uL *.0125 = _____uL TdT ENZYME 
ii. ____ 40 ul REACTION BUFFER (negative controls). 
c. ____ Incubate in humidified chamber at 37°C for 1 hour. 
7) Apply Stop/Wash Buffer 
a. ____ Agitate slides for 15 seconds in WORKING STRENGTH STOP/WASH BUFFER 
in a coplin jar then incubate for 10 min at RT. (13) 
b. ____ Remove an aliquot of ANTI-DIGOXIGENIN CONJUGATE from the stock vial 
sufficient to process the desired number of specimens. Warm the aliquot to RT. 
i. _____ # sections x 60 ul/section = ______Total ul Aliquot 
8) Apply Anti-Digoxigenin Conjugate 
a. ____  ____  ____ 1X PBS; 1 min ea. (14-16) 
b. ____ Gently tap off excess liquid and carefully blot or aspirate around the section. 
c. ____ Apply RT Anti-Digoxigenin Conjugate (60 ul/section). 
d. ____ Incubate in a humidified chamber for 30 min. at RT.  
9) Wash in PBS 
a. ____  ____  ____  ____ 1X PBS; 2 min ea. RT (17-20) 
b. While slides are washing, prepare WORKING STRENGTH PEROXIDASE 
SUBSTRATE. 
i. _____ # Sections x 60 uL = _____Total uL WSPS 
ii. _____Total uL WSPS *.0125 = _____uL DAB Substrate 
iii. _____Total uL WSPS -_____uL DAB Substrate = _____uL DAB Dilution 
Buffer 
10) Develop Color in Peroxidase Substrate 
a. ____ Gently tap off excess liquid and carefully blot or aspirate around the section. 
b. ____ Apply 60 uL/section of PEROXIDASE SUBSTRATE to cover specimen. 
c. ____ Stain for 45 s at RT. Humid chamber not necessary. _____min stained. 
d. In order to obtain optimal staining time, observe under microscope.  
11) Wash Specimen 
a. ____  ____  ____ dH2O; 1 min ea. (21-23) 
b. ____ dH2O; 5 min RT (24) 
12) Counterstain Specimen 
a. ____ 0.1% Methyl green; 15 sec, RT (25) 
b. ____  ____  ____ dH2O; Dip 10 times ea. (1 and 2), 30 secs no agitation (3) (26-28) 
c. ____  ____  ____ N-BUTANOL; Dip 10 times ea. (1 and 2), 30 secs no agitation (3) (29-
31) 
13) Mount Specimen 
a. ____  ____  ____ XYLENE; 2 min ea. (32-34) 
b. Remove slides 1 at a time from jar. Gently tap the side to drain, but do not allow to dry! 
c. Apply Permount and then apply cover glass.  





Chapter II measurement of gene expression using real-time PCR 
Scraped mucosal samples were obtained at termination, placed into RNA protective 
solution and stored at -80°C until further analysis. Total RNA was isolated from mucosal 
samples using the RNAqueous™ Total RNA Isolation Kit (Invitrogen, AM1912) followed by 
DNase treatment (DNA-free™ Kit, Ambion, AM1906). Eppietubes containing homogenized 
scraped mucosa and Denaturation Solution were removed from -80°C storage and thawed on ice. 
Total RNA was isolated using the following protocol: 
A.  Before Using the Kit for the First Time 
a. Prepare 64% Ethanol Solution—Add 38.4 mL of 100% ethanol (ACS grade or 
equivalent) to the bottle labeled “Water for 64% Ethanol,” which contains 21.6 
mL of RNase-free water. Mix well, and mark the empty box on the label to 
indicate that the ethanol was added.  
b. Prepare Wash Solution #2/3—Add 64 mL of 100% ethanol (ACS grade or 
equivalent) to the bottle labeled “Wash Solution #2/3 Concentrate.” Mix well, and 
mark the empty box on the label to indicate that the ethanol was added.  
B. Work Area and Equipment Preparation 
a. Lab Bench and Pipettors—Before working with RNA, clean the lab bench, and 
pipettors with an RNase decontamination solution such as Ambion RNase Zap. 
b. Gloves and RNase-free technique—Wear laboratory gloves at all times during 
this procedure and change them frequently. They will protect you from the 
reagents, and they will protect the RNA from nucleases that are present on the 
skin.  Use RNase-free pipette tips to handle the kit reagents. 
c. Washing/sterilization of equipment—The equipment used for tissue 
disruption/homogenization should be washed well with detergent and rinsed 
thoroughly. Baking is unnecessary, because the Lysis/Binding Solution will 
inactivate any low level RNase contamination.   
I. As you start procedure: 
1. Heat an aliquot of Elution Solution (typically 50-200 uL per prep) in an RNase-free 
microcentrifuge tube in a heat block set to 70-80°C. 
2. Briefly inspect the filter cartridges before use. Occasionally, the glass fiber filters may 
become dislodged during shipping. If this is the case, gently push the filter down to the 
bottom of the cartridge using the wide end of an RNase-free pipette tip. 
II. Preparation of the lysate for RNA isolation 
1. Ensure lysate is somewhat viscous, but if the solution is very viscous, or contains 
gelatinous material (likely genomic DNA), then it should be sonicated, homogenized in a 
rotor-stator homogenizer, or passed through a 25 gauge syringe needle several times until 




III. Filter Binding, Washing, and Elution of RNA 
1. Add an equal volume (for PLUM  500 ul) of 64% Ethanol and mix by carefully 
pipetting or vortexing. 
2. Apply up to 700 ul of the lysate/ethanol mixture to a Filter Cartridge assembled in a 
collection tube.  
3. Centrifuge at RCF 10,000-15,000 x g (typically 10,000-14,000 rpm) for ~45 seconds.  
4. Discard the flow-through and, if necessary, add any remaining lysate/ethanol mixture to 
the column. Centrifuge as before and discard flow-through. 
5. Apply 700 ul Wash Solution #1 to the filter cartridge. 
6. Centrifuge at RCF 10,000-15,000 x g (typically 10,000-14,000 rpm) for ~45 seconds. 
Discard flow-through. 
7. Add 500 ul Wash Solution #2/3.  
8. Centrifuge at RCF 10,000-15,000 x g (typically 10,000-14,000 rpm) for ~45 seconds. 
Discard flow-through. 
9. Repeat Step 7 and 8 with a second 500 ul aliquot of Wash Solution #2/3. 
10. Centrifuge at RCF 10,000-15,000 x g (typically 10,000-14,000 rpm) for ~45 seconds. 
This additional drying step ensures no wash solution remains in the filter. 
11. Place Filter Cartridge into a fresh Collection Tube. Discard old Collection Tube. 
12. Pipet preheated Elution Solution to the center of the filter. This step is carried out with 
two sequential elutions. First pipet 40 ul of preheated Elution Solution (1st step of 
sequential elution) onto the center of the column. Recover eluate by centrifugation for 
~30 seconds at room temperature (RCF 10000-15000 x g).  
13. Pipet 20 ul of preheated Elution Solution (2nd step of sequential elution). Recover eluate 
by centrifugation as in step 11.  
14. Proceed to DNase Treatment. 
DNase treatment protocol 
1. Add .1 Volume (for 60 ul elution 6 ul) 10X DNase I Buffer and 1 ul rDNase I to the 
RNA, and mix gently. 
2. Incubate at 37°C for 20-30 min. 
3. Add resuspended DNase Inactivation Reagent (typically 0.1 volume6.7 ul) and mix 
well. 
4. Incubate 2 min at room temperature, mixing occasionally. 
5. Centrifuge at 10,000 x g for 1.5 min and transfer the RNA to a fresh RNase free tube.  
6. Aliquot 4 ul into RNase free PCR tube for Nanodrop and Agilent QC. 
Following DNase treatment, the concentration of the isolated RNA was assessed on the 
Nanodrop instrument and the quality (RIN, RNA integrity number) was assessed on the Agilent 
Bioanalyzer (448). After quantitation and quality assessment of total RNA, 1100 ng of cDNA 




for RT-PCR kit (Life Technologies, 18080-051). The following protocol was used, which is a 
slightly modified version of the manufacturers’ protocol. 
1) Add the following components to a nuclease-free microcentrifuge tube: 1 µl of 
oligo(dT)20 (50 µM), 50–250 ng of random primers, 10 pg–5 µg total RNA, 1 µl 10 mM 
dNTP Mix (10 mM each dATP, dGTP, dCTP and dTTP at neutral pH), sterile, distilled 
water to 13 µl. 
2) Heat mixture to 65°C for 5 minutes and incubate on ice for at least 1 minute. 
3) Collect the contents of the tube by brief centrifugation and add: 4 µl 5X First-Strand 
Buffer , 1 µl 0.1 M DTT, 1 µl RNaseOUT™ Recombinant RNase Inhibitor (Cat. no. 
10777-019, 40 units/µl), 1 µl of SuperScript™ III RT (200 units/µl). 
4) Mix by pipetting gently up and down. If using random primers, incubate tube at 25°C for 
5 minutes. 
5) Incubate at 50°C for 60 minutes. 
6) Inactivate the reaction by heating at 70°C for 15 minutes.  
7) cDNA was used directly in a PCR reaction or stored at -20°C. 
Real-time PCR was performed on select genes (Tlr2, Tlr4, Tollip, Slc5a8, Slc16a1, Nfkb1, 
Nfkbia, Ptgs2 (Cox2), Acads, Acadm, Muc1, Muc2, Muc3a, Muc4, Muc5ac, 18s rRNA, and 
Gapdh) using Taqman® Array Micro Fluidic Cards (Applied Biosystems, Foster City, CA) and a 
ABI 7900 HT thermocycler (Applied Biosystems, Foster City, CA) using the following protocol: 
1) For each sample, determine the total number of reservoirs to be filled, based on the 
format of your TaqMan Array card. Prepare the PCR reaction mix (cDNA master mix). 
Fill the TaqMan Array card with the reaction mix. Centrifuge the TaqMan Array card. 
Seal the TaqMan Array card. 
2) Calculate the total volume required for each reaction component. 
3) If frozen, thaw the cDNA samples on ice. Resuspend the cDNA samples by inverting the 
tube, then gently vortexing. 
4) Mix the master mix thoroughly by swirling the bottle. 
5) For each sample, label a 1.5-mL microcentrifuge tube, then add the required components 
to the labeled tube. 
6) Cap the microcentrifuge tubes, then gently vortex the tubes to thoroughly mix the 
solution. 
7) Briefly centrifuge the tubes to spin down the contents and eliminate air bubbles. 
8) Fill each fill reservoir with sample-specific PCR mix made from a single cDNA sample 
(1000 ng) + nuclease-free water, 50.0 microliters TaqMan® Gene Expression Master 
Mix. 
9) Allow the TaqMan Array card to reach room temperature, then carefully remove it from 





10) Place the TaqMan Array card on a lab bench, with the foil side down. 
11) Load 100 μL of the desired sample-specific PCR reaction mix into a 100-μL 
micropipette. 
12) Hold the micropipette at an angled position and place the tip in the fill port (the larger of 
the two holes) IMPORTANT! Do not allow the tip to contact and possibly damage the 
coated foil beneath the fill port. 
13) Dispense the sample-specific PCR reaction mix so that it sweeps in and around the fill 
reservoir toward the vent port. IMPORTANT! Pipette the entire 100 μL into the fill 
reservoir. Be careful when pushing the micropipette plunger to its second stop position 
(to expel the sample-specific PCR reaction mix from the tip). If a large amount of air is 
released, it can push the reaction mix out of the fill reservoir via the vent port or 
introduce bubbles into the fill reservoir. 
14) After the fill reservoirs have been filled with the sample-specific PCR reaction mix, 
centrifuge the TaqMan Array card to distribute the reaction mix to the reaction wells. 
IMPORTANT! You must use a Sorvall® or Heraeus centrifuge with the Sorvall/Heraeus 
Custom Buckets and card holders. The Custom Buckets and card holders are custom-
made for the TaqMan Array cards. Do not use any other centrifuge or bucket/card holder 
system for this procedure.  
15) Place TaqMan Array cards into the Sorvall/Heraeus buckets: 
a. Obtain an empty Sorvall/Heraeus Custom Bucket and card holder. 
b. Place the bucket on a lab bench, with the label facing you. 
c. Insert TaqMan Array cards into the card holder, making sure that the fill 
reservoirs project upwards out of the card holder and the reaction wells face the 
same direction as the “This Side Out” label. You use blank balance cards to fill 
any open positions in the card holder. Use the blank balance cards provided with 
the installation kits. IMPORTANT! Be sure to use the blank balance cards to fill 
any open positions. The blank balance cards will balance the centrifuge and 
prevent damage to the card holder. If the card holder is not completely filled, the 
TaqMan Array card may become displaced during centrifugation, resulting in 
uneven filling.  
d. Place a filled card holder in the bucket so that the “This Side Out” label faces out. 
16) Set the centrifuge: 
a. Power on the centrifuge. 
b. Use the front panel controls to set the bucket type to 15679. IMPORTANT! To 
ensure that the maximum rotational speed stays within the manufacturer’s 
specified limits, be sure to set the correct bucket type. 
c. Use the front panel controls to set the following operations parameters: Parameter 
EASYSet (touchpad), Up ramp rate 9, Down ramp rate 9, Rotational speed 1200 
rpm (331 × g) 1200 rpm, Centrifugation time 2 × 1 min. 
17) Place the buckets into the centrifuge: 
a. Press the Open button on the centrifuge to open the centrifuge cover. 
b. Place each loaded bucket onto an open rotor arm of the centrifuge. Make sure 
each bucket can swing easily within its slotted position on the rotor arm. 
IMPORTANT! The manufacturer recommends running the centrifuge with all 




containing the sample-specific PCR reaction mix, place blank balance cards and 
card holders into the buckets. Make sure the buckets and their contents are 
balanced; opposing buckets should have matching weights. 
c. Close the centrifuge cover. 
18) Run the centrifuge: 
a. Press the Start button. The centrifuge starts, then automatically stops after 1 min, 
per the programmed sequence. 
b. Repeat step a so that the TaqMan Array cards are centrifuged for a total of two 
consecutive, 1minute spins. IMPORTANT! To ensure complete distribution of 
the PCR reaction mix, you must centrifuge the TaqMan Array cards for a total of 
two consecutive, 1-minute spins. 
19) Remove the TaqMan Array cards: 
a. Press the Open button. 
b. When the cover has fully opened, remove the buckets from the centrifuge, then 
remove the card holders from the buckets. 
c. Remove all TaqMan Array cards from the buckets by gently lifting them by their 
carrier sides. 
20) Examine the TaqMan Array cards to be sure filling is complete. The amount of PCR 
reaction mix remaining in the fill reservoirs should be consistent from reservoir to 
reservoir. 
21) Seal the TaqMan Array Card. Position the sealer: 
a. Place the sealer on a sturdy lab bench, approximately waist high so that it can be 
easily used. 
b. Turn the sealer so that the front end (the “starting position” shown below) is 
closest to you and the back end is farthest from you. In the correct position, the 
arrows on the sealer are pointing away from you.  
c. Place the sealer’s carriage in its starting position. IMPORTANT! Never insert a 
TaqMan Array card into the sealer if the carriage is not in its starting position. 
The TaqMan Array card will be irreparably damaged if the carriage is moved 
across it toward its starting position. 
22) Insert a TaqMan Array card into the sealer: 
a. Orient the TaqMan Array card in the proper direction over the sealer’s insert 
plate. The card’s fill reservoir end should be the end closest to the arrows etched 
in the base of the sealer.  
b. Line up the card’s rear pin grooves, foil side up, to the stylus pins on the sealer. 
c. Gently place the card on top of the insert plate and ensure that the front end of the 
card is held securely in place by the spring clips. 
d. Gently push the card until it is seated securely in the insert plate. Note: When 
properly seated, the TaqMan Array card’s foil surface should be level with the 
base of the sealer. The four spring clips ensure that the card is held in the proper 
position.  
e. Push the carriage across the base of the sealer in the direction of the arrows. Use a 
slow, steady, and deliberate motion to push the carriage across the entire length of 
the TaqMan Array card until the carriage reaches the mechanical stops. It is 




mechanical stops at both ends to prevent the carriage from coming off. Therefore, 
do not use excessive force or speed when pushing the carriage. IMPORTANT! 
Do not move the carriage back before removing the TaqMan Array card. 
23) Remove the sealed TaqMan Array card by grasping its sides and lifting it off the sealer’s 
insert plate. In the middle of the sealer’s insert plate, there is a thumb slot to help you 
easily access one side of the card.  
24) Inspect the TaqMan Array card for proper sealing. The indentations from the stylus 
assembly should match up with the card’s main channels. If the indentations do not 
match up, or if the foil is in any way damaged, do not use the TaqMan Array card. 
25) Using scissors, trim the fill strip from the TaqMan Array card. Use the edge of the card’s 
carrier as a guide. After the TaqMan Array cards have been loaded and sealed, they are 
stable for at least 64 hours.  
26) Set Up the SDS Plate Document. Start SDS Software v2.1 or later. 
27) Select File, New. 
28) Complete the New Document dialog box: 
a. From the Assay dropdown menu, select ΔΔCT (RQ) or Relative Quantification. 
b. From the Container dropdown menu, select 384 Wells TaqMan Low Density 
Array. 
c. Complete the remaining fields as shown, then click OK. 
29) Import the SDS Setup File (*.txt) into the new SDS plate document: 
a. In the CD drive, insert the Array Information CD that shipped with your TaqMan 
Array card. 
b. In the SDS software, select FileImport. In the SDS software, set up the 
experiment (SDS plate document), using the SDS Setup File included on the 
Array Information CD (this page). 
c. In the Import dialog box, navigate to the SDS Setup File for your TaqMan Array 
card, then click Import. The SDS software imports information from the SDS 
Setup File into the SDS plate document. Note: The SDS software uses the 
information from the SDS Setup File to automatically configure the plate grid and 
setup table with detector, detector task, marker, and sample data. For details on 
the SDS Setup File, see page 26. IMPORTANT! Modifying the contents of the 
SDS Setup File can corrupt the file, making the file unusable (that is, you will not 
be able to access information for the TaqMan Array card). 
30) Save the SDS plate document: 
a. Select File, Save As. 
b. Navigate to a save location. 
c. Enter a name for the SDS plate document. 
d. For Files of Type, select SDS 7900HT Document (*.sds) or SDS 7900HT 
Template Document (*.sdt). Note: You can save the plate document as an SDS 
plate document (*.sds) or SDS template (*.sdt). Saving the plate document as an 
SDS template is recommended when you want to create duplicate plate 
documents for a series of TaqMan Array cards with identical assay 
configurations. 
e. Click Save. 




32) Select the Instrument tab. 
33) Use the default thermal cycling conditions, as shown in the Thermal Cycler tab. Note: 
When you selected 384 Well TaqMan Low Density Array, the SDS software 
automatically set the appropriate thermal cycling conditions for the TaqMan Array cards. 
34) Select the Real-Time tab. If the software is not connected to the instrument, click 
Connect to Instrument. 
35) If the instrument tray is inside the instrument, click Open/Close to rotate the instrument 
tray to the OUT position. 
36) Verify that the TaqMan Array Micro Fluidic Card Thermal Cycling Block is installed in 
the instrument tray.  
37) Place the prepared TaqMan Array card in the instrument tray with: Well A1at the top left 
corner of the tray and the notched corner at the top right and the barcode toward the front 
of the instrument. 
38) Click Start Run. The instrument tray rotates to the IN position. During the run, the 
instrument displays real-time status information in the Instrument Real-Time tabs and 
records the fluorescence emissions. During the run, you can view the data (as the data are 
generated in real-time). 
39) When the Run Complete dialog box appears, click OK to close the dialog box, click 
Open/Close, then remove the TaqMan Array card from the instrument tray. 
Expression levels were normalized to 18S gene expression. 
Table B-1. Assay ID for selected gene targets in Chapter II. 
Gene Symbol Alias Assay ID 
Tlr2 - Rn02133647_s1 
Tlr4 - Rn00569848_m1 
Tollip - Rn01479669_m1 
18s rRNA - Hs99999901_s1 
Slc5a8 RGD1564146 Rn01503812_m1 
Slc16a1 MCT1;RATMCT1;RNMCT1 Rn00562332_m1 
Nfkb1 NF-kB Rn01399583_m1 
Nfkbia RL/IF-1 Rn01473657_g1 
Ptgs2 COX-2;Cox2 Rn01483828_m1 
Acads Scad Rn00574634_m1 
Acadm MCAD Rn00566390_m1 
Muc1 - Rn01462585_m1 
Muc2 HH-Muc Rn01498196_g1 
Muc3a Muc3 Rn01481134_m1 
Muc4 ASGP-1;Psmc Rn01475265_m1 





Chapter II microbial DNA isolation and quantification for sequencing 
Luminal contents collected at termination (Chapter II) were immediately transferred to 
sterile cryotubes, placed on ice, then stored at -80°C. DNA was isolated from homogenized fecal 
samples using a FastDNA SPIN kit for Feces according to the manufacturer’s instructions (MP 
Biomedicals, Solon, OH). Fecal samples were weighed and then homogenized in the FastPrep 24 
instrument with kit provided buffers (825 ul Sodium Phosphate Buffer, 275 ul PLS solution, 122 
ul MT Buffer) in Lysing Matrix E tubes. Following homogenization, tubes were centrifuged at 
14,000 x g for 5 min, and the supernatant was transferred to a clean 2.0 ml centrifuge tube. 
Proteins were precipitated from the supernatant by adding 250 ul PPS solution and incubating at 
4°C for 10 min. Solution was centrifuged at 14,000 x g for 2 min, and the supernatant was 
transferred to 15 ml conical tubes containing 1 ml Binding Matrix Solution and placed on a plate 
rocker for 3 min. Following a 2 min centrifugation at 14,000 x g, the supernatant was decanted 
and remaining pellet resuspended with 1 ml Wash Buffer #1. This solution was transferred into a 
kit provided SPIN filter tube and centrifuged for 1 min at 14,000 x g. A 500 ul aliquot of Wash 
Buffer #2 was added to the SPIN filter and all flow through was discarded following a 2 min 
centrifugation at 14,000 x g. The SPIN filter was then transferred to a clean catch tube. To elute 
purified DNA, 50 ul of TES was added to the SPIN filter and the tubes were centrifuged at 
14,000 x g for 2 min. Purified DNA was stored at -80°C. A negative control containing H2O 
instead of sample was purified in parallel to each extraction batch to screen for contamination of 
extraction reagents.  
 Double-stranded DNA was quantified using the Quant-iT™ PicoGreen™ dsDNA Assay 
Kit (Invitrogen, P11496) according to the manufacturers’ protocol. To begin, a ‘high-range’ (1 




buffer was made. The lambda DNA standard, provided at 100 μg/mL in the Quant-iT™ 
PicoGreen® Kits, was diluted 50-fold in TE to make the 2 μg/mL working solution. Thirty μL of 
the DNA standard mixed with 1.47 mL of TE was sufficient for the standard curve described 
below.  
Volume (µl) of TE 
Volume (µl)  
of 2 µg/ml DNA Stock 






0 1000 1000 1 µg/ml 
900 100 1000 100 µg/ml 
990 10 1000 10 ng/ml 
999 1 1000 1 ng/ml 
1000 0 1000 blank 
1) Prepare the Quant-iT™ PicoGreen® Reagent by making a 200-fold dilution of the 
concentrated DMSO solution in TE. To assay 20 samples in a 2 ml final volume, add 100 
µl Quant-iT™ PicoGreen® Reagent to 19.9 mk TE. Cover the vial containing the prepared 
reagent in foil. 
2) Dilute the stock solution into disposable cuvettes (or plastic test tubes) according to the 
table above.  
3) Add 1.0 ml of the aqueous working solution of PicoGreen® reagent. Mix well and 
incubate for 2 to 5 minutes at room temperature, protected from light.  
4) After incubation, measure the sample fluorescence using a fluorescence microplate reader 
and stand fluorescein wavelengths (excitation ~480 nm, emission ~520 nm).  
5) Subtract the fluorescence value of the reagent blank from that of each of the samples. Use 
corrected data to generate a standard curve of fluorescence versus DNA concentration.  
6) Dilute the experimental DNA solution in TE to a final volume of 1.0 ml in disposable 
cuvettes or test tubes.  
7) Add 1.0 ml of the aqueous working solution of the Quant-iT™ PicoGreen® Reagent to 
each sample. Incubate for 2 to 5 minutes at RT, protected from light. 
8) Measure the fluorescence of the sample using instrument parameters that correspond to 
those used when generating your standard curve. To minimize photobleaching effects, 
keep the time for fluorescence measurement constant for all samples.  
9) Subtract the fluorescence value of the reagent blank from that of each of the samples. 
Determine the DNA concentration of the sample from the standard curve generated 
previously.  
10) The assay may be repeated using a different dilution for the sample to confirm the 
quantitation results.   
 
 
 
 
 
